Hoba personal page - To The Moon

Hoba

Hoba

No personal profile

221Follow

4Followers

0Topic

0Badge

2021-08-29

Huat

Researchers, cybersecurity agency urge action by Microsoft cloud database users

2021-08-04

Huat

Treasury To Start Reducing Bond Auction Sizes As Soon As November

2021-07-24

Huat

Wall Street surges to all-time closing high on earnings, economic revival

2021-07-20

Huat

Sorry, the original content has been removed

2021-06-01

Huat

China’s Infant-Care Stocks Extend Gains on Three-Child Policy

2021-09-05

Huat

Beat the market with this quant system that’s very bullish on stocks at record highs

2021-08-16

Huat

4 Pharma Stocks You Can Buy and Hold for 20 Years

2021-08-06

Huat

Sorry, the original content has been removed

2021-07-25

Huat

Amazon's stock looks tired. Consider buying shares of these five fast-growing e-commerce plays instead

2021-07-21

Huat huat

Jeff Bezos Reveals Blue Origin Has Sold $100M Worth Of Tickets, 'Demand Is Very, Very High'

2021-07-19

Huat huat huat

Netflix, AT&T, Snap, Chipotle, Twitter, and Other Stocks for Investors to Watch This Week

2021-09-21

Huat

Why Apple, Facebook, Amazon, and Other Tech Stocks Dropped Monday

2021-09-17

Genius

3 Ultra-Popular Stocks With 81% to 98% Downside, According to Wall Street

2021-08-20

Huat

3 Reasons BioNTech Isn't Nearly as Big as Moderna

2021-06-23

Huat

Sprinklr Announces Pricing of Initial Public Offering

2021-05-13

Huat

Oil pulls back from 8-week high as coronavirus cases surge in India

2021-08-27

Huat

Palantir Stock Will Stay Strong Until the Markets Get Volatile

2021-08-22

Huat

Expect Fed tapering to start in November and look like this, says BofA Global

2021-08-10

Huat

5 Growth Stocks With 110% to 393% Upside, According to Wall Street

2021-08-10

Huat

U.S. Senate poised to pass $1 trillion infrastructure bill, debate $3.5 trillion budget plan

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3582928782122574,"uuid":"3582928782122574","gmtCreate":1619842187435,"gmtModify":1620026687214,"name":"Hoba","pinyin":"hoba","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":221,"tweetSize":65,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":860762857,"gmtCreate":1632215433279,"gmtModify":1676530726698,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860762857","repostId":"1169324317","repostType":4,"repost":{"id":"1169324317","pubTimestamp":1632214355,"share":"https://ttm.financial/m/news/1169324317?lang=&edition=fundamental","pubTime":"2021-09-21 16:52","market":"us","language":"en","title":"Why Apple, Facebook, Amazon, and Other Tech Stocks Dropped Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1169324317","media":"Motley Fool","summary":"Fear has returned to the global financial markets.\n\nWhat happened\nMounting concerns of a potential f","content":"<blockquote>\n <b>Fear has returned to the global financial markets.</b>\n</blockquote>\n<p><b>What happened</b></p>\n<p>Mounting concerns of a potential financial crisis in <a href=\"https://laohu8.com/S/CAAS\">China</a> drove investors to reduce risk on Monday.</p>\n<p>Here's how some of the largest and most popula&nbsp;rtech&nbsp;stocks fared Monday:</p>\n<ul>\n <li><b><a href=\"https://laohu8.com/S/AAPL\">Apple</a></b>, down 2.1%</li>\n <li><b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b>, down 2.5%</li>\n <li><b><a href=\"https://laohu8.com/S/AMZN\">Amazon.com</a></b>, down 3.1%</li>\n <li><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a></b>, down 3.5%</li>\n <li><b><a href=\"https://laohu8.com/S/NVDA\">NVIDIA Corp</a></b> , down 3.6%</li>\n</ul>\n<p><b>So what</b></p>\n<p>China Evergrande Group is struggling to pay its bills. The mammoth Chinese property developer has warned that it could default on its debt, which, in total, is believed to exceed a staggering $300 billion. <a href=\"https://laohu8.com/S/ISBC\">Investors</a>, in turn, are scared that Evergrande's seemingly imminent collapse could drive China's real estate and banking industries into a crisis -- and stall its massive economy.</p>\n<p>Should that worst-case scenario play out, U.S. companies like Apple and Nvidia that rely on China for a large portion of their raw materials and manufacturing capacity could experience supply chain disruptions. Additionally, e-commerce leaders like Amazon and Shopify, whose third-party merchants often source goods from China, could see their booming growth slow. Worse still, if China's economic slowdown and banking troubles spread to other global markets, advertisers might pull back on their marketing investments, thereby denting the profits of Facebook and other social media companies.</p>\n<p><b>Now what</b></p>\n<p>While certainly unsettling, Evergrande's troubles don't necessarily need to send the world's financial markets into a tailspin. The likelihood that a potential Evergrande collapse weakens the long-term prospects of these U.S.-based tech titans is faint, particularly if the Chinese government intervenes to reduce the chances of widespread carnage in its all-important real estate and banking industries. So, while we may see continued declines in the coming days as traders price in these risks, there's no reason for long-term investors to panic and sell their shares.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Apple, Facebook, Amazon, and Other Tech Stocks Dropped Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Apple, Facebook, Amazon, and Other Tech Stocks Dropped Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-21 16:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/20/why-apple-facebook-amazon-and-other-tech-stocks-dr/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fear has returned to the global financial markets.\n\nWhat happened\nMounting concerns of a potential financial crisis in China drove investors to reduce risk on Monday.\nHere's how some of the largest ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/20/why-apple-facebook-amazon-and-other-tech-stocks-dr/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","SHOP":"Shopify Inc","AAPL":"苹果","AMZN":"亚马逊"},"source_url":"https://www.fool.com/investing/2021/09/20/why-apple-facebook-amazon-and-other-tech-stocks-dr/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169324317","content_text":"Fear has returned to the global financial markets.\n\nWhat happened\nMounting concerns of a potential financial crisis in China drove investors to reduce risk on Monday.\nHere's how some of the largest and most popula rtech stocks fared Monday:\n\nApple, down 2.1%\nFacebook, down 2.5%\nAmazon.com, down 3.1%\nShopify, down 3.5%\nNVIDIA Corp , down 3.6%\n\nSo what\nChina Evergrande Group is struggling to pay its bills. The mammoth Chinese property developer has warned that it could default on its debt, which, in total, is believed to exceed a staggering $300 billion. Investors, in turn, are scared that Evergrande's seemingly imminent collapse could drive China's real estate and banking industries into a crisis -- and stall its massive economy.\nShould that worst-case scenario play out, U.S. companies like Apple and Nvidia that rely on China for a large portion of their raw materials and manufacturing capacity could experience supply chain disruptions. Additionally, e-commerce leaders like Amazon and Shopify, whose third-party merchants often source goods from China, could see their booming growth slow. Worse still, if China's economic slowdown and banking troubles spread to other global markets, advertisers might pull back on their marketing investments, thereby denting the profits of Facebook and other social media companies.\nNow what\nWhile certainly unsettling, Evergrande's troubles don't necessarily need to send the world's financial markets into a tailspin. The likelihood that a potential Evergrande collapse weakens the long-term prospects of these U.S.-based tech titans is faint, particularly if the Chinese government intervenes to reduce the chances of widespread carnage in its all-important real estate and banking industries. So, while we may see continued declines in the coming days as traders price in these risks, there's no reason for long-term investors to panic and sell their shares.","news_type":1},"isVote":1,"tweetType":1,"viewCount":410,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885466600,"gmtCreate":1631816594700,"gmtModify":1676530643827,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Genius","listText":"Genius","text":"Genius","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/885466600","repostId":"2167651799","repostType":4,"repost":{"id":"2167651799","pubTimestamp":1631806223,"share":"https://ttm.financial/m/news/2167651799?lang=&edition=fundamental","pubTime":"2021-09-16 23:30","market":"us","language":"en","title":"3 Ultra-Popular Stocks With 81% to 98% Downside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2167651799","media":"Motley Fool","summary":"Certain analysts and investment banks see these stocks losing a majority of their value.","content":"<p>A quick look at the long-term chart of the benchmark <b>S&amp;P 500</b> will demonstrate to any investor that optimism is rewarded over the long run. However, just because the broader market indexes head higher over time, it doesn't mean all stocks will be winners -- and Wall Street knows it.</p>\n<p>Although a vast majority of Wall Street ratings and price targets on publicly traded companies portend upside, some analysts see nothing short of calamity in the months and years that lie ahead for some of the most popular stocks. Based on the lowest Wall Street price target, the following three ultra-popular stocks could tumble between 81% and 98%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4445b731e2c9c6acb2e5395056b6719\" tg-width=\"700\" tg-height=\"524\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna: Implied downside of 81%</h2>\n<p>Biotech stock <b>Moderna</b> (NASDAQ:MRNA) has been <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the fastest-growing and most successful investments since the beginning of 2020. However, Leerink Partners analyst Mani Foroohar sees things differently. Foroohar and Leerink have stuck by their sell rating and $85 price target on the company as it's soared. If Moderna were to fall back to $85, it would shed 81% of its value.</p>\n<p>On one hand, Moderna has been practically unstoppable, thanks to the successful development of mRNA-1273, one of the coronavirus disease 2019 (COVID-19) vaccines to receive emergency-use authorization in the United States. In late-stage clinical studies released last November, Moderna's two-dose regimen of mRNA-1273 led to a vaccine efficacy (VE) of 94.1%. Even though recent studies have shown that VE wanes over time, the initial VE offered by mRNA-1273 has made it one of the two most-popular inoculation options in developed markets.</p>\n<p>Also working in Moderna's favor is the possibility that COVID-19 vaccines could become a recurring/seasonal thing. Mutations and variations of COVID-19 make it increasingly likely that it'll become an endemic disease. Without the ability to rid COVID-19 from the U.S. and other countries, booster shots may be necessary to combat it. In other words, Moderna's one-hit wonder could become a regular revenue stream.</p>\n<p>On the other hand, mRNA-1273 is Moderna's only revenue-producing asset, and competition in the vaccine space is only destined to become more crowded. Even if Moderna's vaccine remains toward the top end in terms of efficacy, the sheer volume of doses that need to be administered globally will open the door to other successful drugmakers.</p>\n<p>While Leerink's price target is potentially too aggressive to the downside, Moderna does have a lot to prove with a $181 billion market cap and only one marketed drug.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642857%2Flordstown-endurance-steve-burns-ceo.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Now-former CEO Steve Burns standing next to a prototype of the Endurance all-electric. pickup. Image source: Lordstown Motors.</span></p>\n<h2>Lordstown Motors: Implied downside of 84%</h2>\n<p>Over the next decade, electric vehicles (EVs) could be one of the fastest-growing industries in North America. But Wall Street isn't too keen on one EV manufacturer, in particular: <b>Lordstown Motors</b> (NASDAQ:RIDE).</p>\n<p>According to analyst Joseph Spak at RBC Capital, Lordstown is worthy of an underperform rating and a $1 price target. If this price target becomes a reality, Lordstown's shares will have fallen 84%.</p>\n<p>Whereas there was both a clear bull and bear argument to share about Moderna above, the same can't be said of Lordstown Motors. It's been nothing short of a disaster.</p>\n<p>In March, a number of allegations were levied against the company by short-side firm Hindenburg Research. Although a number of these allegations proved to be without merit, a committee formed by Lordstown's independent directors found that the company had exaggerated the number of pre-orders of its Endurance EV pickup. Both Lordstown's CEO Steve Burns and CFO Julio Rodriguez resigned in the wake of these findings.</p>\n<p>To make matters worse, Lordstown Motors may not have enough capital to survive the next year. It costs a pretty penny to build a new automaker from the ground up. Even though the company ended June with $366 million in cash, it reported a second-quarter loss of $108 million.</p>\n<p>The real issue, as my auto-focused colleague John Rosevear notes, is that the company's Endurance pickup isn't anywhere close to being on schedule. Lordstown will probably see Endurance deliveries to customers commence in the second quarter of 2022, which doesn't exactly align with the idea put forward by the company that production would begin in September.</p>\n<p>With few avenues to raise cash and lukewarm demand for Endurance, a $1 price target may even prove too generous.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/15eab863c856018bec9ca4a17856fe6d\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment: Implied downside of 98%</h2>\n<p>And then there was meme stock kingpin <b>AMC Entertainment</b> (NYSE:AMC). AMC shouldn't be a surprise on this list, as the most bullish investment bank on Wall Street sees the company losing nearly 70% of its value, as of this past weekend. On the other end of the spectrum, Alan Gould at Loop Capital foresees AMC eventually heading back to $1 a share. That would be a decline of 98%, for those of you keeping score at home.</p>\n<p>The reason AMC has shot out of a cannon and pushed well beyond Wall Street's collective price targets is the unwavering support of retail investors who believe it'll undergo another short squeeze. This is a very short-term event whereby pessimists who are betting against a stock (i.e., short-sellers) run for the exit at the same time. Since short-sellers have to buy shares to cover their short positions, it can cause a rising stock price to briefly go parabolic.</p>\n<p>But as Gould and other analysts have noted with AMC, the numbers don't add up. While it's impossible to pinpoint when emotion will stop being the driving force behind AMC, the operating performance of a company and its balance sheet always dictate the long-term price performance of a company's stock. In this respect, the movie-theater industry has been in a nearly two-decade decline, with streaming services siphoning off moviegoers and AMC building up share in an industry where the proverbial pie is getting smaller.</p>\n<p>The far greater concern for AMC is the amount of leverage it took on to survive the pandemic. Although the company ended June with $2.023 billion in liquidity ($1.81 billion of which is cash), it's also sitting on nearly $5.5 billion in corporate debt, $420 million in deferred rent, and close to $4.9 billion in lease liabilities.</p>\n<p>By the end of 2023, the company expects to lay out $2.51 billion, at minimum, for lease liabilities and will likely have to repay its $420 million in back rent. That's $2.9 billion in upcoming payments over a 30-month period for a company that's still burning cash and has only $2 billion in liquidity.</p>\n<p>To boot, AMC's retail investors won't approve any additional share offerings, leaving the company with no avenues to further raise capital. As with Lordstown, even a $1 price target might be generous when given enough time.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With 81% to 98% Downside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With 81% to 98% Downside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-16 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/16/3-ultra-popular-stocks-with-81-to-98-downside/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A quick look at the long-term chart of the benchmark S&P 500 will demonstrate to any investor that optimism is rewarded over the long run. However, just because the broader market indexes head higher ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/16/3-ultra-popular-stocks-with-81-to-98-downside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/16/3-ultra-popular-stocks-with-81-to-98-downside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167651799","content_text":"A quick look at the long-term chart of the benchmark S&P 500 will demonstrate to any investor that optimism is rewarded over the long run. However, just because the broader market indexes head higher over time, it doesn't mean all stocks will be winners -- and Wall Street knows it.\nAlthough a vast majority of Wall Street ratings and price targets on publicly traded companies portend upside, some analysts see nothing short of calamity in the months and years that lie ahead for some of the most popular stocks. Based on the lowest Wall Street price target, the following three ultra-popular stocks could tumble between 81% and 98%.\nImage source: Getty Images.\nModerna: Implied downside of 81%\nBiotech stock Moderna (NASDAQ:MRNA) has been one of the fastest-growing and most successful investments since the beginning of 2020. However, Leerink Partners analyst Mani Foroohar sees things differently. Foroohar and Leerink have stuck by their sell rating and $85 price target on the company as it's soared. If Moderna were to fall back to $85, it would shed 81% of its value.\nOn one hand, Moderna has been practically unstoppable, thanks to the successful development of mRNA-1273, one of the coronavirus disease 2019 (COVID-19) vaccines to receive emergency-use authorization in the United States. In late-stage clinical studies released last November, Moderna's two-dose regimen of mRNA-1273 led to a vaccine efficacy (VE) of 94.1%. Even though recent studies have shown that VE wanes over time, the initial VE offered by mRNA-1273 has made it one of the two most-popular inoculation options in developed markets.\nAlso working in Moderna's favor is the possibility that COVID-19 vaccines could become a recurring/seasonal thing. Mutations and variations of COVID-19 make it increasingly likely that it'll become an endemic disease. Without the ability to rid COVID-19 from the U.S. and other countries, booster shots may be necessary to combat it. In other words, Moderna's one-hit wonder could become a regular revenue stream.\nOn the other hand, mRNA-1273 is Moderna's only revenue-producing asset, and competition in the vaccine space is only destined to become more crowded. Even if Moderna's vaccine remains toward the top end in terms of efficacy, the sheer volume of doses that need to be administered globally will open the door to other successful drugmakers.\nWhile Leerink's price target is potentially too aggressive to the downside, Moderna does have a lot to prove with a $181 billion market cap and only one marketed drug.\nNow-former CEO Steve Burns standing next to a prototype of the Endurance all-electric. pickup. Image source: Lordstown Motors.\nLordstown Motors: Implied downside of 84%\nOver the next decade, electric vehicles (EVs) could be one of the fastest-growing industries in North America. But Wall Street isn't too keen on one EV manufacturer, in particular: Lordstown Motors (NASDAQ:RIDE).\nAccording to analyst Joseph Spak at RBC Capital, Lordstown is worthy of an underperform rating and a $1 price target. If this price target becomes a reality, Lordstown's shares will have fallen 84%.\nWhereas there was both a clear bull and bear argument to share about Moderna above, the same can't be said of Lordstown Motors. It's been nothing short of a disaster.\nIn March, a number of allegations were levied against the company by short-side firm Hindenburg Research. Although a number of these allegations proved to be without merit, a committee formed by Lordstown's independent directors found that the company had exaggerated the number of pre-orders of its Endurance EV pickup. Both Lordstown's CEO Steve Burns and CFO Julio Rodriguez resigned in the wake of these findings.\nTo make matters worse, Lordstown Motors may not have enough capital to survive the next year. It costs a pretty penny to build a new automaker from the ground up. Even though the company ended June with $366 million in cash, it reported a second-quarter loss of $108 million.\nThe real issue, as my auto-focused colleague John Rosevear notes, is that the company's Endurance pickup isn't anywhere close to being on schedule. Lordstown will probably see Endurance deliveries to customers commence in the second quarter of 2022, which doesn't exactly align with the idea put forward by the company that production would begin in September.\nWith few avenues to raise cash and lukewarm demand for Endurance, a $1 price target may even prove too generous.\nImage source: Getty Images.\nAMC Entertainment: Implied downside of 98%\nAnd then there was meme stock kingpin AMC Entertainment (NYSE:AMC). AMC shouldn't be a surprise on this list, as the most bullish investment bank on Wall Street sees the company losing nearly 70% of its value, as of this past weekend. On the other end of the spectrum, Alan Gould at Loop Capital foresees AMC eventually heading back to $1 a share. That would be a decline of 98%, for those of you keeping score at home.\nThe reason AMC has shot out of a cannon and pushed well beyond Wall Street's collective price targets is the unwavering support of retail investors who believe it'll undergo another short squeeze. This is a very short-term event whereby pessimists who are betting against a stock (i.e., short-sellers) run for the exit at the same time. Since short-sellers have to buy shares to cover their short positions, it can cause a rising stock price to briefly go parabolic.\nBut as Gould and other analysts have noted with AMC, the numbers don't add up. While it's impossible to pinpoint when emotion will stop being the driving force behind AMC, the operating performance of a company and its balance sheet always dictate the long-term price performance of a company's stock. In this respect, the movie-theater industry has been in a nearly two-decade decline, with streaming services siphoning off moviegoers and AMC building up share in an industry where the proverbial pie is getting smaller.\nThe far greater concern for AMC is the amount of leverage it took on to survive the pandemic. Although the company ended June with $2.023 billion in liquidity ($1.81 billion of which is cash), it's also sitting on nearly $5.5 billion in corporate debt, $420 million in deferred rent, and close to $4.9 billion in lease liabilities.\nBy the end of 2023, the company expects to lay out $2.51 billion, at minimum, for lease liabilities and will likely have to repay its $420 million in back rent. That's $2.9 billion in upcoming payments over a 30-month period for a company that's still burning cash and has only $2 billion in liquidity.\nTo boot, AMC's retail investors won't approve any additional share offerings, leaving the company with no avenues to further raise capital. As with Lordstown, even a $1 price target might be generous when given enough time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":667,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880876350,"gmtCreate":1631049281770,"gmtModify":1676530450439,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880876350","repostId":"1130130857","repostType":4,"repost":{"id":"1130130857","pubTimestamp":1631007146,"share":"https://ttm.financial/m/news/1130130857?lang=&edition=fundamental","pubTime":"2021-09-07 17:32","market":"us","language":"en","title":"Strategists Say the Stock Market Could Struggle This Fall. What to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=1130130857","media":"Barron's","summary":"What a year this has been for the markets!Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and  a mostly receding pandemic, theS&P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.Tailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnin","content":"<p>What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&amp;P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.</p>\n<p>Tailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnings growth are likely to decelerate through the end of the year. What’s more, theFederal Reserve has all but promised to start tapering its bond buyingin coming months, and the Biden administration has proposed hiking corporate and personal tax rates. None of this is apt to sit well with holders of increasingly pricey shares.</p>\n<p>In other words,brace for a volatile fallin which conflicting forces buffet stocks, bonds, and investors. “The everything rally is behind us,” says Saira Malik, chief investment officer of global equities at Nuveen. “It’s not going to be a sharply rising economic tide that lifts all boats from here.”</p>\n<p>That’s the general consensus among the six market strategists and chief investment officers whom<i>Barron’s</i>recently consulted. All see the S&amp;P 500 ending the year near Thursday’s close of 4536. Their average target: 4585.</p>\n<p>Next year’s gains look muted, as well, relative to recent trends. The group expects the S&amp;P 500 to tack on another 6% in 2022, rising to about 4800.</p>\n<p><img src=\"https://static.tigerbbs.com/eb61c7b74b9b0f18a019afb4ac44ad59\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">With stocks trading for about 21 times the coming year’s expected earnings,bonds yielding little, and cash yielding less than nothing after accounting for inflation, investors face tough asset-allocation decisions. In place of the “everything rally,” which lifted fast-growing tech stocks, no-growth meme stocks, and the Dogecoins of the digital world, our market watchers recommend focusing on “quality” investments. In equities, that means shares of businesses with solid balance sheets, expanding profit margins, and ample and recurring free cash flow. Even if the averages do little in coming months, these stocks are likely to shine.</p>\n<p>The stock market’s massive rally in the past year was a gift of sorts from the Federal Reserve, which flooded the financial system with money to stave off theeconomic damage wrought by the Covid pandemic. Since March 2020, the U.S. central bank has been buying a combined $120 billion a month of U.S. Treasuries and mortgage-backed securities, while keeping its benchmark federal-funds rate target at 0% to 0.25%. These moves have depressed bond yields and pushed investors into riskier assets, including stocks.</p>\n<p>Fed Chairman Jerome <a href=\"https://laohu8.com/S/POWL\">Powell</a> has said that the central bank might begin to wind down, or taper, its emergency asset purchases sometime in the coming quarters, a move that could roil risk assets of all sorts. “For us, it’s very simple: Tapering is tightening,” says Mike Wilson, chief investment officer and chief U.S. equity strategist atMorgan Stanley.“It’s the first step away from maximum accommodation [by the Fed]. They’re being very calculated about it this time, but the bottom line is that it should have a negative effect on equity valuations.”</p>\n<p>The government’s stimulus spending, too, has peaked, the strategists note. Supplemental federal unemployment benefits of $300 a week expire as of Sept. 6. Although Congress seems likely to pass a bipartisan infrastructure bill this fall, the near-term economic impact will pale in comparison to the multiple rounds of stimulus introduced since March 2020.</p>\n<p><img src=\"https://static.tigerbbs.com/c2cb76c498c1c4c980139e3d0514c261\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">The bill includes about $550 billion in new spending—a fraction of the trillions authorized by previous laws—and it will be spread out over many years. The short-term boost that infrastructure stimulus will give to consumer spending, which accounts for almost 70% of U.S. growth domestic product, won’t come close to what the economy saw after millions of Americans received checks from the government this past year.</p>\n<p>A budget bill approved by Democrats only should follow the infrastructure bill, and include spending to support Medicare expansion, child-care funding, free community-college tuition, public housing, and climate-related measures, among other party priorities. Congress could vote to lift taxes on corporations and high-earning individuals to offset that spending—another near-term risk to the market.</p>\n<p><img src=\"https://static.tigerbbs.com/6693da658db16059fc99e08a7531675f\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">Other politically charged issues likewise could derail equities this fall. Congress needs to pass a debt-ceiling increase to fund the government, and a stop-gap spending bill later this month to avoid a <a href=\"https://laohu8.com/S/WASH\">Washington</a> shutdown in October.</p>\n<p>For now, our market experts are relatively sanguine about the economic impact of the Delta variant of Covid-19. As long as vaccines remain effective in minimizing severe infections that lead to hospitalizations and deaths, the negative effects of the current Covid wave will be limited largely to the travel industry and movie theaters, they say. Wall Street’s base case for the market doesn’t include a renewed wave of lockdowns that would undermine economic growth.</p>\n<p>Inflation has been a hot topic at the Fed and among investors, partly because it has been running so hot of late. The U.S. consumer price index rose at an annualized 5.4% in both June and July—a spike the Fed calls transitory, although others aren’t so sure. The strategists are taking Powell’s side of the argument; they expect inflation to fall significantly next year. Their forecasts fall between 2.5% and 3.5%, which they consider manageable for consumers and companies, and an acceptable side effect of rapid economic growth. An inflation rate above 2.5%, however, combined with Fed tapering, would mean that now ultralow bond yields should rise.</p>\n<p>“We think inflation will continue to run hotter than it has since the financial crisis, but it’s hard for us to see inflation much over 2.5% once many of the reopening-related pressures start to dissipate,” says Michael Fredericks, head of income investing for theBlackRockMulti-Asset Strategies Group. “So bond yields do need to move up, but that will happen gradually.”</p>\n<p>The strategists see the yield on the 10-year U.S. Treasury note climbing to around 1.65% by year end. That’s about 35 basis points—or hundredths of a percentage point—above current levels, but below the 1.75% that the yield reached at its March 2021 highs. By next year, the 10-year Treasury could yield 2%, the group says. Those aren’t big moves in absolute terms, but they’re meaningful for&nbsp;the bond market—and could be even more so for stocks.</p>\n<p>Rising yields tend to weigh on stock valuations for two reasons. Higher-yielding bonds offer competition to stocks, and companies’ future earnings are worthless in the present when discounting them at a higher rate. Still, a 10-year yield around 2% won’t be enough to knock stock valuations down to pre-Covid levels. Even if yields climb, market strategists see the price/earnings multiple of the S&amp;P 500 holding well above its 30-year average of 16 times forward earnings. The index’s forward P/E topped 23 last fall.</p>\n<p><img src=\"https://static.tigerbbs.com/e08d24cb421d7cc13debd76a9c6fea01\" tg-width=\"660\" tg-height=\"434\" referrerpolicy=\"no-referrer\"></p>\n<p>As long as 10-year Treasury yields stay in the 2% range, the S&amp;P 500 should be able to command a forward P/E in the high teens, strategists say. A return to the 16-times long-term average isn’t in the cards until there is more pressure from much higher yields—or something else that causes stocks to fall.</p>\n<p>If yields surge past 2% or 2.25%, investors could start to question equity valuations more seriously, says&nbsp;<a href=\"https://laohu8.com/S/STT\">State</a> Street’schief portfolio strategist, Gaurav Mallik: “We haven’t seen [the 10-year yield] above 2% for some time now, so that’s an important sentiment level for investors.”</p>\n<p><img src=\"https://static.tigerbbs.com/93ff6490069ab5dc1b4057f1ff7966f3\" tg-width=\"664\" tg-height=\"441\" referrerpolicy=\"no-referrer\"></p>\n<p>Wilson is more concerned, noting that the stock market’s valuation risk is asymmetric: “It’s very unlikely that multiples are going to go up, and there’s a good chance that they go down more than 10% given the deceleration in growth and where we are in the cycle,” he says</p>\n<p>If 16 to 23 times forward earnings is the range, he adds, “you’re already at the very high end of that. There’s more potential risk than reward.”</p>\n<p>Some P/E-multiple compression is baked into all six strategists’ forecasts, heaping greater importance on the path of profit growth. On average, the strategists expect S&amp;P 500 earnings to jump 46% this year, to about $204, after last year’s earnings depression. That could be followed by a more normalized gain of 9% in 2022, to about $222.50.</p>\n<p>A potential headwind would be a higher federal corporate-tax rate in 2022. The details of Democrats’ spending and taxation plans will be worked out in the coming weeks, and investors can expect to hear a lot more about potential tax increases. Several strategists see a 25% federal rate on corporate profits as a likely compromise figure, above the 21% in place since 2018, but below the 28% sought by the Biden administration.</p>\n<p>An increase of that magnitude would shave about 5% off S&amp;P 500 earnings next year. The index could drop by a similar amount as the passage of the Democrats’ reconciliation bill nears this fall, but the impact should be limited to that initial correction. As with the tax cuts in December 2017, the change should be a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time event for the market, some strategists predict.</p>\n<p>These concerns aside, investors shouldn’t miss the bigger picture: The U.S. economy is in good shape and growing robustly. The strategists expect gross domestic product to rise 6.3% this year and about 4% in 2022. “The cyclical uplift and above-trend growth will continue at least through 2022, and we want to be biased toward assets that have that exposure,” says Mallik.</p>\n<blockquote>\n “We’re going to have a hot economy this year and next. When GDP growth is above average, value beats growth and cyclicals beat defensives.”— Lori Calvasina, RBC Capital Markets\n</blockquote>\n<p>The State Street strategist recommends overweighting materials, financials, and technology in investment portfolios. That approach includes both economically sensitive companies, such as banks and miners, and steady growers in the tech sector.</p>\n<p>RBC Capital Markets’ head of U.S. equity strategy, Lori Calvasina, likewise takes a barbell approach, with both cyclical and growth exposure. Her preferred sectors are energy, financials, and technology.</p>\n<p>“Valuations are still a lot more attractive in financials and energy than growth [sectors such as technology or consumer discretionary,]” Calvasina says. “The catalyst in the near term is getting out of the current Covid wave... We’re going to have a hot economy this year and next, and traditionally when GDP growth is above average, value beats growth and cyclicals beat defensives.”</p>\n<p>But the focus on quality will be pivotal, especially moving into the second half of 2022. That’s when the Fed is likely to hike interest rates for the first time in this cycle. By 2023, the economy could return to pre-Covid growth on the order of 2%.</p>\n<p>“The historical playbook is that coming out of a recession, you tend to see low-quality outperformance that lasts about a year, then leadership flips back to high quality,” Calvasina says. “But that transition from low quality back to high quality tends to be very bumpy.”</p>\n<p><b>A Shopping List for Fall</b></p>\n<p>Most strategists favor a combination of economically sensitive stocks and steady growers, including tech shares. Financials should do well, particularly if bond yields rise.</p>\n<p><img src=\"https://static.tigerbbs.com/a54c4bd114c1a5f7f700d1fc14d30d8e\" tg-width=\"970\" tg-height=\"230\" referrerpolicy=\"no-referrer\"></p>\n<p>Although stocks with quality attributes have outperformed the market this summer, according to a <a href=\"https://laohu8.com/S/BLK\">BlackRock</a> analysis, the quality factor has lagged since positive vaccine news was first reported last November.</p>\n<p>“We’re moving into a mid-cycle environment, when underlying economic growth remains strong but momentum begins to decelerate,” BlackRock’s Fredericks says. “Our research shows that quality stocks perform particularly well in such a period.”</p>\n<p>He recommends overweighting profitable technology companies; financials, including banks, and consumer staples and industrials with those quality characteristics.</p>\n<p>For <a href=\"https://laohu8.com/S/WFC\">Wells Fargo</a>’s head of equity strategy, Christopher Harvey, a mix of post-pandemic beneficiaries and defensive exposure is the way to go. He constructed a basket of stocks with lower-than-average volatility—which should outperform during periods of market uncertainty or stress this fall—and high “Covid beta,” or sensitivity to good or bad news about the pandemic. One requirement; The stocks had to be rated the equivalent of Buy by Wells Fargo’s equity analysts.</p>\n<p>“There’s near-term economic uncertainty, interest-rate uncertainty, and Covid risk, and generally we’re in a seasonally weaker part of the year around September,” says Harvey. “If we can balance low vol and high Covid beta, we can mitigate a lot of the upcoming uncertainty and volatility around timing of several of those catalysts. Longer-term, though, we still want to have that [reopening exposure.]”</p>\n<p>Harvey’s list of low-volatility stocks with high Covid beta includesApple(AAPL),<a href=\"https://laohu8.com/S/BAC\">Bank of America</a>(BAC),<a href=\"https://laohu8.com/S/NTRSP\">Northern</a> Trust(NTRS),Lowe’s(LOW),<a href=\"https://laohu8.com/S/IQV\">IQVIA</a> Holdings(IQV), andMasco(MAS).</p>\n<p>Overall, banks are the most frequently recommended group for the months ahead. TheInvesco KBW Bankexchange-traded fund (KBWB) provides broad exposure to the sector in the U.S.</p>\n<p>“We like the valuations [and] credit quality; they are now allowed to buy back shares and increase dividends, and there’s higher Covid beta,” says Harvey.</p>\n<p>Cheaper valuations mean less potential downside in a market correction. And, contrary to much of the rest of the stock market, higher interest rates would be a tailwind for the banks, which could then charge more for loans.</p>\n<p><a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> stocks also have some fans. “<a href=\"https://laohu8.com/S/HR\">Healthcare</a> has both defensive and growth attributes to it,” Wilson says. “You’re paying a lot less per unit of growth in healthcare today than you are in other sectors. So we think it provides good balance in this market when we’re worried about valuation.” Health insurerHumana(HUM) makes Wilson’s “Fresh Money Buy List” of stocks Buy-rated by <a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a> analysts and fitting his macro views.</p>\n<p>Nuveen’s Malik is also looking toward health care for relatively underpriced growth exposure, namely in the pharmaceuticals and biotechnology groups. She points toSeagen(SGEN), which is focused on oncology drugs and could be an attractive acquisition target for a pharma giant.</p>\n<p>Malik also likesAbbVie(ABBV) which trades at an undemanding eight times forward earnings and sports a 4.7% dividend yield. The coming expiration of patents on its blockbuster anti-inflammatory drug Humira has kept some investors away, but Malik is confident that management can limit the damage and sees promising drugs in development at the $200 billion company.</p>\n<p>Both stocks have had a tough time in recent days. Seagen fell more than 8% last week, to around $152, on news that its co-founder and CEO sold a large number of shares recently. AndAbbVietanked 7% Wednesday, to $112.27, after the Food and Drug Administration required new warning labels for JAK inhibitors, a type of anti-rheumatoid drug that includes one of <a href=\"https://laohu8.com/S/ABBV\">AbbVie</a>’s most promising post-Humira products.</p>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>(PFE),<a href=\"https://laohu8.com/S/AXP\">American Express</a>(AXP),Johnson &amp; Johnson(JNJ), andCisco Systems(CSCO) are other S&amp;P 500 members that pass a<i>Barron’s</i>screen for quality attributes.</p>\n<p>After a year of steady gains, investors might be reminded this fall that stocks can also decline, as growth momentum and policy support begin to fade. But underlying economic strength supports buying the dip, should the market drop from its highs. <a href=\"https://laohu8.com/S/JE\">Just</a> be more selective. And go with quality.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Strategists Say the Stock Market Could Struggle This Fall. What to Buy Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStrategists Say the Stock Market Could Struggle This Fall. What to Buy Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-07 17:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-could-struggle-this-fall-market-strategists-say-stick-with-quality-companies-51630699840?siteid=yhoof2><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&P 500stock index has...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-could-struggle-this-fall-market-strategists-say-stick-with-quality-companies-51630699840?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","SPY":"标普500ETF"},"source_url":"https://www.barrons.com/articles/stocks-could-struggle-this-fall-market-strategists-say-stick-with-quality-companies-51630699840?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130130857","content_text":"What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.\nTailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnings growth are likely to decelerate through the end of the year. What’s more, theFederal Reserve has all but promised to start tapering its bond buyingin coming months, and the Biden administration has proposed hiking corporate and personal tax rates. None of this is apt to sit well with holders of increasingly pricey shares.\nIn other words,brace for a volatile fallin which conflicting forces buffet stocks, bonds, and investors. “The everything rally is behind us,” says Saira Malik, chief investment officer of global equities at Nuveen. “It’s not going to be a sharply rising economic tide that lifts all boats from here.”\nThat’s the general consensus among the six market strategists and chief investment officers whomBarron’srecently consulted. All see the S&P 500 ending the year near Thursday’s close of 4536. Their average target: 4585.\nNext year’s gains look muted, as well, relative to recent trends. The group expects the S&P 500 to tack on another 6% in 2022, rising to about 4800.\nWith stocks trading for about 21 times the coming year’s expected earnings,bonds yielding little, and cash yielding less than nothing after accounting for inflation, investors face tough asset-allocation decisions. In place of the “everything rally,” which lifted fast-growing tech stocks, no-growth meme stocks, and the Dogecoins of the digital world, our market watchers recommend focusing on “quality” investments. In equities, that means shares of businesses with solid balance sheets, expanding profit margins, and ample and recurring free cash flow. Even if the averages do little in coming months, these stocks are likely to shine.\nThe stock market’s massive rally in the past year was a gift of sorts from the Federal Reserve, which flooded the financial system with money to stave off theeconomic damage wrought by the Covid pandemic. Since March 2020, the U.S. central bank has been buying a combined $120 billion a month of U.S. Treasuries and mortgage-backed securities, while keeping its benchmark federal-funds rate target at 0% to 0.25%. These moves have depressed bond yields and pushed investors into riskier assets, including stocks.\nFed Chairman Jerome Powell has said that the central bank might begin to wind down, or taper, its emergency asset purchases sometime in the coming quarters, a move that could roil risk assets of all sorts. “For us, it’s very simple: Tapering is tightening,” says Mike Wilson, chief investment officer and chief U.S. equity strategist atMorgan Stanley.“It’s the first step away from maximum accommodation [by the Fed]. They’re being very calculated about it this time, but the bottom line is that it should have a negative effect on equity valuations.”\nThe government’s stimulus spending, too, has peaked, the strategists note. Supplemental federal unemployment benefits of $300 a week expire as of Sept. 6. Although Congress seems likely to pass a bipartisan infrastructure bill this fall, the near-term economic impact will pale in comparison to the multiple rounds of stimulus introduced since March 2020.\nThe bill includes about $550 billion in new spending—a fraction of the trillions authorized by previous laws—and it will be spread out over many years. The short-term boost that infrastructure stimulus will give to consumer spending, which accounts for almost 70% of U.S. growth domestic product, won’t come close to what the economy saw after millions of Americans received checks from the government this past year.\nA budget bill approved by Democrats only should follow the infrastructure bill, and include spending to support Medicare expansion, child-care funding, free community-college tuition, public housing, and climate-related measures, among other party priorities. Congress could vote to lift taxes on corporations and high-earning individuals to offset that spending—another near-term risk to the market.\nOther politically charged issues likewise could derail equities this fall. Congress needs to pass a debt-ceiling increase to fund the government, and a stop-gap spending bill later this month to avoid a Washington shutdown in October.\nFor now, our market experts are relatively sanguine about the economic impact of the Delta variant of Covid-19. As long as vaccines remain effective in minimizing severe infections that lead to hospitalizations and deaths, the negative effects of the current Covid wave will be limited largely to the travel industry and movie theaters, they say. Wall Street’s base case for the market doesn’t include a renewed wave of lockdowns that would undermine economic growth.\nInflation has been a hot topic at the Fed and among investors, partly because it has been running so hot of late. The U.S. consumer price index rose at an annualized 5.4% in both June and July—a spike the Fed calls transitory, although others aren’t so sure. The strategists are taking Powell’s side of the argument; they expect inflation to fall significantly next year. Their forecasts fall between 2.5% and 3.5%, which they consider manageable for consumers and companies, and an acceptable side effect of rapid economic growth. An inflation rate above 2.5%, however, combined with Fed tapering, would mean that now ultralow bond yields should rise.\n“We think inflation will continue to run hotter than it has since the financial crisis, but it’s hard for us to see inflation much over 2.5% once many of the reopening-related pressures start to dissipate,” says Michael Fredericks, head of income investing for theBlackRockMulti-Asset Strategies Group. “So bond yields do need to move up, but that will happen gradually.”\nThe strategists see the yield on the 10-year U.S. Treasury note climbing to around 1.65% by year end. That’s about 35 basis points—or hundredths of a percentage point—above current levels, but below the 1.75% that the yield reached at its March 2021 highs. By next year, the 10-year Treasury could yield 2%, the group says. Those aren’t big moves in absolute terms, but they’re meaningful for the bond market—and could be even more so for stocks.\nRising yields tend to weigh on stock valuations for two reasons. Higher-yielding bonds offer competition to stocks, and companies’ future earnings are worthless in the present when discounting them at a higher rate. Still, a 10-year yield around 2% won’t be enough to knock stock valuations down to pre-Covid levels. Even if yields climb, market strategists see the price/earnings multiple of the S&P 500 holding well above its 30-year average of 16 times forward earnings. The index’s forward P/E topped 23 last fall.\n\nAs long as 10-year Treasury yields stay in the 2% range, the S&P 500 should be able to command a forward P/E in the high teens, strategists say. A return to the 16-times long-term average isn’t in the cards until there is more pressure from much higher yields—or something else that causes stocks to fall.\nIf yields surge past 2% or 2.25%, investors could start to question equity valuations more seriously, says State Street’schief portfolio strategist, Gaurav Mallik: “We haven’t seen [the 10-year yield] above 2% for some time now, so that’s an important sentiment level for investors.”\n\nWilson is more concerned, noting that the stock market’s valuation risk is asymmetric: “It’s very unlikely that multiples are going to go up, and there’s a good chance that they go down more than 10% given the deceleration in growth and where we are in the cycle,” he says\nIf 16 to 23 times forward earnings is the range, he adds, “you’re already at the very high end of that. There’s more potential risk than reward.”\nSome P/E-multiple compression is baked into all six strategists’ forecasts, heaping greater importance on the path of profit growth. On average, the strategists expect S&P 500 earnings to jump 46% this year, to about $204, after last year’s earnings depression. That could be followed by a more normalized gain of 9% in 2022, to about $222.50.\nA potential headwind would be a higher federal corporate-tax rate in 2022. The details of Democrats’ spending and taxation plans will be worked out in the coming weeks, and investors can expect to hear a lot more about potential tax increases. Several strategists see a 25% federal rate on corporate profits as a likely compromise figure, above the 21% in place since 2018, but below the 28% sought by the Biden administration.\nAn increase of that magnitude would shave about 5% off S&P 500 earnings next year. The index could drop by a similar amount as the passage of the Democrats’ reconciliation bill nears this fall, but the impact should be limited to that initial correction. As with the tax cuts in December 2017, the change should be a one-time event for the market, some strategists predict.\nThese concerns aside, investors shouldn’t miss the bigger picture: The U.S. economy is in good shape and growing robustly. The strategists expect gross domestic product to rise 6.3% this year and about 4% in 2022. “The cyclical uplift and above-trend growth will continue at least through 2022, and we want to be biased toward assets that have that exposure,” says Mallik.\n\n “We’re going to have a hot economy this year and next. When GDP growth is above average, value beats growth and cyclicals beat defensives.”— Lori Calvasina, RBC Capital Markets\n\nThe State Street strategist recommends overweighting materials, financials, and technology in investment portfolios. That approach includes both economically sensitive companies, such as banks and miners, and steady growers in the tech sector.\nRBC Capital Markets’ head of U.S. equity strategy, Lori Calvasina, likewise takes a barbell approach, with both cyclical and growth exposure. Her preferred sectors are energy, financials, and technology.\n“Valuations are still a lot more attractive in financials and energy than growth [sectors such as technology or consumer discretionary,]” Calvasina says. “The catalyst in the near term is getting out of the current Covid wave... We’re going to have a hot economy this year and next, and traditionally when GDP growth is above average, value beats growth and cyclicals beat defensives.”\nBut the focus on quality will be pivotal, especially moving into the second half of 2022. That’s when the Fed is likely to hike interest rates for the first time in this cycle. By 2023, the economy could return to pre-Covid growth on the order of 2%.\n“The historical playbook is that coming out of a recession, you tend to see low-quality outperformance that lasts about a year, then leadership flips back to high quality,” Calvasina says. “But that transition from low quality back to high quality tends to be very bumpy.”\nA Shopping List for Fall\nMost strategists favor a combination of economically sensitive stocks and steady growers, including tech shares. Financials should do well, particularly if bond yields rise.\n\nAlthough stocks with quality attributes have outperformed the market this summer, according to a BlackRock analysis, the quality factor has lagged since positive vaccine news was first reported last November.\n“We’re moving into a mid-cycle environment, when underlying economic growth remains strong but momentum begins to decelerate,” BlackRock’s Fredericks says. “Our research shows that quality stocks perform particularly well in such a period.”\nHe recommends overweighting profitable technology companies; financials, including banks, and consumer staples and industrials with those quality characteristics.\nFor Wells Fargo’s head of equity strategy, Christopher Harvey, a mix of post-pandemic beneficiaries and defensive exposure is the way to go. He constructed a basket of stocks with lower-than-average volatility—which should outperform during periods of market uncertainty or stress this fall—and high “Covid beta,” or sensitivity to good or bad news about the pandemic. One requirement; The stocks had to be rated the equivalent of Buy by Wells Fargo’s equity analysts.\n“There’s near-term economic uncertainty, interest-rate uncertainty, and Covid risk, and generally we’re in a seasonally weaker part of the year around September,” says Harvey. “If we can balance low vol and high Covid beta, we can mitigate a lot of the upcoming uncertainty and volatility around timing of several of those catalysts. Longer-term, though, we still want to have that [reopening exposure.]”\nHarvey’s list of low-volatility stocks with high Covid beta includesApple(AAPL),Bank of America(BAC),Northern Trust(NTRS),Lowe’s(LOW),IQVIA Holdings(IQV), andMasco(MAS).\nOverall, banks are the most frequently recommended group for the months ahead. TheInvesco KBW Bankexchange-traded fund (KBWB) provides broad exposure to the sector in the U.S.\n“We like the valuations [and] credit quality; they are now allowed to buy back shares and increase dividends, and there’s higher Covid beta,” says Harvey.\nCheaper valuations mean less potential downside in a market correction. And, contrary to much of the rest of the stock market, higher interest rates would be a tailwind for the banks, which could then charge more for loans.\nHealthcare stocks also have some fans. “Healthcare has both defensive and growth attributes to it,” Wilson says. “You’re paying a lot less per unit of growth in healthcare today than you are in other sectors. So we think it provides good balance in this market when we’re worried about valuation.” Health insurerHumana(HUM) makes Wilson’s “Fresh Money Buy List” of stocks Buy-rated by Morgan Stanley analysts and fitting his macro views.\nNuveen’s Malik is also looking toward health care for relatively underpriced growth exposure, namely in the pharmaceuticals and biotechnology groups. She points toSeagen(SGEN), which is focused on oncology drugs and could be an attractive acquisition target for a pharma giant.\nMalik also likesAbbVie(ABBV) which trades at an undemanding eight times forward earnings and sports a 4.7% dividend yield. The coming expiration of patents on its blockbuster anti-inflammatory drug Humira has kept some investors away, but Malik is confident that management can limit the damage and sees promising drugs in development at the $200 billion company.\nBoth stocks have had a tough time in recent days. Seagen fell more than 8% last week, to around $152, on news that its co-founder and CEO sold a large number of shares recently. AndAbbVietanked 7% Wednesday, to $112.27, after the Food and Drug Administration required new warning labels for JAK inhibitors, a type of anti-rheumatoid drug that includes one of AbbVie’s most promising post-Humira products.\nPfizer(PFE),American Express(AXP),Johnson & Johnson(JNJ), andCisco Systems(CSCO) are other S&P 500 members that pass aBarron’sscreen for quality attributes.\nAfter a year of steady gains, investors might be reminded this fall that stocks can also decline, as growth momentum and policy support begin to fade. But underlying economic strength supports buying the dip, should the market drop from its highs. Just be more selective. And go with quality.","news_type":1},"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814588613,"gmtCreate":1630844568932,"gmtModify":1676530404645,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/814588613","repostId":"1157895022","repostType":4,"repost":{"id":"1157895022","pubTimestamp":1630810619,"share":"https://ttm.financial/m/news/1157895022?lang=&edition=fundamental","pubTime":"2021-09-05 10:56","market":"us","language":"en","title":"Beat the market with this quant system that’s very bullish on stocks at record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=1157895022","media":"MarketWatch","summary":"Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do ","content":"<blockquote>\n <b>Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do so. So far his team of computer scientists’ strategy has paid off.</b>\n</blockquote>\n<p>Imagine you had a money-making machine to harvest gains in the stock market while you sat back to enjoy life.</p>\n<p>That’s everyone’s dream, right? Investor Vance Howard thinks he’s found it.</p>\n<p>Howard and his small army of computer programmers atHoward Capital Managementin Roswell, Ga., have a quantitative system that posts great returns.</p>\n<p>His HCM Tactical Growth Fund&nbsp;HCMGX,+0.35%beats its Russell 1000&nbsp;benchmark index and large-blend fund category by 8.5-10.4 percentage points annualized over the past five years, according to Morningstar. That is no small feat, and not only because it has to overcome a 2.22% fee. Beating the market is simply not easy. His HCM Dividend Sector PlusHCMQX,-0.05%) and HCM Income PlusHCMLX,+0.30%funds post similar outperformance.</p>\n<p>There are drawbacks, which I detail below. (Among them: Potentially long stretches of underperformance and regular tax bills.) But first, what can we learn from this winner?</p>\n<p>So-called quants never share all the details of their proprietary systems, but Howard shares a lot, as you’ll see. And this Texas rancher has a lot of good advice based on “horse sense” — not surprising, given his infectious passion for the markets, and his three decades of experience as a pro.</p>\n<p>Here are five lessons, 12 exchange traded funds (ETFs) and four stocks to consider, from a recent interview with him.</p>\n<p><b>Lesson #1: Don’t be emotional</b></p>\n<p>It’s no surprise so many people do poorly in the market. Evolution has programmed us to fail. For survival, we’ve learned to run from things that frightens us. And crave more of things that are pleasurable — like sweets or fats to store calories ahead of what might be a long stretch without food. But in the market, acting on the emotions of fear and greed invariably make us do the wrong thing at the wrong time. Sell at the bottom, buy at the top.</p>\n<p>Likewise, we’re programmed to believe being with the crowd brings safety. If you’re a zebra on the Savanna, you are more likely to get picked off by a predator if you go it alone. The problem here is being part of a crowd — and crowd psychology — dumb us down to a purely emotional level. This is why people in crowds do terrible things they would never do on their own. It doesn’t matter how smart you are. When you join a crowd, you lose a lot of IQ points. Base emotions take over.</p>\n<p>To do well in the market, you have to counteract these tendencies. “One of the biggest mistakes individual investors and money managers make is getting emotional,” says Howard. “Let your emotions go.”</p>\n<p><b>Lesson #2: Have a system and stick to it</b></p>\n<p>To exorcise emotion, have a system. “And don’t second guess it,” says Howard. “This keeps you from letting the pandemic or Afghanistan scare you out of the market.” He calls his system the HCM-BuyLine. It is basically a momentum and trend-following system — which often works well in the markets.</p>\n<p>The HCM-BuyLine basically works like this. First, rather than use the S&amp;P 500SPX,-0.03%or the Dow Jones Industrial AverageDJIA,-0.21%,Howard blends several stock indices to create his own index. Then he uses a moving average that tells him whether the market is in an uptrend or downtrend.</p>\n<p>When the moving average drops 3.5%, he sells 35%. If it drops 6.5%, he sells another 35%. He rarely goes to 100% cash.</p>\n<p>“If the BuyLine is positive, we will stay long no matter what,” he says. “We take all the emotion out of the equation by letting the math decide.”</p>\n<p>Right now, it’s bullish. (More on this below.)</p>\n<p>Your system also has to tell you when to get back in.</p>\n<p>“That’s where most people screw up,” he says. “They get out of the market, and they don’t know when to get back in.” The HCM-BuyLine gives a buy signal when his custom index trades above its moving average for six consecutive sessions, and then goes on to trade above the high hit during those six days.</p>\n<p>You don’t need a system that calls exact market tops or bottoms. Instead, the BuyLine keeps Howard out of down markets 85% of the time, and in for 85% of the good times.</p>\n<p>“If we can do that consistently, we have superior returns and a less stressful life,” he says. “Being all in during a bad tape is no fun.”</p>\n<p>His system is slow to get him out of the market, but quick to get him back in. Not even a 10% correction will necessarily move him out. He’s often buying those pullbacks. Getting back in fast makes sense, because recoveries off bottoms tend to happen fast.</p>\n<p>“The HCM-BuyLine takes all the emotion out of the process,” says Howard.</p>\n<p><b>Lesson #3: Don’t fight the tape</b></p>\n<p>This concept is one of the core pieces of wisdom from Marty Zweig’s classic book, “Winning on Wall Street.”</p>\n<p>“You have to stay on the right side of market,” agrees Howard. “If you try to trade long in a bad market, it is painful.”</p>\n<p>In other words, don’t try to be a hero.</p>\n<p>“Sometimes, not losing money is where you want to be,” he says.</p>\n<p>Likewise, don’t turn cautious just because the market hits new highs — like now. You should love new highs, because it is a sign of market strength that may likely endure.</p>\n<p><b>Lesson #4: Keep it simple</b></p>\n<p>As you’ll see below, Howard doesn’t use esoteric instruments such as derivatives, swaps or index options. He doesn’t even trade foreign stocks or currencies. This is refreshing for individual investors, because we have a harder time accessing those tools.</p>\n<p>“You don’t have to trade crazy stuff,” he says. “You can trade plain-vanilla ETFs and beat everybody out there.”</p>\n<p><b>Lesson #5: How to trade the current market</b></p>\n<p>First, be long.</p>\n<p>“The HCM-BuyLine is very positive. We are 100% in,” says Howard. “The market is broadening out. It is getting pretty exciting. We do not see it turn around any time soon. We are buying pullbacks.”</p>\n<p>One bullish signal is all the cash on the sidelines. “If there is any relief in Covid, we may see a big rally. We may end up with a great fall [season].”</p>\n<p>Howard uses momentum indicators to select stocks and ETFs, too. For sectors he favors the following.</p>\n<p>He likes health care, tradable through the iShares US HealthcareIYH,-0.04%and ProShares Ultra Health CareRXL,+0.12%ETFs. He’s turning more bullish on biotech, which he plays via the iShares Biotechnology ETFIBB,-0.11%.</p>\n<p>He likes consumer discretionary tradable through the iShares US Consumer ServicesIYC,-0.30%,and airlines via US Global JetsJETS,-1.17%.He also likes tech exposure via the Invesco QQQ TrustQQQ,+0.31%,iShares US TechnologyIYW,+0.50%and&nbsp;iShares SemiconductorSOXX,+0.75%.</p>\n<p>He likes small-caps via the Vanguard Small-Cap Growth Index FundVBK,+0.07%.And convertible bonds via SPDR Bloomberg Barclays Convertible SecuritiesCWB,+0.64%and iShares Convertible BondICVT,+0.37%.</p>\n<p>As for individual names, he singles out MicrosoftMSFT,-0.00%and AppleAAPL,+0.42%in tech, as well as Amazon.comAMZN,+0.43%and TeslaTSLA,+0.16%.</p>\n<p>Also consider Howard’s two ETFs: The HCM Defender 100 IndexQQH,+0.62%and HCM Defender 500 IndexLGH,+1.32%.</p>\n<p>He prefers to add to holdings on 1%-3% dips.</p>\n<p><b>A few drawbacks</b></p>\n<p>His HCM Tactical Growth fund has a history of posting two-year stretches of underperformance of 1.5% to 8.8%, since it was launched in 2015. The fund then came roaring back to net the very positive five-year outperformance cited above. Investing in his system can require patience.</p>\n<p>Every manager, including Warren Buffett, can have a stretch of underperformance, says Howard.</p>\n<p>“We are in the odds game,” he says. “Even in the odds game, you can have a bad hand or two thrown at you.”</p>\n<p>Another challenge is the high turnover, which is 140% a year for Tactical Growth. This means Uncle Sam takes a big cut in the good years. So if you buy Howard’s funds, you may want to do so in a tax-protected account.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beat the market with this quant system that’s very bullish on stocks at record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeat the market with this quant system that’s very bullish on stocks at record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-05 10:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/beat-the-market-with-this-quant-system-thats-very-bullish-on-stocks-at-record-highs-11630761531?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do so. So far his team of computer scientists’ strategy has paid off.\n\nImagine you had a money-making ...</p>\n\n<a href=\"https://www.marketwatch.com/story/beat-the-market-with-this-quant-system-thats-very-bullish-on-stocks-at-record-highs-11630761531?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/beat-the-market-with-this-quant-system-thats-very-bullish-on-stocks-at-record-highs-11630761531?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157895022","content_text":"Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do so. So far his team of computer scientists’ strategy has paid off.\n\nImagine you had a money-making machine to harvest gains in the stock market while you sat back to enjoy life.\nThat’s everyone’s dream, right? Investor Vance Howard thinks he’s found it.\nHoward and his small army of computer programmers atHoward Capital Managementin Roswell, Ga., have a quantitative system that posts great returns.\nHis HCM Tactical Growth Fund HCMGX,+0.35%beats its Russell 1000 benchmark index and large-blend fund category by 8.5-10.4 percentage points annualized over the past five years, according to Morningstar. That is no small feat, and not only because it has to overcome a 2.22% fee. Beating the market is simply not easy. His HCM Dividend Sector PlusHCMQX,-0.05%) and HCM Income PlusHCMLX,+0.30%funds post similar outperformance.\nThere are drawbacks, which I detail below. (Among them: Potentially long stretches of underperformance and regular tax bills.) But first, what can we learn from this winner?\nSo-called quants never share all the details of their proprietary systems, but Howard shares a lot, as you’ll see. And this Texas rancher has a lot of good advice based on “horse sense” — not surprising, given his infectious passion for the markets, and his three decades of experience as a pro.\nHere are five lessons, 12 exchange traded funds (ETFs) and four stocks to consider, from a recent interview with him.\nLesson #1: Don’t be emotional\nIt’s no surprise so many people do poorly in the market. Evolution has programmed us to fail. For survival, we’ve learned to run from things that frightens us. And crave more of things that are pleasurable — like sweets or fats to store calories ahead of what might be a long stretch without food. But in the market, acting on the emotions of fear and greed invariably make us do the wrong thing at the wrong time. Sell at the bottom, buy at the top.\nLikewise, we’re programmed to believe being with the crowd brings safety. If you’re a zebra on the Savanna, you are more likely to get picked off by a predator if you go it alone. The problem here is being part of a crowd — and crowd psychology — dumb us down to a purely emotional level. This is why people in crowds do terrible things they would never do on their own. It doesn’t matter how smart you are. When you join a crowd, you lose a lot of IQ points. Base emotions take over.\nTo do well in the market, you have to counteract these tendencies. “One of the biggest mistakes individual investors and money managers make is getting emotional,” says Howard. “Let your emotions go.”\nLesson #2: Have a system and stick to it\nTo exorcise emotion, have a system. “And don’t second guess it,” says Howard. “This keeps you from letting the pandemic or Afghanistan scare you out of the market.” He calls his system the HCM-BuyLine. It is basically a momentum and trend-following system — which often works well in the markets.\nThe HCM-BuyLine basically works like this. First, rather than use the S&P 500SPX,-0.03%or the Dow Jones Industrial AverageDJIA,-0.21%,Howard blends several stock indices to create his own index. Then he uses a moving average that tells him whether the market is in an uptrend or downtrend.\nWhen the moving average drops 3.5%, he sells 35%. If it drops 6.5%, he sells another 35%. He rarely goes to 100% cash.\n“If the BuyLine is positive, we will stay long no matter what,” he says. “We take all the emotion out of the equation by letting the math decide.”\nRight now, it’s bullish. (More on this below.)\nYour system also has to tell you when to get back in.\n“That’s where most people screw up,” he says. “They get out of the market, and they don’t know when to get back in.” The HCM-BuyLine gives a buy signal when his custom index trades above its moving average for six consecutive sessions, and then goes on to trade above the high hit during those six days.\nYou don’t need a system that calls exact market tops or bottoms. Instead, the BuyLine keeps Howard out of down markets 85% of the time, and in for 85% of the good times.\n“If we can do that consistently, we have superior returns and a less stressful life,” he says. “Being all in during a bad tape is no fun.”\nHis system is slow to get him out of the market, but quick to get him back in. Not even a 10% correction will necessarily move him out. He’s often buying those pullbacks. Getting back in fast makes sense, because recoveries off bottoms tend to happen fast.\n“The HCM-BuyLine takes all the emotion out of the process,” says Howard.\nLesson #3: Don’t fight the tape\nThis concept is one of the core pieces of wisdom from Marty Zweig’s classic book, “Winning on Wall Street.”\n“You have to stay on the right side of market,” agrees Howard. “If you try to trade long in a bad market, it is painful.”\nIn other words, don’t try to be a hero.\n“Sometimes, not losing money is where you want to be,” he says.\nLikewise, don’t turn cautious just because the market hits new highs — like now. You should love new highs, because it is a sign of market strength that may likely endure.\nLesson #4: Keep it simple\nAs you’ll see below, Howard doesn’t use esoteric instruments such as derivatives, swaps or index options. He doesn’t even trade foreign stocks or currencies. This is refreshing for individual investors, because we have a harder time accessing those tools.\n“You don’t have to trade crazy stuff,” he says. “You can trade plain-vanilla ETFs and beat everybody out there.”\nLesson #5: How to trade the current market\nFirst, be long.\n“The HCM-BuyLine is very positive. We are 100% in,” says Howard. “The market is broadening out. It is getting pretty exciting. We do not see it turn around any time soon. We are buying pullbacks.”\nOne bullish signal is all the cash on the sidelines. “If there is any relief in Covid, we may see a big rally. We may end up with a great fall [season].”\nHoward uses momentum indicators to select stocks and ETFs, too. For sectors he favors the following.\nHe likes health care, tradable through the iShares US HealthcareIYH,-0.04%and ProShares Ultra Health CareRXL,+0.12%ETFs. He’s turning more bullish on biotech, which he plays via the iShares Biotechnology ETFIBB,-0.11%.\nHe likes consumer discretionary tradable through the iShares US Consumer ServicesIYC,-0.30%,and airlines via US Global JetsJETS,-1.17%.He also likes tech exposure via the Invesco QQQ TrustQQQ,+0.31%,iShares US TechnologyIYW,+0.50%and iShares SemiconductorSOXX,+0.75%.\nHe likes small-caps via the Vanguard Small-Cap Growth Index FundVBK,+0.07%.And convertible bonds via SPDR Bloomberg Barclays Convertible SecuritiesCWB,+0.64%and iShares Convertible BondICVT,+0.37%.\nAs for individual names, he singles out MicrosoftMSFT,-0.00%and AppleAAPL,+0.42%in tech, as well as Amazon.comAMZN,+0.43%and TeslaTSLA,+0.16%.\nAlso consider Howard’s two ETFs: The HCM Defender 100 IndexQQH,+0.62%and HCM Defender 500 IndexLGH,+1.32%.\nHe prefers to add to holdings on 1%-3% dips.\nA few drawbacks\nHis HCM Tactical Growth fund has a history of posting two-year stretches of underperformance of 1.5% to 8.8%, since it was launched in 2015. The fund then came roaring back to net the very positive five-year outperformance cited above. Investing in his system can require patience.\nEvery manager, including Warren Buffett, can have a stretch of underperformance, says Howard.\n“We are in the odds game,” he says. “Even in the odds game, you can have a bad hand or two thrown at you.”\nAnother challenge is the high turnover, which is 140% a year for Tactical Growth. This means Uncle Sam takes a big cut in the good years. So if you buy Howard’s funds, you may want to do so in a tax-protected account.","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815233066,"gmtCreate":1630679567255,"gmtModify":1676530375089,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815233066","repostId":"1185745995","repostType":2,"repost":{"id":"1185745995","pubTimestamp":1630656384,"share":"https://ttm.financial/m/news/1185745995?lang=&edition=fundamental","pubTime":"2021-09-03 16:06","market":"us","language":"en","title":"How to Play the Squeeze: A Look at Support.com and 2 Other Shorted Names","url":"https://stock-news.laohu8.com/highlight/detail?id=1185745995","media":"The Street","summary":"When you're chasing or riding, you need to have an idea of when or where you are going to sell.\n\nSto","content":"<blockquote>\n When you're chasing or riding, you need to have an idea of when or where you are going to sell.\n</blockquote>\n<p><i>Stocks quotes in this article:</i>&nbsp;<i>GME,</i>&nbsp;<i>AMC,</i>&nbsp;<i>SPRT,</i>&nbsp;<i>BBIG,</i>&nbsp;<i>ANY</i></p>\n<p>When the music stops, it is time to get off. That's what we're seeing with most of the short-squeezes.</p>\n<p>Oh, every so often you get the exception that holds its squeeze. GameStop (GME) is a prime example with AMC Entertainment (AMC) not far behind.</p>\n<p>Calling a top is extremely different and I'm not a proponent of shorting these names but when you're chasing or riding, you need to have an idea of when or where you are going to sell.</p>\n<p>The \"where\" is a pure guess. You can put a target of $10 on a $2 stock squeezing only see it roll to $50 after you sold at $10. At the same time, you don't want to roundtrip the position, riding it from $2 to $50 back down to $2.</p>\n<p>Most folks will say that will never happen to them. It does. Way too often.</p>\n<p>We get stuck with the idea that as soon as we sell the stock it is going to turn around and blastoff again. Every so often it will. Most of the time, it doesn't. Even the times we do see it happen, often there is still time to reenter and catch a good amount of upside.</p>\n<p>There's one sign I look for, though: exhaustion.</p>\n<p>Let's look at two names that have already pulled back a good amount, along with one that went into squeeze mode Thursday.</p>\n<p><b>Support.com (SPRT)</b></p>\n<p>This name was a huge winner for a lot of people. Judging by Twitter, everyone was a winner. The stock shot up from the low single digits all the way to $60 per share. That's an amazing run even if you caught half of it, but the end did come with a big warning signal.</p>\n<p>It becomes clear on the candlestick daily chart, below. Traders can see a big wick to the upside. That means the stock touched those levels intraday but closed well below them.</p>\n<p><img src=\"https://static.tigerbbs.com/01a8c35cd7397266d863f600d434ee21\" tg-width=\"575\" tg-height=\"700\" width=\"100%\" height=\"auto\">One might ask, \"What about the wick back on August 24th?\" And that's a great question. The wick in and of itself is a flag, but what happens the next two days is the kicker.</p>\n<p>Back in August, the next day after the wick, the shares gapped higher and remained strong. This time around, the shares probed both higher and lower the next day, forming a doji. This is often the size of a pending change in movement. That was another flag.</p>\n<p>When it opened lower on day 3 and trending down, it was time to exit. Now, if the stock pushed back through $38, you could always buy back in and play the momentum, but the signs were there that the squeeze ended.</p>\n<p><b>Vinco Ventures (BBIG)</b></p>\n<p>This one hasn't yet moved to the levels of SPRT insanity, but it's still a move from $3 to $12. BBIG, too, had an upper wick, but it wasn't nearly as pronounced as SPRT's.</p>\n<p><img src=\"https://static.tigerbbs.com/9c5d69355ae2a92321fd555b2faf295d\" tg-width=\"575\" tg-height=\"700\" width=\"100%\" height=\"auto\">The first big move before the end of August had a wick, but it gapped higher the next day. As we saw above that gap higher negates a lot of the concerns of the previous day's wick. So, day 2 continued with the gap up, wicks on both sides, but a wide range. Again, no real flags.</p>\n<p>Day 3 actually saw the wick go in the opposite direction. That rejection from selling down provided hints that staying with the stock another day or two was likely worth the risk.</p>\n<p>It's that fourth day when the first flag came out. And the fourth day flag exists because we opened lower on day 5 and failed to rally. This means the pressure is on the bulls in a big way Friday.</p>\n<p>At this point, our red flag is a break under $7, whereas our all systems go is above $9.50.</p>\n<p><b>Sphere 3D Corp. (ANY)</b></p>\n<p>While higher for a week now, Thursday was the first big breakout for ANY. We did get a fade on this one in the afternoon, so there's another pesky exhaustion wick. That being said, it's going to be how the stock opens Friday and trades in the early going that determines if this wick is the flag that should make you a seller on Friday.</p>\n<p>If ANY gaps higher, then one has to watch for a run to $12 or a reversal through Thursday's close. The wick won't mean too much if it gaps higher and closes higher. The wick will matter if ANY gaps higher and fades or simply gaps lower and fails to rally quickly.</p>\n<p><img src=\"https://static.tigerbbs.com/26d178fb37e25697ffebf07409a4a402\" tg-width=\"575\" tg-height=\"700\" width=\"100%\" height=\"auto\">These won't always trade exactly the same, but the pattern concept is pretty repeatable across most squeeze plays. Stay safe out there!</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How to Play the Squeeze: A Look at Support.com and 2 Other Shorted Names</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow to Play the Squeeze: A Look at Support.com and 2 Other Shorted Names\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 16:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://realmoney.thestreet.com/investing/stocks/how-to-play-the-squeeze-a-look-at-support-com-and-2-other-shorted-names-15759039><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When you're chasing or riding, you need to have an idea of when or where you are going to sell.\n\nStocks quotes in this article: GME, AMC, SPRT, BBIG, ANY\nWhen the music stops, it is time to get off. ...</p>\n\n<a href=\"https://realmoney.thestreet.com/investing/stocks/how-to-play-the-squeeze-a-look-at-support-com-and-2-other-shorted-names-15759039\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ANY":"Sphere 3D Corp","AMC":"AMC院线","GME":"游戏驿站","BBIG":"Vinco Ventures, Inc."},"source_url":"https://realmoney.thestreet.com/investing/stocks/how-to-play-the-squeeze-a-look-at-support-com-and-2-other-shorted-names-15759039","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185745995","content_text":"When you're chasing or riding, you need to have an idea of when or where you are going to sell.\n\nStocks quotes in this article: GME, AMC, SPRT, BBIG, ANY\nWhen the music stops, it is time to get off. That's what we're seeing with most of the short-squeezes.\nOh, every so often you get the exception that holds its squeeze. GameStop (GME) is a prime example with AMC Entertainment (AMC) not far behind.\nCalling a top is extremely different and I'm not a proponent of shorting these names but when you're chasing or riding, you need to have an idea of when or where you are going to sell.\nThe \"where\" is a pure guess. You can put a target of $10 on a $2 stock squeezing only see it roll to $50 after you sold at $10. At the same time, you don't want to roundtrip the position, riding it from $2 to $50 back down to $2.\nMost folks will say that will never happen to them. It does. Way too often.\nWe get stuck with the idea that as soon as we sell the stock it is going to turn around and blastoff again. Every so often it will. Most of the time, it doesn't. Even the times we do see it happen, often there is still time to reenter and catch a good amount of upside.\nThere's one sign I look for, though: exhaustion.\nLet's look at two names that have already pulled back a good amount, along with one that went into squeeze mode Thursday.\nSupport.com (SPRT)\nThis name was a huge winner for a lot of people. Judging by Twitter, everyone was a winner. The stock shot up from the low single digits all the way to $60 per share. That's an amazing run even if you caught half of it, but the end did come with a big warning signal.\nIt becomes clear on the candlestick daily chart, below. Traders can see a big wick to the upside. That means the stock touched those levels intraday but closed well below them.\nOne might ask, \"What about the wick back on August 24th?\" And that's a great question. The wick in and of itself is a flag, but what happens the next two days is the kicker.\nBack in August, the next day after the wick, the shares gapped higher and remained strong. This time around, the shares probed both higher and lower the next day, forming a doji. This is often the size of a pending change in movement. That was another flag.\nWhen it opened lower on day 3 and trending down, it was time to exit. Now, if the stock pushed back through $38, you could always buy back in and play the momentum, but the signs were there that the squeeze ended.\nVinco Ventures (BBIG)\nThis one hasn't yet moved to the levels of SPRT insanity, but it's still a move from $3 to $12. BBIG, too, had an upper wick, but it wasn't nearly as pronounced as SPRT's.\nThe first big move before the end of August had a wick, but it gapped higher the next day. As we saw above that gap higher negates a lot of the concerns of the previous day's wick. So, day 2 continued with the gap up, wicks on both sides, but a wide range. Again, no real flags.\nDay 3 actually saw the wick go in the opposite direction. That rejection from selling down provided hints that staying with the stock another day or two was likely worth the risk.\nIt's that fourth day when the first flag came out. And the fourth day flag exists because we opened lower on day 5 and failed to rally. This means the pressure is on the bulls in a big way Friday.\nAt this point, our red flag is a break under $7, whereas our all systems go is above $9.50.\nSphere 3D Corp. (ANY)\nWhile higher for a week now, Thursday was the first big breakout for ANY. We did get a fade on this one in the afternoon, so there's another pesky exhaustion wick. That being said, it's going to be how the stock opens Friday and trades in the early going that determines if this wick is the flag that should make you a seller on Friday.\nIf ANY gaps higher, then one has to watch for a run to $12 or a reversal through Thursday's close. The wick won't mean too much if it gaps higher and closes higher. The wick will matter if ANY gaps higher and fades or simply gaps lower and fails to rally quickly.\nThese won't always trade exactly the same, but the pattern concept is pretty repeatable across most squeeze plays. Stay safe out there!","news_type":1},"isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815297392,"gmtCreate":1630679442516,"gmtModify":1676530375014,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815297392","repostId":"815922363","repostType":1,"repost":{"id":815922363,"gmtCreate":1630637152448,"gmtModify":1676530362883,"author":{"id":"3527667596890271","authorId":"3527667596890271","authorIdStr":"3527667596890271","name":"Buy_Sell","avatar":"https://static.tigerbbs.com/a5f0ed79a338c758a22e0b4ea13bf9d2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667596890271"},"themes":[],"title":"?【9月3日】能源股回升，區塊鏈上揚！今天買什麼？","htmlText":"聊聊今日份的交易想法，包括對於大盤走勢後續的看法？看漲/看跌哪隻股票、曬曬單等等。 港股市場 9月3日，恆生指數開盤下跌67.76點，跌幅0.26%，報26022.67點；國企指數開盤下跌21.67點，跌幅0.23%，報9319.63點；紅籌指數開盤上漲3.53點，漲幅0.09%，報3977.99點。 恆生科技指數跌0.34%，科技股多數下跌，<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 跌超2%，<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09888\">$百度集團-SW(09888)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09626\">$嗶哩嗶哩-SW(09626)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美團-W(03690)$</a> 跌超1% 中資券商股集體高開，<a target=\"_blank\" href=\"https://laohu8.com/S/06806\">$申萬宏源(06806)$</a> 大漲9.6%，<a target=\"_blank\" href=\"https://laohu8.com/S/06066\">$中信建投證券(06066)$</a> 漲超6%，<a target=\"_blank\" href=\"https://laohu8.com/S/03908\">$中金公司(03908)$</a> 漲超5%，中信證券、中國","listText":"聊聊今日份的交易想法，包括對於大盤走勢後續的看法？看漲/看跌哪隻股票、曬曬單等等。 港股市場 9月3日，恆生指數開盤下跌67.76點，跌幅0.26%，報26022.67點；國企指數開盤下跌21.67點，跌幅0.23%，報9319.63點；紅籌指數開盤上漲3.53點，漲幅0.09%，報3977.99點。 恆生科技指數跌0.34%，科技股多數下跌，<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 跌超2%，<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09888\">$百度集團-SW(09888)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09626\">$嗶哩嗶哩-SW(09626)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美團-W(03690)$</a> 跌超1% 中資券商股集體高開，<a target=\"_blank\" href=\"https://laohu8.com/S/06806\">$申萬宏源(06806)$</a> 大漲9.6%，<a target=\"_blank\" href=\"https://laohu8.com/S/06066\">$中信建投證券(06066)$</a> 漲超6%，<a target=\"_blank\" href=\"https://laohu8.com/S/03908\">$中金公司(03908)$</a> 漲超5%，中信證券、中國","text":"聊聊今日份的交易想法，包括對於大盤走勢後續的看法？看漲/看跌哪隻股票、曬曬單等等。 港股市場 9月3日，恆生指數開盤下跌67.76點，跌幅0.26%，報26022.67點；國企指數開盤下跌21.67點，跌幅0.23%，報9319.63點；紅籌指數開盤上漲3.53點，漲幅0.09%，報3977.99點。 恆生科技指數跌0.34%，科技股多數下跌，$快手-W(01024)$ 跌超2%，$阿里巴巴-SW(09988)$ 、$百度集團-SW(09888)$ 、$嗶哩嗶哩-SW(09626)$ 、$美團-W(03690)$ 跌超1% 中資券商股集體高開，$申萬宏源(06806)$ 大漲9.6%，$中信建投證券(06066)$ 漲超6%，$中金公司(03908)$ 漲超5%，中信證券、中國","images":[{"img":"https://static.tigerbbs.com/8ef6c9cd81a136f5fb3809e3654109e6","width":"500","height":"278"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815922363","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":1,"subType":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813702652,"gmtCreate":1630242065476,"gmtModify":1676530249644,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat//<a href=\"https://laohu8.com/U/4088390766152690\">@mingliang104</a>: Nice sale! Like pls&nbsp;","listText":"Huat//<a href=\"https://laohu8.com/U/4088390766152690\">@mingliang104</a>: Nice sale! Like pls&nbsp;","text":"Huat//@mingliang104: Nice sale! Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/813702652","repostId":"1160859146","repostType":4,"repost":{"id":"1160859146","pubTimestamp":1626920814,"share":"https://ttm.financial/m/news/1160859146?lang=&edition=fundamental","pubTime":"2021-07-22 10:26","market":"us","language":"en","title":"Prudential to Sell Its Retirement Division to Great-West for $3.55 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1160859146","media":"Bloomberg","summary":"(Bloomberg) -- Prudential Financial Inc. said it would sell its full-service retirement business to ","content":"<p>(Bloomberg) -- Prudential Financial Inc. said it would sell its full-service retirement business to a unit of Canada’s Great-West Lifeco Inc. for $3.55 billion as the life insurer continues implementing Chief Executive Officer Charles Lowrey’s three-year transformation plan.</p>\n<p>The business will be purchased by Great-West’s Greenwood Village, Colorado-based Empower Retirement division. Prudential expects total proceeds of about $2.8 billion from the sale, which is expected to close in the first quarter of next year, the companies said in a statement. It will boost Empower’s customer base by about 4 million people to 16.6 million participants.</p>\n<p>Lowrey is working to transform Prudential’s business through deals, cost savings and share buybacks, including selling off interest-rate sensitive businesses and making acquisitions in growth markets. Prudential will continue participating in the retirement market, serving retirees, employers and those collecting on annuities, through businesses including its individual-annuities unit and PGIM, Prudential’s asset manager.</p>\n<p>“Today’s announcement is a significant milestone in Prudential’s transformation and the execution of our strategy to become a higher growth, less market sensitive, more nimble business,” Lowrey said in the statement.</p>\n<p>Prudential, based in Newark, New Jersey, said it will use proceeds from the transaction for general corporate purposes. It now plans to increase capital returned to shareholders by 2023 to $11 billion from the $10.5 billion announced in May, and will reduce financial leverage.</p>\n<p>Bloomberg News reported earlier this year that Prudential was exploring a sale of its retirement business. The deal comes as insurers part with retirement-related assets to focus on core operations. Great-West agreed last year to buy Massachusetts Mutual Life Insurance Co.’s retirement-services arm for $3.4 billion.</p>\n<p>“Empower’s acquisition of Prudential’s full-service retirement business will add significant scale and capabilities, further solidifying its leadership position in the world’s largest retirement market,” Great-West CEO Paul Mahon said in a separate statement.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prudential to Sell Its Retirement Division to Great-West for $3.55 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrudential to Sell Its Retirement Division to Great-West for $3.55 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/prudential-sell-retirement-division-great-132237534.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Prudential Financial Inc. said it would sell its full-service retirement business to a unit of Canada’s Great-West Lifeco Inc. for $3.55 billion as the life insurer continues ...</p>\n\n<a href=\"https://finance.yahoo.com/news/prudential-sell-retirement-division-great-132237534.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFH":"Prudential Financial Inc"},"source_url":"https://finance.yahoo.com/news/prudential-sell-retirement-division-great-132237534.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160859146","content_text":"(Bloomberg) -- Prudential Financial Inc. said it would sell its full-service retirement business to a unit of Canada’s Great-West Lifeco Inc. for $3.55 billion as the life insurer continues implementing Chief Executive Officer Charles Lowrey’s three-year transformation plan.\nThe business will be purchased by Great-West’s Greenwood Village, Colorado-based Empower Retirement division. Prudential expects total proceeds of about $2.8 billion from the sale, which is expected to close in the first quarter of next year, the companies said in a statement. It will boost Empower’s customer base by about 4 million people to 16.6 million participants.\nLowrey is working to transform Prudential’s business through deals, cost savings and share buybacks, including selling off interest-rate sensitive businesses and making acquisitions in growth markets. Prudential will continue participating in the retirement market, serving retirees, employers and those collecting on annuities, through businesses including its individual-annuities unit and PGIM, Prudential’s asset manager.\n“Today’s announcement is a significant milestone in Prudential’s transformation and the execution of our strategy to become a higher growth, less market sensitive, more nimble business,” Lowrey said in the statement.\nPrudential, based in Newark, New Jersey, said it will use proceeds from the transaction for general corporate purposes. It now plans to increase capital returned to shareholders by 2023 to $11 billion from the $10.5 billion announced in May, and will reduce financial leverage.\nBloomberg News reported earlier this year that Prudential was exploring a sale of its retirement business. The deal comes as insurers part with retirement-related assets to focus on core operations. Great-West agreed last year to buy Massachusetts Mutual Life Insurance Co.’s retirement-services arm for $3.4 billion.\n“Empower’s acquisition of Prudential’s full-service retirement business will add significant scale and capabilities, further solidifying its leadership position in the world’s largest retirement market,” Great-West CEO Paul Mahon said in a separate statement.","news_type":1},"isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813702171,"gmtCreate":1630241961193,"gmtModify":1676530249644,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/813702171","repostId":"2163304079","repostType":4,"repost":{"id":"2163304079","pubTimestamp":1630193325,"share":"https://ttm.financial/m/news/2163304079?lang=&edition=fundamental","pubTime":"2021-08-29 07:28","market":"us","language":"en","title":"Researchers, cybersecurity agency urge action by Microsoft cloud database users","url":"https://stock-news.laohu8.com/highlight/detail?id=2163304079","media":"Reuters","summary":"(Reuters) - Researchers who discovered a massive flaw in the main databases stored in Microsoft Corp","content":"<p>(Reuters) - Researchers who discovered a massive flaw in the main databases stored in Microsoft Corp's Azure cloud platform on Saturday urged all users to change their digital access keys, not just the 3,300 it notified this week.</p>\n<p>As first reported by Reuters https://www.reuters.com/technology/exclusive-microsoft-warns-thousands-cloud-customers-exposed-databases-emails-2021-08-26, researchers at a cloud security company called Wiz discovered this month they could have gained access to the primary digital keys for most users of the Cosmos DB database system, allowing them to steal, change or delete millions of records.</p>\n<p>Alerted by Wiz, Microsoft rapidly fixed the configuration mistake that would have made it easy for any Cosmos user to get into other customers' databases, then notified some users Thursday to change their keys.</p>\n<p>In a blog post Friday, Microsoft said it warned customers which had set up Cosmos access during the weeklong research period. It found no evidence that any attackers had used the same flaw to get into customer data, it noted.</p>\n<p>\"Our investigation shows no unauthorized access other than the researcher activity,\" Microsoft wrote. \"Notifications have been sent to all customers that could be potentially affected due to researcher activity,\" it said, perhaps referring to the chance that the technique had leaked from Wiz.</p>\n<p>\"Though no customer data was accessed, it is recommended you regenerate your primary read-write keys,\" it said.</p>\n<p>The U.S. Department of Homeland Security's Cybersecurity and Infrastructure Security Agency used stronger language in a bulletin Friday, making clear it was speaking not just to those notified.</p>\n<p>\"CISA strongly encourages Azure Cosmos DB customers to roll and regenerate their certificate key,\" the agency said https://us-cert.cisa.gov/ncas/current-activity/2021/08/27/microsoft-azure-cosmos-db-guidance.</p>\n<p>Experts at Wiz, founded by four veterans of Azure's in-house security team, agreed.</p>\n<p>\"In my estimation, it's really hard for them, if not impossible, to completely rule out that someone used this before,\" said <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the four, Wiz Chief Technology Officer Ami Luttwak. At Microsoft he developed tools for logging cloud security incidents.</p>\n<p>Microsoft did not give a direct answer when asked if it had comprehensive logs for the two years when the Jupyter Notebook feature was misconfigured, or had used another way to rule out access abuse.</p>\n<p>\"We expanded our search beyond the researcher's activities to look for all possible activity for current and similar events in the past,\" said spokesman Ross Richendrfer, declining to address other questions.</p>\n<p>Wiz said Microsoft had worked closely with it on the research but had declined to say how it could be sure earlier customers were safe.</p>\n<p>\"It's terrifying. I really hope than no one besides us found this bug,\" said one of the lead researchers on the project at Wiz, Sagi Tzadik.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Researchers, cybersecurity agency urge action by Microsoft cloud database users</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResearchers, cybersecurity agency urge action by Microsoft cloud database users\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-29 07:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/researchers-cybersecurity-agency-urge-action-232845273.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Researchers who discovered a massive flaw in the main databases stored in Microsoft Corp's Azure cloud platform on Saturday urged all users to change their digital access keys, not just ...</p>\n\n<a href=\"https://finance.yahoo.com/news/researchers-cybersecurity-agency-urge-action-232845273.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://finance.yahoo.com/news/researchers-cybersecurity-agency-urge-action-232845273.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2163304079","content_text":"(Reuters) - Researchers who discovered a massive flaw in the main databases stored in Microsoft Corp's Azure cloud platform on Saturday urged all users to change their digital access keys, not just the 3,300 it notified this week.\nAs first reported by Reuters https://www.reuters.com/technology/exclusive-microsoft-warns-thousands-cloud-customers-exposed-databases-emails-2021-08-26, researchers at a cloud security company called Wiz discovered this month they could have gained access to the primary digital keys for most users of the Cosmos DB database system, allowing them to steal, change or delete millions of records.\nAlerted by Wiz, Microsoft rapidly fixed the configuration mistake that would have made it easy for any Cosmos user to get into other customers' databases, then notified some users Thursday to change their keys.\nIn a blog post Friday, Microsoft said it warned customers which had set up Cosmos access during the weeklong research period. It found no evidence that any attackers had used the same flaw to get into customer data, it noted.\n\"Our investigation shows no unauthorized access other than the researcher activity,\" Microsoft wrote. \"Notifications have been sent to all customers that could be potentially affected due to researcher activity,\" it said, perhaps referring to the chance that the technique had leaked from Wiz.\n\"Though no customer data was accessed, it is recommended you regenerate your primary read-write keys,\" it said.\nThe U.S. Department of Homeland Security's Cybersecurity and Infrastructure Security Agency used stronger language in a bulletin Friday, making clear it was speaking not just to those notified.\n\"CISA strongly encourages Azure Cosmos DB customers to roll and regenerate their certificate key,\" the agency said https://us-cert.cisa.gov/ncas/current-activity/2021/08/27/microsoft-azure-cosmos-db-guidance.\nExperts at Wiz, founded by four veterans of Azure's in-house security team, agreed.\n\"In my estimation, it's really hard for them, if not impossible, to completely rule out that someone used this before,\" said one of the four, Wiz Chief Technology Officer Ami Luttwak. At Microsoft he developed tools for logging cloud security incidents.\nMicrosoft did not give a direct answer when asked if it had comprehensive logs for the two years when the Jupyter Notebook feature was misconfigured, or had used another way to rule out access abuse.\n\"We expanded our search beyond the researcher's activities to look for all possible activity for current and similar events in the past,\" said spokesman Ross Richendrfer, declining to address other questions.\nWiz said Microsoft had worked closely with it on the research but had declined to say how it could be sure earlier customers were safe.\n\"It's terrifying. I really hope than no one besides us found this bug,\" said one of the lead researchers on the project at Wiz, Sagi Tzadik.","news_type":1},"isVote":1,"tweetType":1,"viewCount":180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813521863,"gmtCreate":1630217025152,"gmtModify":1676530245766,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/813521863","repostId":"836486908","repostType":1,"repost":{"id":836486908,"gmtCreate":1629514628204,"gmtModify":1676530063144,"author":{"id":"3579574507989417","authorId":"3579574507989417","authorIdStr":"3579574507989417","name":"jingshen","avatar":"https://static.tigerbbs.com/9f2e7a9c8bf801981646c34ca8c306f4","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579574507989417"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>this regulation really killingus","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>this regulation really killingus","text":"$Alibaba(BABA)$this regulation really killingus","images":[{"img":"https://static.tigerbbs.com/dfd8669cae68501729908e968a9c1d9a","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836486908","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":206,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819581245,"gmtCreate":1630077296487,"gmtModify":1676530219561,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819581245","repostId":"1113000704","repostType":4,"repost":{"id":"1113000704","pubTimestamp":1630076703,"share":"https://ttm.financial/m/news/1113000704?lang=&edition=fundamental","pubTime":"2021-08-27 23:05","market":"us","language":"en","title":"Palantir Stock Will Stay Strong Until the Markets Get Volatile","url":"https://stock-news.laohu8.com/highlight/detail?id=1113000704","media":"InvestorPlace","summary":"PLTR stock may be vulnerable to a market correction caused by the Fed's tightening\nIs going long Pal","content":"<p>PLTR stock may be vulnerable to a market correction caused by the Fed's tightening</p>\n<p>Is going long&nbsp;<b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) stock a bet on the big data dynamo continuing to knock things out of the park? Or is it a bet that the “growth at any price” environment that the market continues to be in will stay intact? The answer is a little bit of Column A, but mostly Column B.</p>\n<p>As shown by its latest earnings report, the company is still knocking the ball out of the park. It beat analysts’ average&nbsp; revenue estimates for the second quarter. And that growth was driven not by its government business, but by its commercial segment. That may signal that the company has more than deep ties with the U.S. federal government on its side.</p>\n<p>Even so, a lot of the stock’s continued strength is derived from the fact that it benefits the most from the U.S. Federal Reserve’s aggressive monetary policy. As a result, its shares will likely remain strong until that policy changes.</p>\n<p>Of course,&nbsp; the Fed’s easy money policies may soon be over, creating a problem for PLTR stock. If the market enters a correction following tightening moves by the central bank, stocks like Palantir could suffer outsized declines.</p>\n<p>But that doesn’t exactly make the shares a sell. Those who believe that the market will experience a soft rather than a hard landing following the Fed’s tightening may think that the long-term potential of Palantir’s&nbsp;“wonderful business”&nbsp; outweighs any possible temporary declines.</p>\n<p><b>Palantir’s Earnings and Why You Shouldn’t Bet Against It</b></p>\n<p>After growing its sales 49% year-over-year&nbsp;in Q2, Palantir remains firmly on the growth train. Not only that, but its success last quarter came from an area that used to be one of its weaknesses. Specifically, its sales to the private sector jumped a stunning 90% year-over-year.</p>\n<p>That stat may put to bed one of the key arguments that bears have made about PLTR stock: their belief that its struggles winning over commercial clients will shorten its growth runway. If the company’s commercial growth continues at similar rates in the upcoming quarters, it could meet or beat its goal of achieving long-term annual revenue growth above 30%.</p>\n<p>One factor that could keep it in high growth mode is its&nbsp;unique strategy of locking in&nbsp; customers over the long-term. That strategy is its PIPE (private investment in public equity) investments in scores of SPACs (special purpose acquisition companies). The SPACs in which it’s invested $310 million purchased just $3 million of its services last quarter. But the company believes that over the long-term, the potential value of the contracts from these clients could be as much as $428 million.</p>\n<p>Palantir’s blowout quarter shows that, despite the hype surrounding the company, no one should bet against. But the stock isn’t&nbsp; bulletproof.</p>\n<p>Again, much of the strong&nbsp; performance of PLTR stock since its debut last fall has been driven by the market’s continued love for high-flying growth names like Palantir. That may be set to change, depending on how the market reacts to the Federal Reserve’s policy changes in the months ahead.</p>\n<p><b>A Correction Could Punish Palantir Stock</b></p>\n<p>Following Palantir’s Q2 earnings, PLTR stock has started to bounce back. In recent weeks, the shares have climbed back from roughly $22 to around $24.87 per share as of yesterday’s market close.</p>\n<p>With&nbsp; the stock’s rich valuation, it may be tough for the shares to make another leap higher. At today’s prices, the stock trades at a forward price-earnings, or P/E, ratio of 153 times. Its forward price-sales ratio&nbsp; of 32 times is sky-high as well.</p>\n<p>Given this factor, the shares may continue to hold steady near their current prices. But while it may be tough for Palantir to add to its gains, a negative catalyst could send it much lower.</p>\n<p>That is the Fed’s likely policy changes, which could soon kick off. As “bond king” Jeffrey Gundlach recently stated in an interview, the start of the Fed’s bond tapering program could&nbsp;put pressure on the stock market. Growth stocks like Palantir would be the most affected by such a development.</p>\n<p>Tightening by the Fed may not push PLTR stock back down to its single-digit lows. Yet even after a 50% drop, its P/E ratio would still be 76.4 times. So it’s best not to shrug off the potential downside risk of PLTR stock.</p>\n<p><b>Despite Its Risks, You May Still Find Palantir Appealing</b></p>\n<p>Not everyone is as bearish as Gundlach on the likely Fed tapering.Depending on the speed of the tapering and when it begins, it may not have that much of an impact on stock prices. So richly priced growth stocks like Palantir may not be at risk of substantial declines.</p>\n<p>If you believe that, at worst, the markets will experience a soft landing once the runaway bull market gives way to a bear market,&nbsp; the long-term potential of PLTR stock may outweigh any upcoming volatility.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir Stock Will Stay Strong Until the Markets Get Volatile</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir Stock Will Stay Strong Until the Markets Get Volatile\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/pltr-stock-stay-strong-until-markets-get-volatile/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PLTR stock may be vulnerable to a market correction caused by the Fed's tightening\nIs going long Palantir(NYSE:PLTR) stock a bet on the big data dynamo continuing to knock things out of the park? Or ...</p>\n\n<a href=\"https://investorplace.com/2021/08/pltr-stock-stay-strong-until-markets-get-volatile/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/08/pltr-stock-stay-strong-until-markets-get-volatile/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113000704","content_text":"PLTR stock may be vulnerable to a market correction caused by the Fed's tightening\nIs going long Palantir(NYSE:PLTR) stock a bet on the big data dynamo continuing to knock things out of the park? Or is it a bet that the “growth at any price” environment that the market continues to be in will stay intact? The answer is a little bit of Column A, but mostly Column B.\nAs shown by its latest earnings report, the company is still knocking the ball out of the park. It beat analysts’ average  revenue estimates for the second quarter. And that growth was driven not by its government business, but by its commercial segment. That may signal that the company has more than deep ties with the U.S. federal government on its side.\nEven so, a lot of the stock’s continued strength is derived from the fact that it benefits the most from the U.S. Federal Reserve’s aggressive monetary policy. As a result, its shares will likely remain strong until that policy changes.\nOf course,  the Fed’s easy money policies may soon be over, creating a problem for PLTR stock. If the market enters a correction following tightening moves by the central bank, stocks like Palantir could suffer outsized declines.\nBut that doesn’t exactly make the shares a sell. Those who believe that the market will experience a soft rather than a hard landing following the Fed’s tightening may think that the long-term potential of Palantir’s “wonderful business”  outweighs any possible temporary declines.\nPalantir’s Earnings and Why You Shouldn’t Bet Against It\nAfter growing its sales 49% year-over-year in Q2, Palantir remains firmly on the growth train. Not only that, but its success last quarter came from an area that used to be one of its weaknesses. Specifically, its sales to the private sector jumped a stunning 90% year-over-year.\nThat stat may put to bed one of the key arguments that bears have made about PLTR stock: their belief that its struggles winning over commercial clients will shorten its growth runway. If the company’s commercial growth continues at similar rates in the upcoming quarters, it could meet or beat its goal of achieving long-term annual revenue growth above 30%.\nOne factor that could keep it in high growth mode is its unique strategy of locking in  customers over the long-term. That strategy is its PIPE (private investment in public equity) investments in scores of SPACs (special purpose acquisition companies). The SPACs in which it’s invested $310 million purchased just $3 million of its services last quarter. But the company believes that over the long-term, the potential value of the contracts from these clients could be as much as $428 million.\nPalantir’s blowout quarter shows that, despite the hype surrounding the company, no one should bet against. But the stock isn’t  bulletproof.\nAgain, much of the strong  performance of PLTR stock since its debut last fall has been driven by the market’s continued love for high-flying growth names like Palantir. That may be set to change, depending on how the market reacts to the Federal Reserve’s policy changes in the months ahead.\nA Correction Could Punish Palantir Stock\nFollowing Palantir’s Q2 earnings, PLTR stock has started to bounce back. In recent weeks, the shares have climbed back from roughly $22 to around $24.87 per share as of yesterday’s market close.\nWith  the stock’s rich valuation, it may be tough for the shares to make another leap higher. At today’s prices, the stock trades at a forward price-earnings, or P/E, ratio of 153 times. Its forward price-sales ratio  of 32 times is sky-high as well.\nGiven this factor, the shares may continue to hold steady near their current prices. But while it may be tough for Palantir to add to its gains, a negative catalyst could send it much lower.\nThat is the Fed’s likely policy changes, which could soon kick off. As “bond king” Jeffrey Gundlach recently stated in an interview, the start of the Fed’s bond tapering program could put pressure on the stock market. Growth stocks like Palantir would be the most affected by such a development.\nTightening by the Fed may not push PLTR stock back down to its single-digit lows. Yet even after a 50% drop, its P/E ratio would still be 76.4 times. So it’s best not to shrug off the potential downside risk of PLTR stock.\nDespite Its Risks, You May Still Find Palantir Appealing\nNot everyone is as bearish as Gundlach on the likely Fed tapering.Depending on the speed of the tapering and when it begins, it may not have that much of an impact on stock prices. So richly priced growth stocks like Palantir may not be at risk of substantial declines.\nIf you believe that, at worst, the markets will experience a soft landing once the runaway bull market gives way to a bear market,  the long-term potential of PLTR stock may outweigh any upcoming volatility.","news_type":1},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832631073,"gmtCreate":1629616839292,"gmtModify":1676530080641,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/832631073","repostId":"2161743804","repostType":4,"repost":{"id":"2161743804","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629604860,"share":"https://ttm.financial/m/news/2161743804?lang=&edition=fundamental","pubTime":"2021-08-22 12:01","market":"hk","language":"en","title":"Expect Fed tapering to start in November and look like this, says BofA Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2161743804","media":"Dow Jones","summary":"BofA: Timing of Fed tapering will be a key, but so will the pace and composition of cutbacks.\n\nBack-","content":"<blockquote>\n BofA: Timing of Fed tapering will be a key, but so will the pace and composition of cutbacks.\n</blockquote>\n<p>Back-to-school isn't the only item on the agenda this fall that could have a big economic impact.</p>\n<p>BofA Global analysts also have penciled in November as the likely start date for the Federal Reserve to make cutbacks to its large-scale asset purchases, up from an earlier forecast for a January kickoff.</p>\n<p>The stepped up timeline comes days after the Federal Reserve's July Federal Open Markets Committee (FOMC) meeting minutes showed most of the 19 top central bank officials felt it appropriate to start reducing the pace of its $120 billion per month bond purchases this year.</p>\n<p>The Fed's program of buying Treasurys and mortgage-backed securities <a href=\"https://laohu8.com/S/MBB\">$(MBB)$</a> each month has been credited with helping to stave off a broader financial crisis during the pandemic, mostly by keeping markets liquid and credit conditions loose, while fueling the economic recovery.</p>\n<p>With children across the nation expected to return to classrooms this fall, hopefully freeing up more parents to return to the workforce, the Fed also looks increasingly poised to begin the process of getting markets back to functioning on their own.</p>\n<p>\"The July FOMC minutes altered our base case for taper, pulling the timeline forward by about two months from January to November, though affirmed our expectation for the Fed to move more slowly and be data-dependent,\" Meghan Swiber's team at BofA Research wrote in a note Friday.</p>\n<p>While the timing of tapering will be a key, so will the pace and composition of cutbacks, the team said.</p>\n<p>To that end, BofA Global put forth this new forecast of what the pullback could look like. Their base-case shows purchases ending around next September.</p>\n<p>Swiber's team argued that the U.S. economic recovery keeps heading toward the Fed's goal of \"substantial further progress\" from the worst shocks of the pandemic last year, but also that any decisions by the central bank on pulling back its extreme monetary support will remain \"data dependent.\"</p>\n<p>Dallas Fed President Rob Kaplan on Friday told Fox Business Network that he may rethink his call for the Fed to quickly start to taper its monthly purchases if it looks like the spread of the coronavirus delta variant is slowing economic growth.</p>\n<p>While a lifeline for markets, the Fed program also has drawn criticism. Some experts fear the central bank's Goliath footprint has eroded risk-based pricing in markets, which can help keep bubbles in check, and fueled an uneven \"K-shaped\" recovery, where most wealth accumulated has been by the rich, not the poor, as stocks, financial assets and home prices have set record highs during the pandemic.</p>\n<p>Read: Home prices could cool when the Fed tapers its bond-buying program. But a crisis? Unlikely .</p>\n<p>The major U.S. stock benchmarks were trading higher Friday, but with the Dow Jones Industrial Average headed for a 1% weekly loss and the S&amp;P 500 index about 0.6% lower on the week, according to FactSet data.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Expect Fed tapering to start in November and look like this, says BofA Global</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExpect Fed tapering to start in November and look like this, says BofA Global\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-22 12:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n BofA: Timing of Fed tapering will be a key, but so will the pace and composition of cutbacks.\n</blockquote>\n<p>Back-to-school isn't the only item on the agenda this fall that could have a big economic impact.</p>\n<p>BofA Global analysts also have penciled in November as the likely start date for the Federal Reserve to make cutbacks to its large-scale asset purchases, up from an earlier forecast for a January kickoff.</p>\n<p>The stepped up timeline comes days after the Federal Reserve's July Federal Open Markets Committee (FOMC) meeting minutes showed most of the 19 top central bank officials felt it appropriate to start reducing the pace of its $120 billion per month bond purchases this year.</p>\n<p>The Fed's program of buying Treasurys and mortgage-backed securities <a href=\"https://laohu8.com/S/MBB\">$(MBB)$</a> each month has been credited with helping to stave off a broader financial crisis during the pandemic, mostly by keeping markets liquid and credit conditions loose, while fueling the economic recovery.</p>\n<p>With children across the nation expected to return to classrooms this fall, hopefully freeing up more parents to return to the workforce, the Fed also looks increasingly poised to begin the process of getting markets back to functioning on their own.</p>\n<p>\"The July FOMC minutes altered our base case for taper, pulling the timeline forward by about two months from January to November, though affirmed our expectation for the Fed to move more slowly and be data-dependent,\" Meghan Swiber's team at BofA Research wrote in a note Friday.</p>\n<p>While the timing of tapering will be a key, so will the pace and composition of cutbacks, the team said.</p>\n<p>To that end, BofA Global put forth this new forecast of what the pullback could look like. Their base-case shows purchases ending around next September.</p>\n<p>Swiber's team argued that the U.S. economic recovery keeps heading toward the Fed's goal of \"substantial further progress\" from the worst shocks of the pandemic last year, but also that any decisions by the central bank on pulling back its extreme monetary support will remain \"data dependent.\"</p>\n<p>Dallas Fed President Rob Kaplan on Friday told Fox Business Network that he may rethink his call for the Fed to quickly start to taper its monthly purchases if it looks like the spread of the coronavirus delta variant is slowing economic growth.</p>\n<p>While a lifeline for markets, the Fed program also has drawn criticism. Some experts fear the central bank's Goliath footprint has eroded risk-based pricing in markets, which can help keep bubbles in check, and fueled an uneven \"K-shaped\" recovery, where most wealth accumulated has been by the rich, not the poor, as stocks, financial assets and home prices have set record highs during the pandemic.</p>\n<p>Read: Home prices could cool when the Fed tapers its bond-buying program. But a crisis? Unlikely .</p>\n<p>The major U.S. stock benchmarks were trading higher Friday, but with the Dow Jones Industrial Average headed for a 1% weekly loss and the S&amp;P 500 index about 0.6% lower on the week, according to FactSet data.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MBB":"美国按揭抵押债券ETF-iShares"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161743804","content_text":"BofA: Timing of Fed tapering will be a key, but so will the pace and composition of cutbacks.\n\nBack-to-school isn't the only item on the agenda this fall that could have a big economic impact.\nBofA Global analysts also have penciled in November as the likely start date for the Federal Reserve to make cutbacks to its large-scale asset purchases, up from an earlier forecast for a January kickoff.\nThe stepped up timeline comes days after the Federal Reserve's July Federal Open Markets Committee (FOMC) meeting minutes showed most of the 19 top central bank officials felt it appropriate to start reducing the pace of its $120 billion per month bond purchases this year.\nThe Fed's program of buying Treasurys and mortgage-backed securities $(MBB)$ each month has been credited with helping to stave off a broader financial crisis during the pandemic, mostly by keeping markets liquid and credit conditions loose, while fueling the economic recovery.\nWith children across the nation expected to return to classrooms this fall, hopefully freeing up more parents to return to the workforce, the Fed also looks increasingly poised to begin the process of getting markets back to functioning on their own.\n\"The July FOMC minutes altered our base case for taper, pulling the timeline forward by about two months from January to November, though affirmed our expectation for the Fed to move more slowly and be data-dependent,\" Meghan Swiber's team at BofA Research wrote in a note Friday.\nWhile the timing of tapering will be a key, so will the pace and composition of cutbacks, the team said.\nTo that end, BofA Global put forth this new forecast of what the pullback could look like. Their base-case shows purchases ending around next September.\nSwiber's team argued that the U.S. economic recovery keeps heading toward the Fed's goal of \"substantial further progress\" from the worst shocks of the pandemic last year, but also that any decisions by the central bank on pulling back its extreme monetary support will remain \"data dependent.\"\nDallas Fed President Rob Kaplan on Friday told Fox Business Network that he may rethink his call for the Fed to quickly start to taper its monthly purchases if it looks like the spread of the coronavirus delta variant is slowing economic growth.\nWhile a lifeline for markets, the Fed program also has drawn criticism. Some experts fear the central bank's Goliath footprint has eroded risk-based pricing in markets, which can help keep bubbles in check, and fueled an uneven \"K-shaped\" recovery, where most wealth accumulated has been by the rich, not the poor, as stocks, financial assets and home prices have set record highs during the pandemic.\nRead: Home prices could cool when the Fed tapers its bond-buying program. But a crisis? Unlikely .\nThe major U.S. stock benchmarks were trading higher Friday, but with the Dow Jones Industrial Average headed for a 1% weekly loss and the S&P 500 index about 0.6% lower on the week, according to FactSet data.","news_type":1},"isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836342371,"gmtCreate":1629459916593,"gmtModify":1676530047873,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836342371","repostId":"2160166577","repostType":4,"repost":{"id":"2160166577","pubTimestamp":1629459420,"share":"https://ttm.financial/m/news/2160166577?lang=&edition=fundamental","pubTime":"2021-08-20 19:37","market":"us","language":"en","title":"3 Reasons BioNTech Isn't Nearly as Big as Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2160166577","media":"Motley Fool","summary":"Bigger isn't always better.","content":"<p><b>Moderna </b>(NASDAQ:MRNA) has delivered impressive stock gains so far in 2021. However,&nbsp;<b>BioNTech</b> (NASDAQ:BNTX) is by far the bigger winner year to date, with its stock skyrocketing more than 330%.</p>\n<p>Despite its stronger stock performance this year, BioNTech's market cap is only a little over half the size of Moderna's. Here are three reasons BioNTech isn't nearly as big as Moderna right now.</p>\n<p><img src=\"https://static.tigerbbs.com/39e79871581641e56cbbd05d9f8a3450\" tg-width=\"700\" tg-height=\"525\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Lower expected sales</h3>\n<p>It makes sense that a company with significantly lower revenue and earnings would have a lower market cap than a rival with stronger financial results. But BioNTech actually outperformed Moderna on both fronts in the companies' latest quarterly updates.</p>\n<p>In the second quarter, BioNTech reported revenue of 5.3 billion euros (around $6.2 billion). The German biotech posted earnings of nearly 2.8 billion euros (close to $3.3 billion). By comparison, Moderna's Q2 revenue totaled $4.4 billion, and it generated earnings of $2.8 billion.</p>\n<p>So why does BioNTech have a lower valuation than Moderna? One main reason is that the company projects lower sales for full-year 2021. BioNTech expects full-year sales of 15.9 billion euros (roughly $18.6 billion). Moderna looks for full-year revenue of $20 billion. BioNTech and <b>Pfizer</b>&nbsp;split the profits on the sales of their COVID-19 vaccine. Moderna, however, pockets all of the revenue from its vaccine.</p>\n<p>Neither BioNTech nor Moderna has provided guidance for 2022 yet. However, Moderna revealed that it has already secured advanced purchase agreements totaling around $12 billion for next year with options worth another $8 billion.</p>\n<h3>2. Less advanced pipeline</h3>\n<p>The differences between BioNTech's and Moderna's financial results don't fully explain the discrepancy in the valuations of the two vaccine stocks. There's another factor likely at play, though.</p>\n<p>Investors are always looking to the future. For biotechs like BioNTech and Moderna, that means their pipelines are important to their valuations. And investors probably are more excited about Moderna's pipeline.</p>\n<p>BioNTech doesn't currently have any late-stage candidate other than its COVID-19 vaccine. Moderna plans to advance its mRNA-1647 cytomegalovirus (CMV) vaccine into late-stage testing this year. The company thinks the CMV vaccine could generate sales of between $2 billion and $5 billion if it goes on to win regulatory approvals.</p>\n<p>Moderna also has a much larger cash stockpile to use in bolstering its pipeline than BioNTech does. As of June 30, 2021, Moderna's cash, cash equivalents, and investments totaled $12.2 billion. BioNTech's cash position stood at 914.1 million euros (nearly $1.1 billion) at the end of the second quarter.</p>\n<h3>3. Lower profile</h3>\n<p>There's another reason why BioNTech is so much smaller than Moderna that could be more important than you might think. BioNTech has a much lower public profile than Moderna does.</p>\n<p>Part of the challenge for BioNTech on this front is that it's overshadowed (especially in the U.S.) by its big partner, Pfizer. Many people refer only to the Pfizer and Moderna vaccines, leaving BioNTech out altogether.</p>\n<p>I wouldn't go as far as to call BioNTech the Rodney Dangerfield of biotech stocks. Unlike the late comedian, BioNTech does get respect from investors. Its sizzling stock performance this year proves the point. However, BioNTech hasn't received nearly as much hype as Moderna has.</p>\n<h3>Bigger isn't always better</h3>\n<p>For right or wrong, these three reasons go a long way toward explaining why BioNTech isn't nearly as big as Moderna. But bigger isn't always better.</p>\n<p>There are major questions about how sustainable Moderna's sky-high market cap actually is. One prominent analyst predicts that the stock will plunge close to 70% because its present valuation isn't warranted.</p>\n<p>Granted, quite a few Wall Street analysts think that BioNTech is overpriced at current levels, as well. However, there's an old saying: \"The bigger they are, the harder they fall.\" BioNTech's smaller size in comparison to Moderna just might be an advantage in the not-too-distant future.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Reasons BioNTech Isn't Nearly as Big as Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Reasons BioNTech Isn't Nearly as Big as Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 19:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/20/3-reasons-biontech-isnt-nearly-as-big-as-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna (NASDAQ:MRNA) has delivered impressive stock gains so far in 2021. However, BioNTech (NASDAQ:BNTX) is by far the bigger winner year to date, with its stock skyrocketing more than 330%.\nDespite...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/20/3-reasons-biontech-isnt-nearly-as-big-as-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/20/3-reasons-biontech-isnt-nearly-as-big-as-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160166577","content_text":"Moderna (NASDAQ:MRNA) has delivered impressive stock gains so far in 2021. However, BioNTech (NASDAQ:BNTX) is by far the bigger winner year to date, with its stock skyrocketing more than 330%.\nDespite its stronger stock performance this year, BioNTech's market cap is only a little over half the size of Moderna's. Here are three reasons BioNTech isn't nearly as big as Moderna right now.\n\nImage source: Getty Images.\n1. Lower expected sales\nIt makes sense that a company with significantly lower revenue and earnings would have a lower market cap than a rival with stronger financial results. But BioNTech actually outperformed Moderna on both fronts in the companies' latest quarterly updates.\nIn the second quarter, BioNTech reported revenue of 5.3 billion euros (around $6.2 billion). The German biotech posted earnings of nearly 2.8 billion euros (close to $3.3 billion). By comparison, Moderna's Q2 revenue totaled $4.4 billion, and it generated earnings of $2.8 billion.\nSo why does BioNTech have a lower valuation than Moderna? One main reason is that the company projects lower sales for full-year 2021. BioNTech expects full-year sales of 15.9 billion euros (roughly $18.6 billion). Moderna looks for full-year revenue of $20 billion. BioNTech and Pfizer split the profits on the sales of their COVID-19 vaccine. Moderna, however, pockets all of the revenue from its vaccine.\nNeither BioNTech nor Moderna has provided guidance for 2022 yet. However, Moderna revealed that it has already secured advanced purchase agreements totaling around $12 billion for next year with options worth another $8 billion.\n2. Less advanced pipeline\nThe differences between BioNTech's and Moderna's financial results don't fully explain the discrepancy in the valuations of the two vaccine stocks. There's another factor likely at play, though.\nInvestors are always looking to the future. For biotechs like BioNTech and Moderna, that means their pipelines are important to their valuations. And investors probably are more excited about Moderna's pipeline.\nBioNTech doesn't currently have any late-stage candidate other than its COVID-19 vaccine. Moderna plans to advance its mRNA-1647 cytomegalovirus (CMV) vaccine into late-stage testing this year. The company thinks the CMV vaccine could generate sales of between $2 billion and $5 billion if it goes on to win regulatory approvals.\nModerna also has a much larger cash stockpile to use in bolstering its pipeline than BioNTech does. As of June 30, 2021, Moderna's cash, cash equivalents, and investments totaled $12.2 billion. BioNTech's cash position stood at 914.1 million euros (nearly $1.1 billion) at the end of the second quarter.\n3. Lower profile\nThere's another reason why BioNTech is so much smaller than Moderna that could be more important than you might think. BioNTech has a much lower public profile than Moderna does.\nPart of the challenge for BioNTech on this front is that it's overshadowed (especially in the U.S.) by its big partner, Pfizer. Many people refer only to the Pfizer and Moderna vaccines, leaving BioNTech out altogether.\nI wouldn't go as far as to call BioNTech the Rodney Dangerfield of biotech stocks. Unlike the late comedian, BioNTech does get respect from investors. Its sizzling stock performance this year proves the point. However, BioNTech hasn't received nearly as much hype as Moderna has.\nBigger isn't always better\nFor right or wrong, these three reasons go a long way toward explaining why BioNTech isn't nearly as big as Moderna. But bigger isn't always better.\nThere are major questions about how sustainable Moderna's sky-high market cap actually is. One prominent analyst predicts that the stock will plunge close to 70% because its present valuation isn't warranted.\nGranted, quite a few Wall Street analysts think that BioNTech is overpriced at current levels, as well. However, there's an old saying: \"The bigger they are, the harder they fall.\" BioNTech's smaller size in comparison to Moderna just might be an advantage in the not-too-distant future.","news_type":1},"isVote":1,"tweetType":1,"viewCount":180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830718093,"gmtCreate":1629098391112,"gmtModify":1676529928975,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/830718093","repostId":"2159210604","repostType":2,"repost":{"id":"2159210604","pubTimestamp":1629097536,"share":"https://ttm.financial/m/news/2159210604?lang=&edition=fundamental","pubTime":"2021-08-16 15:05","market":"us","language":"en","title":"4 Pharma Stocks You Can Buy and Hold for 20 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2159210604","media":"Motley Fool","summary":"These drugmakers are built for the long run.","content":"<p><b>Key Points</b></p>\n<ul>\n <li>These two Motley Fool contributors picked two of the same big pharma stocks to buy and hold for 20 years: <a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> and <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a>.</li>\n <li>Bristol Myers Squibb and Pfizer also stand out as great pharma picks for the long term.</li>\n</ul>\n<p>A buy-and-hold strategy can work really well -- if you pick the right stocks.&nbsp;In this <i>Motley Fool Live</i> video <b>recorded on Aug. 4, 2021</b>, Motley Fool contributors Keith Speights and Brian Orelli discuss their top pharma stocks to buy and hold for 20 years.</p>\n<p><b>Keith Speights: </b>We had another question on Monday. I like this question. The person asked, \"Can you both rank your top three pharma/biotech holdings to hold for 10-20 years.\" Brian, I'll let you go first with your top three and then I'll chime in. Let's go with that longer time horizon of 20 years to hold.</p>\n<p><b>Brian Orelli:</b> Twenty years is an awful long time to hold. I think the obvious choice here is probably<b> <a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b>. Given the history and the diversity across the healthcare sector, I can almost guarantee it will be around in 20 years.</p>\n<p>I think it's probably also likely to beat the S&amp;P 500 over that time frame. The company does a really good job at growing earnings faster than revenue. That should drive the stock price. Even if the growth of the revenue is a little bit slower than the average S&amp;P 500 company.</p>\n<p>A few years ago, I probably would've gone with Celgene as my number two pick. But <b><a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb</a></b> obviously bought it out. A lot of that was due to the company's ability to do deals to in-license drugs and Bristol-Myers has a lot of those same qualities and where it looks to partner with companies and invest in them early and then develop those drugs. I'm going to pick up Bristol-Myers Squibb as my second pick, the ticker there's BMY.</p>\n<p>Then for my third pick, I'd go for <b><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></b>, taker there's VRTX. It's a bit more risky than the other two because we don't really know what Vertex's next growth franchise will be after it maximizes the opportunity in cystic fibrosis.</p>\n<p>But if you've been following the industry long enough and Vertex specifically long enough, you know, the Vertex was actually a hepatitis C drug developer pivoted to cystic fibrosis as its next move. That turned out to be a really good choice because <b>Gilead</b>&nbsp;came along with Sovaldi.</p>\n<p>Basically, that was so much of a better drug that doctors just stopped prescribing Vertex's Hepatitis C drug. But the company seemed to manage through that process fairly seamlessly. I think that they can manage through the next transition just as seamlessly, I hope.</p>\n<p><b>Speights:</b> Brian, I would definitely have to agree with you on Johnson &amp; Johnson, it's really diversified across healthcare. It's a leader in nearly every market, probably every market where it operates.</p>\n<p>The company is a cash cow. It has lots of money to invest and its own research and development plus make strategic acquisitions, and that's what it's done through the years. I think Johnson &amp; Johnson is an easy number <a href=\"https://laohu8.com/S/AONE.U\">one</a> pick to hold for 20 years. It's just so solid.</p>\n<p>I think I will go with Pfizer though maybe as my second pick. There's some uncertainty for the company with losing some exclusivity for drugs in the second half of this decade. But like Johnson and Johnson, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>&nbsp;has survived and thrived for a long time. It's adapted.</p>\n<p>The company has a huge pipeline. It's flushed with cash, especially with more money rolling in from its COVID-19 vaccine. I fully expect Pfizer to invest, if not in acquiring other companies and beefing up its pipeline through licensing deals.</p>\n<p>I think Pfizer is a pretty safe pick to hold for 20 years. Again, like Johnson and Johnson, it could beat the market. It might not give you these jaw-dropping returns, but I think it will be solid.</p>\n<p>My third pick, I hate to be a copycat, Brian, but I am going to go along with you on Vertex. I own the stock. I really like the stock. I think Vertex's monopoly in cystic fibrosis sets it up really nicely, at least into the next decade. There really aren't many competitors that are nipping at its heels at all. I think the most advanced CF drugs outside of Vertex's pipeline are in Phase II testing. Vertex just has a monopoly there.</p>\n<p>Also, look for the company to rack up some pipeline wins beyond CF. I'm not sure exactly where and I look for Vertex to make some acquisitions along the way too. It also has a really huge and growing cash stock policy. I like all those three.</p>\n<p>But you mentioned Bristol-Myers Squibb. I like it too. It's one of the stocks in my portfolio. I think investors couldn't go wrong with any of these stocks that we've mentioned.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Pharma Stocks You Can Buy and Hold for 20 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Pharma Stocks You Can Buy and Hold for 20 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-16 15:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/15/4-pharma-stocks-you-can-buy-and-hold-for-20-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nThese two Motley Fool contributors picked two of the same big pharma stocks to buy and hold for 20 years: Johnson & Johnson and Vertex Pharmaceuticals.\nBristol Myers Squibb and Pfizer also...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/15/4-pharma-stocks-you-can-buy-and-hold-for-20-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","VRTX":"福泰制药","PFE":"辉瑞","BMY":"施贵宝"},"source_url":"https://www.fool.com/investing/2021/08/15/4-pharma-stocks-you-can-buy-and-hold-for-20-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2159210604","content_text":"Key Points\n\nThese two Motley Fool contributors picked two of the same big pharma stocks to buy and hold for 20 years: Johnson & Johnson and Vertex Pharmaceuticals.\nBristol Myers Squibb and Pfizer also stand out as great pharma picks for the long term.\n\nA buy-and-hold strategy can work really well -- if you pick the right stocks. In this Motley Fool Live video recorded on Aug. 4, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss their top pharma stocks to buy and hold for 20 years.\nKeith Speights: We had another question on Monday. I like this question. The person asked, \"Can you both rank your top three pharma/biotech holdings to hold for 10-20 years.\" Brian, I'll let you go first with your top three and then I'll chime in. Let's go with that longer time horizon of 20 years to hold.\nBrian Orelli: Twenty years is an awful long time to hold. I think the obvious choice here is probably Johnson & Johnson. Given the history and the diversity across the healthcare sector, I can almost guarantee it will be around in 20 years.\nI think it's probably also likely to beat the S&P 500 over that time frame. The company does a really good job at growing earnings faster than revenue. That should drive the stock price. Even if the growth of the revenue is a little bit slower than the average S&P 500 company.\nA few years ago, I probably would've gone with Celgene as my number two pick. But Bristol-Myers Squibb obviously bought it out. A lot of that was due to the company's ability to do deals to in-license drugs and Bristol-Myers has a lot of those same qualities and where it looks to partner with companies and invest in them early and then develop those drugs. I'm going to pick up Bristol-Myers Squibb as my second pick, the ticker there's BMY.\nThen for my third pick, I'd go for Vertex Pharmaceuticals, taker there's VRTX. It's a bit more risky than the other two because we don't really know what Vertex's next growth franchise will be after it maximizes the opportunity in cystic fibrosis.\nBut if you've been following the industry long enough and Vertex specifically long enough, you know, the Vertex was actually a hepatitis C drug developer pivoted to cystic fibrosis as its next move. That turned out to be a really good choice because Gilead came along with Sovaldi.\nBasically, that was so much of a better drug that doctors just stopped prescribing Vertex's Hepatitis C drug. But the company seemed to manage through that process fairly seamlessly. I think that they can manage through the next transition just as seamlessly, I hope.\nSpeights: Brian, I would definitely have to agree with you on Johnson & Johnson, it's really diversified across healthcare. It's a leader in nearly every market, probably every market where it operates.\nThe company is a cash cow. It has lots of money to invest and its own research and development plus make strategic acquisitions, and that's what it's done through the years. I think Johnson & Johnson is an easy number one pick to hold for 20 years. It's just so solid.\nI think I will go with Pfizer though maybe as my second pick. There's some uncertainty for the company with losing some exclusivity for drugs in the second half of this decade. But like Johnson and Johnson, Pfizer has survived and thrived for a long time. It's adapted.\nThe company has a huge pipeline. It's flushed with cash, especially with more money rolling in from its COVID-19 vaccine. I fully expect Pfizer to invest, if not in acquiring other companies and beefing up its pipeline through licensing deals.\nI think Pfizer is a pretty safe pick to hold for 20 years. Again, like Johnson and Johnson, it could beat the market. It might not give you these jaw-dropping returns, but I think it will be solid.\nMy third pick, I hate to be a copycat, Brian, but I am going to go along with you on Vertex. I own the stock. I really like the stock. I think Vertex's monopoly in cystic fibrosis sets it up really nicely, at least into the next decade. There really aren't many competitors that are nipping at its heels at all. I think the most advanced CF drugs outside of Vertex's pipeline are in Phase II testing. Vertex just has a monopoly there.\nAlso, look for the company to rack up some pipeline wins beyond CF. I'm not sure exactly where and I look for Vertex to make some acquisitions along the way too. It also has a really huge and growing cash stock policy. I like all those three.\nBut you mentioned Bristol-Myers Squibb. I like it too. It's one of the stocks in my portfolio. I think investors couldn't go wrong with any of these stocks that we've mentioned.","news_type":1},"isVote":1,"tweetType":1,"viewCount":255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897029179,"gmtCreate":1628863726091,"gmtModify":1676529879430,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat//<a href=\"https://laohu8.com/U/3559509365538602\">@xavjy</a>: 9Ok","listText":"Huat//<a href=\"https://laohu8.com/U/3559509365538602\">@xavjy</a>: 9Ok","text":"Huat//@xavjy: 9Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/897029179","repostId":"1141206470","repostType":4,"repost":{"id":"1141206470","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628861824,"share":"https://ttm.financial/m/news/1141206470?lang=&edition=fundamental","pubTime":"2021-08-13 21:37","market":"us","language":"en","title":"BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1141206470","media":"Tiger Newspress","summary":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster ","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141206470","content_text":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.\nBioNTech was up 3% and Moderna gained 3%, while Pfizer , which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.\n\nLate on Thursday, the U.S. Food and Drug Administration authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.\nPfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.\nGoing forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.","news_type":1},"isVote":1,"tweetType":1,"viewCount":62,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897020683,"gmtCreate":1628863698842,"gmtModify":1676529879403,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/897020683","repostId":"1114512346","repostType":4,"repost":{"id":"1114512346","pubTimestamp":1628862113,"share":"https://ttm.financial/m/news/1114512346?lang=&edition=fundamental","pubTime":"2021-08-13 21:41","market":"us","language":"en","title":"Virgin Galactic falls as billionaire Branson sells stake worth $300 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1114512346","media":"Reuters","summary":"Shares of Virgin Galactic Holdings Inc fell more than 1% on Friday after its founder and British bil","content":"<p>Shares of Virgin Galactic Holdings Inc fell more than 1% on Friday after its founder and British billionaire Richard Branson sold a portion of his stake for nearly $300 million.</p>\n<p>Branson sold more than 10 million shares between Aug. 10 and 12, according to a regulatory filing&nbsp;from late Thursday.</p>\n<p>The move comes a month after the space tourism company completed its first fully crewed test flight into space with Branson on board.</p>\n<p>The latest share sale leaves Branson with about 46.3 million shares worth roughly $1.2 billion as of stock's last closing price. He had in April sold stock worth over $150 million.</p>\n<p>Branson's Virgin Investments is one of the biggest shareholders of the space tourism company and has a stake of about 22% as of June, according to Refinitiv data.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Virgin Galactic falls as billionaire Branson sells stake worth $300 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVirgin Galactic falls as billionaire Branson sells stake worth $300 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 21:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/virgin-galactic-falls-billionaire-branson-132508203.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Virgin Galactic Holdings Inc fell more than 1% on Friday after its founder and British billionaire Richard Branson sold a portion of his stake for nearly $300 million.\nBranson sold more than...</p>\n\n<a href=\"https://finance.yahoo.com/news/virgin-galactic-falls-billionaire-branson-132508203.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"source_url":"https://finance.yahoo.com/news/virgin-galactic-falls-billionaire-branson-132508203.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114512346","content_text":"Shares of Virgin Galactic Holdings Inc fell more than 1% on Friday after its founder and British billionaire Richard Branson sold a portion of his stake for nearly $300 million.\nBranson sold more than 10 million shares between Aug. 10 and 12, according to a regulatory filing from late Thursday.\nThe move comes a month after the space tourism company completed its first fully crewed test flight into space with Branson on board.\nThe latest share sale leaves Branson with about 46.3 million shares worth roughly $1.2 billion as of stock's last closing price. He had in April sold stock worth over $150 million.\nBranson's Virgin Investments is one of the biggest shareholders of the space tourism company and has a stake of about 22% as of June, according to Refinitiv data.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896421758,"gmtCreate":1628602439074,"gmtModify":1676529793251,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/896421758","repostId":"2158475046","repostType":4,"repost":{"id":"2158475046","pubTimestamp":1628600400,"share":"https://ttm.financial/m/news/2158475046?lang=&edition=fundamental","pubTime":"2021-08-10 21:00","market":"us","language":"en","title":"5 Growth Stocks With 110% to 393% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2158475046","media":"Motley Fool","summary":"Analysts are calling for significant gains in these fast-paced stocks.","content":"<p>For the past nine months, the stock market has been practically unstoppable. The benchmark <b>S&amp;P 500</b> hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March 23, 2020.</p>\n<p>But despite this record-breaking rally, Wall Street still sees value in a number of high-growth stocks. Based on the highest price target issued by a Wall Street investment bank or analyst, the following five growth stocks are expected to return 110% to as much as 393% to shareholders.</p>\n<h2>Coinbase Global: Implied upside of 152%</h2>\n<p>The first rapidly growing stock with abundant upside, at least according to investment firm D.A. Davidson, is cryptocurrency brokerage and ecosystem <b>Coinbase Global</b> (NASDAQ:COIN). If the lofty $650 price target set by D.A. Davidson comes to fruition, Coinbase would deliver gains of 152% to its shareholders, relative to where it closed this past weekend.</p>\n<p>On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, revenue and profits have soared for Coinbase. Net revenue in the first quarter catapulted to $1.6 billion from $179 million in the year-ago period, with net income of $771 million, up from $32 million.&nbsp; Growing institutional interest in digital currencies like <b>Bitcoin</b>&nbsp;and <b>Ethereum</b>, along with rapidly rising prices for the Big <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> in crypto, drove investors to the platform.</p>\n<p>On the other hand, the Coinbase operating model has virtually no barriers to entry, and its trading fees are at risk of constantly being undercut by other cryptocurrency exchanges. Additionally, instead of thriving off of innovation, Coinbase is effectively held hostage by external interest in Bitcoin and Ethereum and the price performance of the Big <a href=\"https://laohu8.com/S/TWOA\">Two</a> digital currencies. When Bitcoin declined by 80% following its late 2017 peak, Coinbase's revenue was nearly halved.</p>\n<p>Long story short, while sales growth has been impressive, Coinbase isn't charting its own path to success. Its reliance on external factors makes $650 a target that's unlikely to be reached.</p>\n<h2>Cresco Labs: Implied upside of 160%</h2>\n<p>One industry where you'll find no shortage of aggressive price targets is cannabis -- specifically the U.S. pot industry. If the highest price target assigned by Wall Street of nearly $29 for <b>Cresco Labs</b> (OTC:CRLBF) proves accurate, investors in this marijuana stock could enjoy upside of 160%. And unlike Coinbase, this is a price target that I believe can eventually be achieved.</p>\n<p>Like other multistate operators, Cresco is expanding its retail operations organically and via acquisition. In June, it opened its 33rd dispensary nationally, and it holds enough retail licenses in its back pocket to eventually have closer to four dozen operating dispensaries.</p>\n<p>From a retail perspective, Cresco appears to be focusing its efforts on high-dollar states, as well as those that issue licenses on a limited basis (e.g., Illinois, Ohio, and Pennsylvania). The advantage of limited-license states is they're purposefully reining in competition. That means Cresco will have a genuine opportunity to build up its brands in key markets without the fear of being overrun by a multistate operator with deeper pockets.</p>\n<p>Cresco is also the cannabis industry's leading wholesaler of weed. Even though wholesale cannabis produces weaker margins than retail, Cresco Labs has more than enough volume to make up for it. That's because it holds one of only a handful of cannabis distribution licenses in California. This license gives the company access to more than 575 dispensaries throughout the Golden State.</p>\n<h2>Baidu: Implied upside of 141%</h2>\n<p>In spite of a recent crackdown by the Chinese government on a host of tech stocks, Wall Street remains largely undeterred that China-based internet search giant <b>Baidu</b> (NASDAQ:BIDU) will head higher. In fact, based on the high-water analyst price target of nearly $395, Baidu could offer gains of as much as 141%.</p>\n<p>The most obvious catalyst for Baidu is its domestically dominant internet search engine. According to GlobalStats, Baidu has controlled between 66.9% and 79.9% of all internet search share in China over the trailing 12 months.&nbsp; Just as advertisers line up for placement on <b>Alphabet</b>'s leading internet search engine Google, they're willing to pay big bucks to reach internet users in China.</p>\n<p>Beyond the sustainable double-digit sales growth potential of internet search, Baidu is seeing exceptional early returns from its investment in cloud services and artificial intelligence (AI). Though these ancillary operations only accounted for 21% of first-quarter sales, revenue jumped by 70%.&nbsp; What's more, cloud services and AI offer higher margins, relative to marketing revenue. Over time, we should see these ancillary segments really boost Baidu's cash flow generation.</p>\n<p>While I wouldn't count on $395 anytime soon, I do believe $395 is a reasonable future price target for the fast-growing Baidu.</p>\n<h2><a href=\"https://laohu8.com/S/ICPT\">Intercept Pharmaceuticals</a>: Implied upside of 393%</h2>\n<p>If you're looking for a company with make-or-break opportunity, biotech stock <b>Intercept Pharmaceuticals</b> (NASDAQ:ICPT) might be for you. This polarizing small-cap drug developer with a focus on therapies to treat liver diseases has price targets from Wall Street ranging from as low as $16 to as high as $82. If this upper target comes to fruition, shareholders would nearly quintuple their money.</p>\n<p>The promise and peril for Intercept lies with obeticholic acid (OCA), an experimental treatment for nonalcoholic steatohepatitis (NASH), which affects between 2% and 5% of adults in this country and has no cure. In one respect, OCA met one of its two co-primary endpoints in the phase 3 Regenerate study -- a statistically significant improvement in fibrosis without a worsening of NASH. However, the highest and most-effective dose also led to a large number of cases of pruritus (itching) in trial participants.</p>\n<p>Ultimately, Intercept's top drug candidate received a Complete Response Letter from the Food and Drug Administration. The plan for Intercept is to provide additional safety and trial data, with the goal of resubmitting the application. Even if OCA is approved and targeted at a small subset of the sickest patients, it could offer blockbuster sales potential in this untapped indication.</p>\n<p>The other consideration here is Ocaliva (the brand-name version of OCA) is already approved to treat primary biliary cholangitis and is on track to bring in $325 million to $340 million in sales this year.&nbsp; With an existing safety profile and a modestly growing sales floor, Intercept's risk/reward ratio looks favorable.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h2>Nio: Implied upside of 110%</h2>\n<p>A fifth and final growth stock with serious upside, according to Wall Street, is China-based electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO). If the loftiest price target of more than $92 were to come true, investors would see their shares more than double in value.</p>\n<p>The excitement surrounding Nio has to do with the impending electrification of China's automobiles. The Society of Automotive Engineers of China predicted back in 2018 that half of all vehicles sold in the world's largest auto market would run on alternative energy by 2035. With the EV industry predominantly nascent in China, the door is wide open for multiple companies to gobble up significant share.</p>\n<p>Having resolved any funding concerns with capital raises, the focus now is on Nio's production expansion. Even facing industrywide chip shortages, Nio still managed to deliver almost 21,900 EVs during the second quarter, which was more than double what it delivered in the year-ago period.&nbsp; Assuming chip supply issues can be resolved somewhat soon, Nio's annual EV run-rate output should climb toward 150,000.</p>\n<p>Additionally, Nio is enticing new buyers with its battery-as-a-service program. Enrolling in this monthly fee-based program can lop thousands of dollars off the initial purchase price of a vehicle, all while improving buyer loyalty for Nio.</p>\n<p>A $92 price target might be a bit much for a company that's produced fewer than 118,000 EVs inception. Nevertheless, its execution of late is commendable.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Growth Stocks With 110% to 393% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Growth Stocks With 110% to 393% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past nine months, the stock market has been practically unstoppable. The benchmark S&P 500 hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRLBF":"Cresco Labs Inc.","COIN":"Coinbase Global, Inc.","BIDU":"百度","ICPT":"Intercept Pharmaceuticals","NIO":"蔚来"},"source_url":"https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158475046","content_text":"For the past nine months, the stock market has been practically unstoppable. The benchmark S&P 500 hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March 23, 2020.\nBut despite this record-breaking rally, Wall Street still sees value in a number of high-growth stocks. Based on the highest price target issued by a Wall Street investment bank or analyst, the following five growth stocks are expected to return 110% to as much as 393% to shareholders.\nCoinbase Global: Implied upside of 152%\nThe first rapidly growing stock with abundant upside, at least according to investment firm D.A. Davidson, is cryptocurrency brokerage and ecosystem Coinbase Global (NASDAQ:COIN). If the lofty $650 price target set by D.A. Davidson comes to fruition, Coinbase would deliver gains of 152% to its shareholders, relative to where it closed this past weekend.\nOn one hand, revenue and profits have soared for Coinbase. Net revenue in the first quarter catapulted to $1.6 billion from $179 million in the year-ago period, with net income of $771 million, up from $32 million.  Growing institutional interest in digital currencies like Bitcoin and Ethereum, along with rapidly rising prices for the Big Two in crypto, drove investors to the platform.\nOn the other hand, the Coinbase operating model has virtually no barriers to entry, and its trading fees are at risk of constantly being undercut by other cryptocurrency exchanges. Additionally, instead of thriving off of innovation, Coinbase is effectively held hostage by external interest in Bitcoin and Ethereum and the price performance of the Big Two digital currencies. When Bitcoin declined by 80% following its late 2017 peak, Coinbase's revenue was nearly halved.\nLong story short, while sales growth has been impressive, Coinbase isn't charting its own path to success. Its reliance on external factors makes $650 a target that's unlikely to be reached.\nCresco Labs: Implied upside of 160%\nOne industry where you'll find no shortage of aggressive price targets is cannabis -- specifically the U.S. pot industry. If the highest price target assigned by Wall Street of nearly $29 for Cresco Labs (OTC:CRLBF) proves accurate, investors in this marijuana stock could enjoy upside of 160%. And unlike Coinbase, this is a price target that I believe can eventually be achieved.\nLike other multistate operators, Cresco is expanding its retail operations organically and via acquisition. In June, it opened its 33rd dispensary nationally, and it holds enough retail licenses in its back pocket to eventually have closer to four dozen operating dispensaries.\nFrom a retail perspective, Cresco appears to be focusing its efforts on high-dollar states, as well as those that issue licenses on a limited basis (e.g., Illinois, Ohio, and Pennsylvania). The advantage of limited-license states is they're purposefully reining in competition. That means Cresco will have a genuine opportunity to build up its brands in key markets without the fear of being overrun by a multistate operator with deeper pockets.\nCresco is also the cannabis industry's leading wholesaler of weed. Even though wholesale cannabis produces weaker margins than retail, Cresco Labs has more than enough volume to make up for it. That's because it holds one of only a handful of cannabis distribution licenses in California. This license gives the company access to more than 575 dispensaries throughout the Golden State.\nBaidu: Implied upside of 141%\nIn spite of a recent crackdown by the Chinese government on a host of tech stocks, Wall Street remains largely undeterred that China-based internet search giant Baidu (NASDAQ:BIDU) will head higher. In fact, based on the high-water analyst price target of nearly $395, Baidu could offer gains of as much as 141%.\nThe most obvious catalyst for Baidu is its domestically dominant internet search engine. According to GlobalStats, Baidu has controlled between 66.9% and 79.9% of all internet search share in China over the trailing 12 months.  Just as advertisers line up for placement on Alphabet's leading internet search engine Google, they're willing to pay big bucks to reach internet users in China.\nBeyond the sustainable double-digit sales growth potential of internet search, Baidu is seeing exceptional early returns from its investment in cloud services and artificial intelligence (AI). Though these ancillary operations only accounted for 21% of first-quarter sales, revenue jumped by 70%.  What's more, cloud services and AI offer higher margins, relative to marketing revenue. Over time, we should see these ancillary segments really boost Baidu's cash flow generation.\nWhile I wouldn't count on $395 anytime soon, I do believe $395 is a reasonable future price target for the fast-growing Baidu.\nIntercept Pharmaceuticals: Implied upside of 393%\nIf you're looking for a company with make-or-break opportunity, biotech stock Intercept Pharmaceuticals (NASDAQ:ICPT) might be for you. This polarizing small-cap drug developer with a focus on therapies to treat liver diseases has price targets from Wall Street ranging from as low as $16 to as high as $82. If this upper target comes to fruition, shareholders would nearly quintuple their money.\nThe promise and peril for Intercept lies with obeticholic acid (OCA), an experimental treatment for nonalcoholic steatohepatitis (NASH), which affects between 2% and 5% of adults in this country and has no cure. In one respect, OCA met one of its two co-primary endpoints in the phase 3 Regenerate study -- a statistically significant improvement in fibrosis without a worsening of NASH. However, the highest and most-effective dose also led to a large number of cases of pruritus (itching) in trial participants.\nUltimately, Intercept's top drug candidate received a Complete Response Letter from the Food and Drug Administration. The plan for Intercept is to provide additional safety and trial data, with the goal of resubmitting the application. Even if OCA is approved and targeted at a small subset of the sickest patients, it could offer blockbuster sales potential in this untapped indication.\nThe other consideration here is Ocaliva (the brand-name version of OCA) is already approved to treat primary biliary cholangitis and is on track to bring in $325 million to $340 million in sales this year.  With an existing safety profile and a modestly growing sales floor, Intercept's risk/reward ratio looks favorable.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: Implied upside of 110%\nA fifth and final growth stock with serious upside, according to Wall Street, is China-based electric vehicle (EV) manufacturer Nio (NYSE:NIO). If the loftiest price target of more than $92 were to come true, investors would see their shares more than double in value.\nThe excitement surrounding Nio has to do with the impending electrification of China's automobiles. The Society of Automotive Engineers of China predicted back in 2018 that half of all vehicles sold in the world's largest auto market would run on alternative energy by 2035. With the EV industry predominantly nascent in China, the door is wide open for multiple companies to gobble up significant share.\nHaving resolved any funding concerns with capital raises, the focus now is on Nio's production expansion. Even facing industrywide chip shortages, Nio still managed to deliver almost 21,900 EVs during the second quarter, which was more than double what it delivered in the year-ago period.  Assuming chip supply issues can be resolved somewhat soon, Nio's annual EV run-rate output should climb toward 150,000.\nAdditionally, Nio is enticing new buyers with its battery-as-a-service program. Enrolling in this monthly fee-based program can lop thousands of dollars off the initial purchase price of a vehicle, all while improving buyer loyalty for Nio.\nA $92 price target might be a bit much for a company that's produced fewer than 118,000 EVs inception. Nevertheless, its execution of late is commendable.","news_type":1},"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896429923,"gmtCreate":1628602346362,"gmtModify":1676529793100,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896429923","repostId":"2158047569","repostType":4,"repost":{"id":"2158047569","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628600820,"share":"https://ttm.financial/m/news/2158047569?lang=&edition=fundamental","pubTime":"2021-08-10 21:07","market":"us","language":"en","title":"U.S. Senate poised to pass $1 trillion infrastructure bill, debate $3.5 trillion budget plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2158047569","media":"Reuters","summary":"WASHINGTON, Aug 10 (Reuters) - The U.S. Senate on Tuesday is set to hand President Joe Biden a $1 tr","content":"<p>WASHINGTON, Aug 10 (Reuters) - The U.S. Senate on Tuesday is set to hand President Joe Biden a $1 trillion victory when it votes to pass <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the largest infrastructure investment bills in decades and then launches debate on a budget framework aimed at setting the stage for $3.5 trillion in additional investments.</p>\n<p>Taken together, the measures, if eventually enacted into law, would jump-start road and bridge-building projects across the United States over the next five years and new social programs over the next decade.</p>\n<p>Democratic Senate Majority Leader Chuck Schumer late on Monday set the vote on the bipartisan infrastructure bill for 11 a.m. (1500 GMT) on Tuesday.</p>\n<p>If the Senate, as expected, passes the bill, many rural communities would be in line to get broadband internet service, potentially boosting their economies.</p>\n<p>Once passed, the legislation would go to the Democratic-controlled House of Representatives for consideration sometime this fall.</p>\n<p>An around-the-clock session could then be in store for the Senate as it aims to debate and pass the larger, $3.5 trillion budget plan.</p>\n<p>In order to move through the evenly divided Senate without Republican support, Democrats aim to employ a \"reconciliation\" procedure that would allow them to advance the budget plan this week and implementing legislation later this year on simple majority votes.</p>\n<p>The budget plan would provide various Senate committees with top-line spending levels for a wide range of federal initiatives, including helping the elderly get home healthcare and more families afford early childhood education.</p>\n<p>It also would provide tuition-free community college and foster major investments in programs to significantly reduce carbon emissions blamed for climate change.</p>\n<p>Later, Senate committees would have to fill in the details for scores of federal programs.</p>\n<p>The budget blueprint was formally unveiled on Monday, the same day a U.N. climate panel warned that global warming was reaching emergency levels, or what United Nations Secretary-General Antonio Guterres described as a \"code red for humanity.\"</p>\n<p>Referring to the budget initiative, Democratic Senator Gary Peters, who represents the auto-manufacturing state of Michigan, said during debate on Monday: \"Not only will this set us on a path to a more sustainable future, it helps grow America's domestic manufacturing sector.\"</p>\n<p>Republicans, however, have dismissed the Democrats' budget plan as a \"socialist\" waste of money. They vow to oppose it.</p>\n<p>House Speaker Nancy Pelosi, the top Democrat in Congress, has warned that the Senate must pass both the $1 trillion infrastructure bill and the $3.5 trillion measures before it will act.</p>\n<p>Senate passage of the infrastructure bill and the budget plan would clear the way for it to begin a month-long summer break.</p>\n<p>When Congress returns in September, it will not only debate the large investment measures but have to fund government activities for the fiscal year beginning on Oct. 1, increase Washington's borrowing authority and possibly try to pass a voting reform bill.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Senate poised to pass $1 trillion infrastructure bill, debate $3.5 trillion budget plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Senate poised to pass $1 trillion infrastructure bill, debate $3.5 trillion budget plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-10 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WASHINGTON, Aug 10 (Reuters) - The U.S. Senate on Tuesday is set to hand President Joe Biden a $1 trillion victory when it votes to pass <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the largest infrastructure investment bills in decades and then launches debate on a budget framework aimed at setting the stage for $3.5 trillion in additional investments.</p>\n<p>Taken together, the measures, if eventually enacted into law, would jump-start road and bridge-building projects across the United States over the next five years and new social programs over the next decade.</p>\n<p>Democratic Senate Majority Leader Chuck Schumer late on Monday set the vote on the bipartisan infrastructure bill for 11 a.m. (1500 GMT) on Tuesday.</p>\n<p>If the Senate, as expected, passes the bill, many rural communities would be in line to get broadband internet service, potentially boosting their economies.</p>\n<p>Once passed, the legislation would go to the Democratic-controlled House of Representatives for consideration sometime this fall.</p>\n<p>An around-the-clock session could then be in store for the Senate as it aims to debate and pass the larger, $3.5 trillion budget plan.</p>\n<p>In order to move through the evenly divided Senate without Republican support, Democrats aim to employ a \"reconciliation\" procedure that would allow them to advance the budget plan this week and implementing legislation later this year on simple majority votes.</p>\n<p>The budget plan would provide various Senate committees with top-line spending levels for a wide range of federal initiatives, including helping the elderly get home healthcare and more families afford early childhood education.</p>\n<p>It also would provide tuition-free community college and foster major investments in programs to significantly reduce carbon emissions blamed for climate change.</p>\n<p>Later, Senate committees would have to fill in the details for scores of federal programs.</p>\n<p>The budget blueprint was formally unveiled on Monday, the same day a U.N. climate panel warned that global warming was reaching emergency levels, or what United Nations Secretary-General Antonio Guterres described as a \"code red for humanity.\"</p>\n<p>Referring to the budget initiative, Democratic Senator Gary Peters, who represents the auto-manufacturing state of Michigan, said during debate on Monday: \"Not only will this set us on a path to a more sustainable future, it helps grow America's domestic manufacturing sector.\"</p>\n<p>Republicans, however, have dismissed the Democrats' budget plan as a \"socialist\" waste of money. They vow to oppose it.</p>\n<p>House Speaker Nancy Pelosi, the top Democrat in Congress, has warned that the Senate must pass both the $1 trillion infrastructure bill and the $3.5 trillion measures before it will act.</p>\n<p>Senate passage of the infrastructure bill and the budget plan would clear the way for it to begin a month-long summer break.</p>\n<p>When Congress returns in September, it will not only debate the large investment measures but have to fund government activities for the fiscal year beginning on Oct. 1, increase Washington's borrowing authority and possibly try to pass a voting reform bill.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158047569","content_text":"WASHINGTON, Aug 10 (Reuters) - The U.S. Senate on Tuesday is set to hand President Joe Biden a $1 trillion victory when it votes to pass one of the largest infrastructure investment bills in decades and then launches debate on a budget framework aimed at setting the stage for $3.5 trillion in additional investments.\nTaken together, the measures, if eventually enacted into law, would jump-start road and bridge-building projects across the United States over the next five years and new social programs over the next decade.\nDemocratic Senate Majority Leader Chuck Schumer late on Monday set the vote on the bipartisan infrastructure bill for 11 a.m. (1500 GMT) on Tuesday.\nIf the Senate, as expected, passes the bill, many rural communities would be in line to get broadband internet service, potentially boosting their economies.\nOnce passed, the legislation would go to the Democratic-controlled House of Representatives for consideration sometime this fall.\nAn around-the-clock session could then be in store for the Senate as it aims to debate and pass the larger, $3.5 trillion budget plan.\nIn order to move through the evenly divided Senate without Republican support, Democrats aim to employ a \"reconciliation\" procedure that would allow them to advance the budget plan this week and implementing legislation later this year on simple majority votes.\nThe budget plan would provide various Senate committees with top-line spending levels for a wide range of federal initiatives, including helping the elderly get home healthcare and more families afford early childhood education.\nIt also would provide tuition-free community college and foster major investments in programs to significantly reduce carbon emissions blamed for climate change.\nLater, Senate committees would have to fill in the details for scores of federal programs.\nThe budget blueprint was formally unveiled on Monday, the same day a U.N. climate panel warned that global warming was reaching emergency levels, or what United Nations Secretary-General Antonio Guterres described as a \"code red for humanity.\"\nReferring to the budget initiative, Democratic Senator Gary Peters, who represents the auto-manufacturing state of Michigan, said during debate on Monday: \"Not only will this set us on a path to a more sustainable future, it helps grow America's domestic manufacturing sector.\"\nRepublicans, however, have dismissed the Democrats' budget plan as a \"socialist\" waste of money. They vow to oppose it.\nHouse Speaker Nancy Pelosi, the top Democrat in Congress, has warned that the Senate must pass both the $1 trillion infrastructure bill and the $3.5 trillion measures before it will act.\nSenate passage of the infrastructure bill and the budget plan would clear the way for it to begin a month-long summer break.\nWhen Congress returns in September, it will not only debate the large investment measures but have to fund government activities for the fiscal year beginning on Oct. 1, increase Washington's borrowing authority and possibly try to pass a voting reform bill.","news_type":1},"isVote":1,"tweetType":1,"viewCount":136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898836610,"gmtCreate":1628483105430,"gmtModify":1703506832482,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898836610","repostId":"1181892026","repostType":2,"isVote":1,"tweetType":1,"viewCount":228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891147187,"gmtCreate":1628359403949,"gmtModify":1703505380889,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/891147187","repostId":"1143051031","repostType":4,"isVote":1,"tweetType":1,"viewCount":75,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899234942,"gmtCreate":1628197535786,"gmtModify":1703502849384,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899234942","repostId":"1173170520","repostType":4,"isVote":1,"tweetType":1,"viewCount":84,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":813702171,"gmtCreate":1630241961193,"gmtModify":1676530249644,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/813702171","repostId":"2163304079","repostType":4,"repost":{"id":"2163304079","pubTimestamp":1630193325,"share":"https://ttm.financial/m/news/2163304079?lang=&edition=fundamental","pubTime":"2021-08-29 07:28","market":"us","language":"en","title":"Researchers, cybersecurity agency urge action by Microsoft cloud database users","url":"https://stock-news.laohu8.com/highlight/detail?id=2163304079","media":"Reuters","summary":"(Reuters) - Researchers who discovered a massive flaw in the main databases stored in Microsoft Corp","content":"<p>(Reuters) - Researchers who discovered a massive flaw in the main databases stored in Microsoft Corp's Azure cloud platform on Saturday urged all users to change their digital access keys, not just the 3,300 it notified this week.</p>\n<p>As first reported by Reuters https://www.reuters.com/technology/exclusive-microsoft-warns-thousands-cloud-customers-exposed-databases-emails-2021-08-26, researchers at a cloud security company called Wiz discovered this month they could have gained access to the primary digital keys for most users of the Cosmos DB database system, allowing them to steal, change or delete millions of records.</p>\n<p>Alerted by Wiz, Microsoft rapidly fixed the configuration mistake that would have made it easy for any Cosmos user to get into other customers' databases, then notified some users Thursday to change their keys.</p>\n<p>In a blog post Friday, Microsoft said it warned customers which had set up Cosmos access during the weeklong research period. It found no evidence that any attackers had used the same flaw to get into customer data, it noted.</p>\n<p>\"Our investigation shows no unauthorized access other than the researcher activity,\" Microsoft wrote. \"Notifications have been sent to all customers that could be potentially affected due to researcher activity,\" it said, perhaps referring to the chance that the technique had leaked from Wiz.</p>\n<p>\"Though no customer data was accessed, it is recommended you regenerate your primary read-write keys,\" it said.</p>\n<p>The U.S. Department of Homeland Security's Cybersecurity and Infrastructure Security Agency used stronger language in a bulletin Friday, making clear it was speaking not just to those notified.</p>\n<p>\"CISA strongly encourages Azure Cosmos DB customers to roll and regenerate their certificate key,\" the agency said https://us-cert.cisa.gov/ncas/current-activity/2021/08/27/microsoft-azure-cosmos-db-guidance.</p>\n<p>Experts at Wiz, founded by four veterans of Azure's in-house security team, agreed.</p>\n<p>\"In my estimation, it's really hard for them, if not impossible, to completely rule out that someone used this before,\" said <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the four, Wiz Chief Technology Officer Ami Luttwak. At Microsoft he developed tools for logging cloud security incidents.</p>\n<p>Microsoft did not give a direct answer when asked if it had comprehensive logs for the two years when the Jupyter Notebook feature was misconfigured, or had used another way to rule out access abuse.</p>\n<p>\"We expanded our search beyond the researcher's activities to look for all possible activity for current and similar events in the past,\" said spokesman Ross Richendrfer, declining to address other questions.</p>\n<p>Wiz said Microsoft had worked closely with it on the research but had declined to say how it could be sure earlier customers were safe.</p>\n<p>\"It's terrifying. I really hope than no one besides us found this bug,\" said one of the lead researchers on the project at Wiz, Sagi Tzadik.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Researchers, cybersecurity agency urge action by Microsoft cloud database users</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResearchers, cybersecurity agency urge action by Microsoft cloud database users\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-29 07:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/researchers-cybersecurity-agency-urge-action-232845273.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Researchers who discovered a massive flaw in the main databases stored in Microsoft Corp's Azure cloud platform on Saturday urged all users to change their digital access keys, not just ...</p>\n\n<a href=\"https://finance.yahoo.com/news/researchers-cybersecurity-agency-urge-action-232845273.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://finance.yahoo.com/news/researchers-cybersecurity-agency-urge-action-232845273.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2163304079","content_text":"(Reuters) - Researchers who discovered a massive flaw in the main databases stored in Microsoft Corp's Azure cloud platform on Saturday urged all users to change their digital access keys, not just the 3,300 it notified this week.\nAs first reported by Reuters https://www.reuters.com/technology/exclusive-microsoft-warns-thousands-cloud-customers-exposed-databases-emails-2021-08-26, researchers at a cloud security company called Wiz discovered this month they could have gained access to the primary digital keys for most users of the Cosmos DB database system, allowing them to steal, change or delete millions of records.\nAlerted by Wiz, Microsoft rapidly fixed the configuration mistake that would have made it easy for any Cosmos user to get into other customers' databases, then notified some users Thursday to change their keys.\nIn a blog post Friday, Microsoft said it warned customers which had set up Cosmos access during the weeklong research period. It found no evidence that any attackers had used the same flaw to get into customer data, it noted.\n\"Our investigation shows no unauthorized access other than the researcher activity,\" Microsoft wrote. \"Notifications have been sent to all customers that could be potentially affected due to researcher activity,\" it said, perhaps referring to the chance that the technique had leaked from Wiz.\n\"Though no customer data was accessed, it is recommended you regenerate your primary read-write keys,\" it said.\nThe U.S. Department of Homeland Security's Cybersecurity and Infrastructure Security Agency used stronger language in a bulletin Friday, making clear it was speaking not just to those notified.\n\"CISA strongly encourages Azure Cosmos DB customers to roll and regenerate their certificate key,\" the agency said https://us-cert.cisa.gov/ncas/current-activity/2021/08/27/microsoft-azure-cosmos-db-guidance.\nExperts at Wiz, founded by four veterans of Azure's in-house security team, agreed.\n\"In my estimation, it's really hard for them, if not impossible, to completely rule out that someone used this before,\" said one of the four, Wiz Chief Technology Officer Ami Luttwak. At Microsoft he developed tools for logging cloud security incidents.\nMicrosoft did not give a direct answer when asked if it had comprehensive logs for the two years when the Jupyter Notebook feature was misconfigured, or had used another way to rule out access abuse.\n\"We expanded our search beyond the researcher's activities to look for all possible activity for current and similar events in the past,\" said spokesman Ross Richendrfer, declining to address other questions.\nWiz said Microsoft had worked closely with it on the research but had declined to say how it could be sure earlier customers were safe.\n\"It's terrifying. I really hope than no one besides us found this bug,\" said one of the lead researchers on the project at Wiz, Sagi Tzadik.","news_type":1},"isVote":1,"tweetType":1,"viewCount":180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890133390,"gmtCreate":1628086203410,"gmtModify":1703500987195,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/890133390","repostId":"1106185106","repostType":4,"repost":{"id":"1106185106","pubTimestamp":1628085241,"share":"https://ttm.financial/m/news/1106185106?lang=&edition=fundamental","pubTime":"2021-08-04 21:54","market":"us","language":"en","title":"Treasury To Start Reducing Bond Auction Sizes As Soon As November","url":"https://stock-news.laohu8.com/highlight/detail?id=1106185106","media":"zerohedge","summary":"Heading into today's quarterly refunding announcement, the bond market was on edge over the (low) po","content":"<p>Heading into today's quarterly refunding announcement, the bond market was on edge over the (low) possibility widely discussed on sellside desks, that the Treasury could cut trim coupon auction sizes in the next few months to coincide with the Fed's tapering as the Treasury's funding needs have gradually emerged to be less than expected thanks to higher than expected tax revenues. In fact, according to some the drop in yields in recent weeks has been not due to the ongoing monster squeeze but due to expectations that there will be less TSY supply than demand.</p>\n<p>So when the Treasury released itslatest refunding statement(whose highlights hit about 10 mins early after some newswire broke the embargo), battered TSY bears breathed a sigh of relief because the Treasury said that contrary growing expectations, it \"<b>does not anticipate making any changes to nominal coupon and FRN auction sizes over the next quarter</b>.\" Here is the proposed treasury issuance scheduled for Q3:</p>\n<p><img src=\"https://static.tigerbbs.com/38e4d7e4d0f23901ba21254476fb0640\" tg-width=\"674\" tg-height=\"923\" width=\"100%\" height=\"auto\"></p>\n<p>However, in line with expectations, \"<b>continuing current issuance sizes and patterns may provide more borrowing capacity than is needed to address borrowing needs over the intermediate-to-long term</b>.\" As a result, the \"Treasury will continue to engage with a variety of market participants to better understand the supply and demand dynamics for existing securities,<b>with an expectation of announcing an initial set of auction size reductions as soon as the November refunding announcement</b>\" which is also in line with what most Primary Dealers had expected (among the 24 primary dealers in U.S. government securities, j<i>ust three expected smaller auctions during the August-to-October quarter, with many more seeing an announcement in November).</i>&nbsp; In other words,<b>shortly after the Fed's taper announcement at or just after Jackson Hole, the Treasury will follow up with an issuance cut of its own.</b></p>\n<p><img src=\"https://static.tigerbbs.com/c4ea04a7e2abe81b943385a9bdeab027\" tg-width=\"661\" tg-height=\"495\" width=\"100%\" height=\"auto\">So if no changes in coupon sizes, will Bill issuance at least shrink? You bet: as the Treasury added, \"seasonal or unexpected variations in borrowing needs over the next quarter is to be met by changes in bill auction sizes and Cash Management Bills (CMBs).\"&nbsp; Additionally, the Treasury will<b>end weekly issuance of 6-week CMBs later this month</b>:</p>\n<blockquote>\n \"the amount of net new cash still being raised from coupon issuance will allow Treasury to continue gradual reductions in bills as a percent of Treasury debt outstanding, in a manner consistent with recommendations made by the Treasury Borrowing Advisory Committee (TBAC) at its November 2020 meeting.&nbsp; Accordingly,\n <b>Treasury plans to further modify its regular cadence of CMBs.&nbsp; Treasury anticipates that weekly issuance of the 6-week CMBs will cease after settlement on August 19, whereas weekly issuance of the 17-week CMBs will continue at least through the end of October</b>.\n</blockquote>\n<p>Also of note, now that the US has triggered the debt ceiling extension measures which have an impact on how much cash the Treasury can hold at the current moment ($450BN), the Treasury said that it is unsure how long extraordinary measures put in place due to the debt ceiling will last:</p>\n<blockquote>\n As Secretary Yellen recently outlined in a July 23 letter to Congress, the period of time that extraordinary measures may last is subject to considerable uncertainty due to a variety of factors, including the challenges of forecasting the payments and receipts of the U.S. government months into the future, exacerbated by the heightened uncertainty in payments and receipts related to the economic impact of the pandemic.\n <b>Given this, Treasury is not able to currently provide a specific estimate of how long extraordinary measures will last.</b>\n</blockquote>\n<p>While it was of secondary importance, the Treasury also revealed the details of next week's auctions a/k/a the quarterly refunding offering, which&nbsp; was in line with expectations. Specifically, the Treasury will offer $126 billion of Treasuries to refund $58.6 billion of Treasury notes and bonds maturing on August 15, 2021.&nbsp;<b>This issuance will raise new cash of approximately $67.4 billion</b>. The securities are:</p>\n<ul>\n <li>A 3-year note in the amount of $58 billion, as expected</li>\n <li>A 10-year note in the amount of $41 billion, as expected</li>\n <li>A 30-year bond in the amount of $27 billion, as expected</li>\n</ul>\n<p>Going back to the Treasury's coupon shrinkage plans, theMinutes of the latest Treasury Borrowing Advisory Committeerevealed that the committee reviewed a presentation presentation about potential adjustments to coupon auction sizes in the coming years,,,</p>\n<p><img src=\"https://static.tigerbbs.com/0e1a37f22f9f748507c3370311dece35\" tg-width=\"1026\" tg-height=\"780\" width=\"100%\" height=\"auto\"></p>\n<p>... based on the presenting member’s assessment that the current auction schedule will likely leave Treasury significantly overfunded.</p>\n<p><img src=\"https://static.tigerbbs.com/54a5416fc7b72a56cb803a006a63256f\" tg-width=\"1022\" tg-height=\"782\" width=\"100%\" height=\"auto\">It noted that several significant financing uncertainties were also highlighted by the presenting member that will require a flexible approach within the regular and predictable paradigm.&nbsp; The resulting share of bills outstanding, the impact on the maturity profile, and the relative persistent supply and demand dynamics at each maturity point were then discussed for each issuance size scenario.</p>\n<p><b>The presenting member concluded by recommending that Treasury begin to move towards a scenario with issuance cuts across the nominal curve, but with relatively larger reductions in the 7-year and 20-year tenors, offset by smaller reductions to the 5-year, 10-year, and 30-year tenors.</b></p>\n<p>The Committee then turned to its financing recommendation for the upcoming quarters.<b>The Committee recommended that Treasury begin to reduce nominal coupon auction sizes at the November 2021 quarterly refunding and attempt to target a bill share of total marketable debt outstanding within the Committee’s past recommendation of 15 to 20 percent</b>.&nbsp; However, the Committee emphasized the current level of fiscal uncertainty and the need to remain flexible if borrowing needs were to change materially.</p>\n<p><img src=\"https://static.tigerbbs.com/8a7f025722c8e8f65c79b40a66f977bc\" tg-width=\"1026\" tg-height=\"770\" width=\"100%\" height=\"auto\">After a discussion, the Committee further recommended that Treasury proceed in November with modestly larger reductions in the 7-year note and 20-year bond.&nbsp; Finally, the Committee recommended that Treasury continue to increase TIPS auction sizes at a pace consistent with the increase in gross issuance for CY2021 that was announced at the November 2020 quarterly refunding.&nbsp; The Committee also reaffirmed its support for Treasury to issue a floating rate note indexed to the Secured Overnight Financing Rate.</p>\n<p>Tangentially, and perhaps linked to the recent discussions of tether, TBAC reviewed a presentation on regulatory reform options for the money market mutual fund (MMF) industry, given the stress experienced by certain types of funds during March 2020.&nbsp; The presenting member noted the vulnerabilities that exist for primmoe MMFs, highlighting common themes in several recent episodes of heightened outflows. During these events, the outflows from prime MMFs have tended to result in similarly sized and simultaneous inflows into government MMFs. The presenting member concluded by arguing that optimal reforms to address the vulnerabilities among prime MMFs should balance allowing these funds to offer attractive yields under normal market conditions while ensuring stability during periods of market stress.</p>\n<p>As Bloomberg notes, if the Treasury does proceed with a reduction in the November-to-January period,<b>it would be the first in more than five years</b>. Issuance had been climbing for years, thanks to surging federal budget deficits in the wake of former President&nbsp;Donald Trump’s tax cuts and, later, the emergency spending caused by the pandemic.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Treasury To Start Reducing Bond Auction Sizes As Soon As November</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTreasury To Start Reducing Bond Auction Sizes As Soon As November\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/treasury-start-reducing-bond-auction-sizes-soon-november><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Heading into today's quarterly refunding announcement, the bond market was on edge over the (low) possibility widely discussed on sellside desks, that the Treasury could cut trim coupon auction sizes ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/treasury-start-reducing-bond-auction-sizes-soon-november\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.zerohedge.com/markets/treasury-start-reducing-bond-auction-sizes-soon-november","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106185106","content_text":"Heading into today's quarterly refunding announcement, the bond market was on edge over the (low) possibility widely discussed on sellside desks, that the Treasury could cut trim coupon auction sizes in the next few months to coincide with the Fed's tapering as the Treasury's funding needs have gradually emerged to be less than expected thanks to higher than expected tax revenues. In fact, according to some the drop in yields in recent weeks has been not due to the ongoing monster squeeze but due to expectations that there will be less TSY supply than demand.\nSo when the Treasury released itslatest refunding statement(whose highlights hit about 10 mins early after some newswire broke the embargo), battered TSY bears breathed a sigh of relief because the Treasury said that contrary growing expectations, it \"does not anticipate making any changes to nominal coupon and FRN auction sizes over the next quarter.\" Here is the proposed treasury issuance scheduled for Q3:\n\nHowever, in line with expectations, \"continuing current issuance sizes and patterns may provide more borrowing capacity than is needed to address borrowing needs over the intermediate-to-long term.\" As a result, the \"Treasury will continue to engage with a variety of market participants to better understand the supply and demand dynamics for existing securities,with an expectation of announcing an initial set of auction size reductions as soon as the November refunding announcement\" which is also in line with what most Primary Dealers had expected (among the 24 primary dealers in U.S. government securities, just three expected smaller auctions during the August-to-October quarter, with many more seeing an announcement in November).  In other words,shortly after the Fed's taper announcement at or just after Jackson Hole, the Treasury will follow up with an issuance cut of its own.\nSo if no changes in coupon sizes, will Bill issuance at least shrink? You bet: as the Treasury added, \"seasonal or unexpected variations in borrowing needs over the next quarter is to be met by changes in bill auction sizes and Cash Management Bills (CMBs).\"  Additionally, the Treasury willend weekly issuance of 6-week CMBs later this month:\n\n \"the amount of net new cash still being raised from coupon issuance will allow Treasury to continue gradual reductions in bills as a percent of Treasury debt outstanding, in a manner consistent with recommendations made by the Treasury Borrowing Advisory Committee (TBAC) at its November 2020 meeting.  Accordingly,\n Treasury plans to further modify its regular cadence of CMBs.  Treasury anticipates that weekly issuance of the 6-week CMBs will cease after settlement on August 19, whereas weekly issuance of the 17-week CMBs will continue at least through the end of October.\n\nAlso of note, now that the US has triggered the debt ceiling extension measures which have an impact on how much cash the Treasury can hold at the current moment ($450BN), the Treasury said that it is unsure how long extraordinary measures put in place due to the debt ceiling will last:\n\n As Secretary Yellen recently outlined in a July 23 letter to Congress, the period of time that extraordinary measures may last is subject to considerable uncertainty due to a variety of factors, including the challenges of forecasting the payments and receipts of the U.S. government months into the future, exacerbated by the heightened uncertainty in payments and receipts related to the economic impact of the pandemic.\n Given this, Treasury is not able to currently provide a specific estimate of how long extraordinary measures will last.\n\nWhile it was of secondary importance, the Treasury also revealed the details of next week's auctions a/k/a the quarterly refunding offering, which  was in line with expectations. Specifically, the Treasury will offer $126 billion of Treasuries to refund $58.6 billion of Treasury notes and bonds maturing on August 15, 2021. This issuance will raise new cash of approximately $67.4 billion. The securities are:\n\nA 3-year note in the amount of $58 billion, as expected\nA 10-year note in the amount of $41 billion, as expected\nA 30-year bond in the amount of $27 billion, as expected\n\nGoing back to the Treasury's coupon shrinkage plans, theMinutes of the latest Treasury Borrowing Advisory Committeerevealed that the committee reviewed a presentation presentation about potential adjustments to coupon auction sizes in the coming years,,,\n\n... based on the presenting member’s assessment that the current auction schedule will likely leave Treasury significantly overfunded.\nIt noted that several significant financing uncertainties were also highlighted by the presenting member that will require a flexible approach within the regular and predictable paradigm.  The resulting share of bills outstanding, the impact on the maturity profile, and the relative persistent supply and demand dynamics at each maturity point were then discussed for each issuance size scenario.\nThe presenting member concluded by recommending that Treasury begin to move towards a scenario with issuance cuts across the nominal curve, but with relatively larger reductions in the 7-year and 20-year tenors, offset by smaller reductions to the 5-year, 10-year, and 30-year tenors.\nThe Committee then turned to its financing recommendation for the upcoming quarters.The Committee recommended that Treasury begin to reduce nominal coupon auction sizes at the November 2021 quarterly refunding and attempt to target a bill share of total marketable debt outstanding within the Committee’s past recommendation of 15 to 20 percent.  However, the Committee emphasized the current level of fiscal uncertainty and the need to remain flexible if borrowing needs were to change materially.\nAfter a discussion, the Committee further recommended that Treasury proceed in November with modestly larger reductions in the 7-year note and 20-year bond.  Finally, the Committee recommended that Treasury continue to increase TIPS auction sizes at a pace consistent with the increase in gross issuance for CY2021 that was announced at the November 2020 quarterly refunding.  The Committee also reaffirmed its support for Treasury to issue a floating rate note indexed to the Secured Overnight Financing Rate.\nTangentially, and perhaps linked to the recent discussions of tether, TBAC reviewed a presentation on regulatory reform options for the money market mutual fund (MMF) industry, given the stress experienced by certain types of funds during March 2020.  The presenting member noted the vulnerabilities that exist for primmoe MMFs, highlighting common themes in several recent episodes of heightened outflows. During these events, the outflows from prime MMFs have tended to result in similarly sized and simultaneous inflows into government MMFs. The presenting member concluded by arguing that optimal reforms to address the vulnerabilities among prime MMFs should balance allowing these funds to offer attractive yields under normal market conditions while ensuring stability during periods of market stress.\nAs Bloomberg notes, if the Treasury does proceed with a reduction in the November-to-January period,it would be the first in more than five years. Issuance had been climbing for years, thanks to surging federal budget deficits in the wake of former President Donald Trump’s tax cuts and, later, the emergency spending caused by the pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174656711,"gmtCreate":1627096959133,"gmtModify":1703484210294,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/174656711","repostId":"2153980423","repostType":4,"repost":{"id":"2153980423","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627081209,"share":"https://ttm.financial/m/news/2153980423?lang=&edition=fundamental","pubTime":"2021-07-24 07:00","market":"us","language":"en","title":"Wall Street surges to all-time closing high on earnings, economic revival","url":"https://stock-news.laohu8.com/highlight/detail?id=2153980423","media":"Reuters","summary":"* All 3 major indexes post weekly gains\n* Dow closes above 35,000 for first time ever\n* Social media","content":"<p>* All 3 major indexes post weekly gains</p>\n<p>* Dow closes above 35,000 for first time ever</p>\n<p>* Social media stocks rally after upbeat results</p>\n<p>* Intel sales forecast implies rocky second half</p>\n<p>* Indexes up: Dow 0.68%, S&amp;P 1.01%, Nasdaq 1.04%</p>\n<p>Wall Street gained ground for the fourth straight session on Friday, extending a rally that pushed all three major U.S. stock indexes to record closing highs as upbeat earnings and signs of economic revival fueled investor risk appetite.</p>\n<p>The Dow closed above 35,000 for the first time ever.</p>\n<p>\"We see a continuation of the last couple days. It's roller coaster in reverse. We did the drop first, and we’ve been climbing back to the top ever since,\" said Chris Zaccarelli, chief investment officer at Independent Advisor Alliance in Charlotte, North Carolina.</p>\n<p>Growth and value stocks seesawed for much of the week as market participants weighed spiking infections of the COVID-19 Delta variant against strong corporate results and signs of economic revival.</p>\n<p>\"There’s push and pull, there’s clearly conflict in the market,\" Zaccarelli added. \"There’s a strong difference of opinion as to whether the future’s bright or whether there are clouds on the horizon.\"</p>\n<p>Market participants now look toward next week with the Federal Reserve's two-day monetary policy meeting and a series of high-profile earnings.</p>\n<p>The Fed's statement will be parsed for clues regarding the timeframe for tightening its accommodative policies, although Chairman Jerome Powell has repeatedly said the economy still needs the central bank's full support.</p>\n<p>The Dow Jones Industrial Average rose 238.2 points, or 0.68%, to 35,061.55, the S&amp;P 500 gained 44.31 points, or 1.01%, to 4,411.79 and the Nasdaq Composite added 152.39 points, or 1.04%, to 14,836.99.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, all but energy&nbsp;closed green, with communications services enjoying the largest gain, rising 2.7%.</p>\n<p>Second-quarter reporting season is in full swing, with 120 of the companies in the S&amp;P 500 having reported. Of those, 88% have beaten consensus, according to Refinitiv.</p>\n<p>\"We’re seeing companies, on average, beat on the top and on the bottom line,\" Zaccarelli said. \"We’re seeing the resilience of the consumer and that’s been the story of the earnings season so far.\"</p>\n<p>Analysts now expect aggregate year-on-year S&amp;P 500 earnings growth of 78.1% for the April to June period, a sizeable increase from the 54% annual growth seen at the beginning of the quarter.</p>\n<p>Chipmaker Intel Corp said late Thursday that it still faces supply constraints and provided disappointing guidance. Its stock fell 5.3%.</p>\n<p>Moderna Inc jumped 7.8% after the European Union approved its COVID-19 vaccine for 12- to 17-year-olds.</p>\n<p>American <a href=\"https://laohu8.com/S/EXPR\">Express</a> Co gained 1.3% after posting second-quarter profit that handily beat expectations on the strength of a global recovery in consumer spending.</p>\n<p>Social media firms <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> Inc and <a href=\"https://laohu8.com/S/SNAP\">Snap Inc</a>&nbsp;advanced 3.0% and 23.8%, respectively, on the back of their upbeat results.</p>\n<p>Those results bode well for <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, which is due to post second-quarter results next week. Its stock surged 5.3%.</p>\n<p>Other high-profile earnings expected next week include Tesla Inc, Apple Inc, Alphabet Inc, Microsoft Corp and Amazon.com.</p>\n<p>Industrials Lockheed Martin Corp, Boeing Co, Ford Motor Co, General Dynamics Corp, <a href=\"https://laohu8.com/S/MMM\">3M</a> Co Caterpillar Inc, Chevron Corp and Exxon Mobil Corp, along with a host of healthcare, consumer goods and others, are also on deck.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.59-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 82 new 52-week highs and no new lows; the Nasdaq Composite recorded 81 new highs and 136 new lows.</p>\n<p>Volume on U.S. exchanges was 9.72 billion shares, compared with the 10.14 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street surges to all-time closing high on earnings, economic revival</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street surges to all-time closing high on earnings, economic revival\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-24 07:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* All 3 major indexes post weekly gains</p>\n<p>* Dow closes above 35,000 for first time ever</p>\n<p>* Social media stocks rally after upbeat results</p>\n<p>* Intel sales forecast implies rocky second half</p>\n<p>* Indexes up: Dow 0.68%, S&amp;P 1.01%, Nasdaq 1.04%</p>\n<p>Wall Street gained ground for the fourth straight session on Friday, extending a rally that pushed all three major U.S. stock indexes to record closing highs as upbeat earnings and signs of economic revival fueled investor risk appetite.</p>\n<p>The Dow closed above 35,000 for the first time ever.</p>\n<p>\"We see a continuation of the last couple days. It's roller coaster in reverse. We did the drop first, and we’ve been climbing back to the top ever since,\" said Chris Zaccarelli, chief investment officer at Independent Advisor Alliance in Charlotte, North Carolina.</p>\n<p>Growth and value stocks seesawed for much of the week as market participants weighed spiking infections of the COVID-19 Delta variant against strong corporate results and signs of economic revival.</p>\n<p>\"There’s push and pull, there’s clearly conflict in the market,\" Zaccarelli added. \"There’s a strong difference of opinion as to whether the future’s bright or whether there are clouds on the horizon.\"</p>\n<p>Market participants now look toward next week with the Federal Reserve's two-day monetary policy meeting and a series of high-profile earnings.</p>\n<p>The Fed's statement will be parsed for clues regarding the timeframe for tightening its accommodative policies, although Chairman Jerome Powell has repeatedly said the economy still needs the central bank's full support.</p>\n<p>The Dow Jones Industrial Average rose 238.2 points, or 0.68%, to 35,061.55, the S&amp;P 500 gained 44.31 points, or 1.01%, to 4,411.79 and the Nasdaq Composite added 152.39 points, or 1.04%, to 14,836.99.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, all but energy&nbsp;closed green, with communications services enjoying the largest gain, rising 2.7%.</p>\n<p>Second-quarter reporting season is in full swing, with 120 of the companies in the S&amp;P 500 having reported. Of those, 88% have beaten consensus, according to Refinitiv.</p>\n<p>\"We’re seeing companies, on average, beat on the top and on the bottom line,\" Zaccarelli said. \"We’re seeing the resilience of the consumer and that’s been the story of the earnings season so far.\"</p>\n<p>Analysts now expect aggregate year-on-year S&amp;P 500 earnings growth of 78.1% for the April to June period, a sizeable increase from the 54% annual growth seen at the beginning of the quarter.</p>\n<p>Chipmaker Intel Corp said late Thursday that it still faces supply constraints and provided disappointing guidance. Its stock fell 5.3%.</p>\n<p>Moderna Inc jumped 7.8% after the European Union approved its COVID-19 vaccine for 12- to 17-year-olds.</p>\n<p>American <a href=\"https://laohu8.com/S/EXPR\">Express</a> Co gained 1.3% after posting second-quarter profit that handily beat expectations on the strength of a global recovery in consumer spending.</p>\n<p>Social media firms <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> Inc and <a href=\"https://laohu8.com/S/SNAP\">Snap Inc</a>&nbsp;advanced 3.0% and 23.8%, respectively, on the back of their upbeat results.</p>\n<p>Those results bode well for <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, which is due to post second-quarter results next week. Its stock surged 5.3%.</p>\n<p>Other high-profile earnings expected next week include Tesla Inc, Apple Inc, Alphabet Inc, Microsoft Corp and Amazon.com.</p>\n<p>Industrials Lockheed Martin Corp, Boeing Co, Ford Motor Co, General Dynamics Corp, <a href=\"https://laohu8.com/S/MMM\">3M</a> Co Caterpillar Inc, Chevron Corp and Exxon Mobil Corp, along with a host of healthcare, consumer goods and others, are also on deck.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.59-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 82 new 52-week highs and no new lows; the Nasdaq Composite recorded 81 new highs and 136 new lows.</p>\n<p>Volume on U.S. exchanges was 9.72 billion shares, compared with the 10.14 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","EXPR":"Express, Inc.","SNAP":"Snap Inc",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","TWTR":"Twitter"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153980423","content_text":"* All 3 major indexes post weekly gains\n* Dow closes above 35,000 for first time ever\n* Social media stocks rally after upbeat results\n* Intel sales forecast implies rocky second half\n* Indexes up: Dow 0.68%, S&P 1.01%, Nasdaq 1.04%\nWall Street gained ground for the fourth straight session on Friday, extending a rally that pushed all three major U.S. stock indexes to record closing highs as upbeat earnings and signs of economic revival fueled investor risk appetite.\nThe Dow closed above 35,000 for the first time ever.\n\"We see a continuation of the last couple days. It's roller coaster in reverse. We did the drop first, and we’ve been climbing back to the top ever since,\" said Chris Zaccarelli, chief investment officer at Independent Advisor Alliance in Charlotte, North Carolina.\nGrowth and value stocks seesawed for much of the week as market participants weighed spiking infections of the COVID-19 Delta variant against strong corporate results and signs of economic revival.\n\"There’s push and pull, there’s clearly conflict in the market,\" Zaccarelli added. \"There’s a strong difference of opinion as to whether the future’s bright or whether there are clouds on the horizon.\"\nMarket participants now look toward next week with the Federal Reserve's two-day monetary policy meeting and a series of high-profile earnings.\nThe Fed's statement will be parsed for clues regarding the timeframe for tightening its accommodative policies, although Chairman Jerome Powell has repeatedly said the economy still needs the central bank's full support.\nThe Dow Jones Industrial Average rose 238.2 points, or 0.68%, to 35,061.55, the S&P 500 gained 44.31 points, or 1.01%, to 4,411.79 and the Nasdaq Composite added 152.39 points, or 1.04%, to 14,836.99.\nOf the 11 major sectors in the S&P 500, all but energy closed green, with communications services enjoying the largest gain, rising 2.7%.\nSecond-quarter reporting season is in full swing, with 120 of the companies in the S&P 500 having reported. Of those, 88% have beaten consensus, according to Refinitiv.\n\"We’re seeing companies, on average, beat on the top and on the bottom line,\" Zaccarelli said. \"We’re seeing the resilience of the consumer and that’s been the story of the earnings season so far.\"\nAnalysts now expect aggregate year-on-year S&P 500 earnings growth of 78.1% for the April to June period, a sizeable increase from the 54% annual growth seen at the beginning of the quarter.\nChipmaker Intel Corp said late Thursday that it still faces supply constraints and provided disappointing guidance. Its stock fell 5.3%.\nModerna Inc jumped 7.8% after the European Union approved its COVID-19 vaccine for 12- to 17-year-olds.\nAmerican Express Co gained 1.3% after posting second-quarter profit that handily beat expectations on the strength of a global recovery in consumer spending.\nSocial media firms Twitter Inc and Snap Inc advanced 3.0% and 23.8%, respectively, on the back of their upbeat results.\nThose results bode well for Facebook Inc, which is due to post second-quarter results next week. Its stock surged 5.3%.\nOther high-profile earnings expected next week include Tesla Inc, Apple Inc, Alphabet Inc, Microsoft Corp and Amazon.com.\nIndustrials Lockheed Martin Corp, Boeing Co, Ford Motor Co, General Dynamics Corp, 3M Co Caterpillar Inc, Chevron Corp and Exxon Mobil Corp, along with a host of healthcare, consumer goods and others, are also on deck.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.59-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored advancers.\nThe S&P 500 posted 82 new 52-week highs and no new lows; the Nasdaq Composite recorded 81 new highs and 136 new lows.\nVolume on U.S. exchanges was 9.72 billion shares, compared with the 10.14 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171586301,"gmtCreate":1626750431203,"gmtModify":1703764478189,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/171586301","repostId":"2152652683","repostType":4,"isVote":1,"tweetType":1,"viewCount":73,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3579568139568178","authorId":"3579568139568178","authorIdStr":"3579568139568178","name":"Gnoixed","avatar":"https://static.tigerbbs.com/02d7e2310e2259dc0abb6c8cd2e1a05b","crmLevel":7,"crmLevelSwitch":0,"idStr":"3579568139568178"},"content":"pls reply","text":"pls reply","html":"pls reply"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119166569,"gmtCreate":1622528017851,"gmtModify":1704185683627,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/119166569","repostId":"1109591824","repostType":4,"repost":{"id":"1109591824","pubTimestamp":1622527159,"share":"https://ttm.financial/m/news/1109591824?lang=&edition=fundamental","pubTime":"2021-06-01 13:59","market":"sh","language":"en","title":"China’s Infant-Care Stocks Extend Gains on Three-Child Policy","url":"https://stock-news.laohu8.com/highlight/detail?id=1109591824","media":"Bloomberg","summary":"Chinese baby-related stocks extended gains for a second day after the nation’s surprise decision to ","content":"<p>Chinese baby-related stocks extended gains for a second day after the nation’s surprise decision to allow all couples to have a third child.</p>\n<p>Dairy firm Beingmate Co. jumped 10% in <a href=\"https://laohu8.com/S/00152\">Shenzhen</a>, while Fertility clinic service provider Jinfa Labi Maternity &amp; Baby Articles Co. rose by a similar magnitude. Hubei Goto Biopharm Co., a manufacturer of steroid hormone active pharmaceutical ingredient, surged 6% and infant goods retailer Shanghai Aiyingshi Co. climbed 10%.</p>\n<p><a href=\"https://laohu8.com/S/CAAS\">China</a>’s new birth policy will boost companies ranging from infant product manufacturers to maternal service providers,analysts say. Citi expects the new rule will benefit lower-tier cities due to low child-raising costs.</p>\n<p><img src=\"https://static.tigerbbs.com/0267f63d8d41c8f83cdbc842bdd3125e\" tg-width=\"620\" tg-height=\"348\" referrerpolicy=\"no-referrer\"></p>\n<p>Citi</p>\n<ul>\n <li>China’s further relaxation of its birth policy is well expected, and the new rule may give a bigger boost to birth rates in lower-tier cities given the lower costs of raising children, analysts including <a href=\"https://laohu8.com/S/TIF\">Tiffany</a> Feng write in note</li>\n <li><a href=\"https://laohu8.com/S/NGD\">New</a> rule is however difficult to turn around birth downtrend, due to falling population base of females at childbearing age</li>\n <li>Citi prefers Feihe and Ausnutria, as the two are likely to benefit most give their higher exposure to lower cities</li>\n</ul>\n<p>CICC</p>\n<ul>\n <li>The themes to find stocks that will benefit from the three-child policy include mother- and baby-care product manufacturers, maternity and parenting services providers, analysts including Fan Junhao write in note</li>\n <li>Consumption upgrade, digitalization and rising impact of domestic brands are the latest trends in China’s infant-related industries</li>\n <li>CICC prefers leading manufacturers of various infant-related products, including Winner Medical, C&amp;S Paper, Hangzhou Haoyue Personal Care, Shanghai M&amp;G Stationery, Pop Mart</li>\n <li>It also likes retailer Shanghai Aiyingshi and maternal service provider Aidigong Maternal &amp; Child Health</li>\n</ul>\n<p>Jefferies</p>\n<ul>\n <li>The new rule is positive, but it’s too early to conclude its effectiveness, analysts including Kerith Chen write in note</li>\n <li>Infant formula brands including Yili and Mengniu, diaper brands like <a href=\"https://laohu8.com/S/01044\">Hengan</a> should benefit first</li>\n <li>In a separate note, Jefferies analyst Mitsuko Miyasako expects the policy to benefit Japanese personal-care firm Pigeon due to its high China composition and high baby products composition</li>\n</ul>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China’s Infant-Care Stocks Extend Gains on Three-Child Policy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina’s Infant-Care Stocks Extend Gains on Three-Child Policy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 13:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-01/china-s-infant-care-stocks-extend-gains-on-three-child-policy?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese baby-related stocks extended gains for a second day after the nation’s surprise decision to allow all couples to have a third child.\nDairy firm Beingmate Co. jumped 10% in Shenzhen, while ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-01/china-s-infant-care-stocks-extend-gains-on-three-child-policy?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.bloomberg.com/news/articles/2021-06-01/china-s-infant-care-stocks-extend-gains-on-three-child-policy?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109591824","content_text":"Chinese baby-related stocks extended gains for a second day after the nation’s surprise decision to allow all couples to have a third child.\nDairy firm Beingmate Co. jumped 10% in Shenzhen, while Fertility clinic service provider Jinfa Labi Maternity & Baby Articles Co. rose by a similar magnitude. Hubei Goto Biopharm Co., a manufacturer of steroid hormone active pharmaceutical ingredient, surged 6% and infant goods retailer Shanghai Aiyingshi Co. climbed 10%.\nChina’s new birth policy will boost companies ranging from infant product manufacturers to maternal service providers,analysts say. Citi expects the new rule will benefit lower-tier cities due to low child-raising costs.\n\nCiti\n\nChina’s further relaxation of its birth policy is well expected, and the new rule may give a bigger boost to birth rates in lower-tier cities given the lower costs of raising children, analysts including Tiffany Feng write in note\nNew rule is however difficult to turn around birth downtrend, due to falling population base of females at childbearing age\nCiti prefers Feihe and Ausnutria, as the two are likely to benefit most give their higher exposure to lower cities\n\nCICC\n\nThe themes to find stocks that will benefit from the three-child policy include mother- and baby-care product manufacturers, maternity and parenting services providers, analysts including Fan Junhao write in note\nConsumption upgrade, digitalization and rising impact of domestic brands are the latest trends in China’s infant-related industries\nCICC prefers leading manufacturers of various infant-related products, including Winner Medical, C&S Paper, Hangzhou Haoyue Personal Care, Shanghai M&G Stationery, Pop Mart\nIt also likes retailer Shanghai Aiyingshi and maternal service provider Aidigong Maternal & Child Health\n\nJefferies\n\nThe new rule is positive, but it’s too early to conclude its effectiveness, analysts including Kerith Chen write in note\nInfant formula brands including Yili and Mengniu, diaper brands like Hengan should benefit first\nIn a separate note, Jefferies analyst Mitsuko Miyasako expects the policy to benefit Japanese personal-care firm Pigeon due to its high China composition and high baby products composition","news_type":1},"isVote":1,"tweetType":1,"viewCount":204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814588613,"gmtCreate":1630844568932,"gmtModify":1676530404645,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/814588613","repostId":"1157895022","repostType":4,"repost":{"id":"1157895022","pubTimestamp":1630810619,"share":"https://ttm.financial/m/news/1157895022?lang=&edition=fundamental","pubTime":"2021-09-05 10:56","market":"us","language":"en","title":"Beat the market with this quant system that’s very bullish on stocks at record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=1157895022","media":"MarketWatch","summary":"Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do ","content":"<blockquote>\n <b>Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do so. So far his team of computer scientists’ strategy has paid off.</b>\n</blockquote>\n<p>Imagine you had a money-making machine to harvest gains in the stock market while you sat back to enjoy life.</p>\n<p>That’s everyone’s dream, right? Investor Vance Howard thinks he’s found it.</p>\n<p>Howard and his small army of computer programmers atHoward Capital Managementin Roswell, Ga., have a quantitative system that posts great returns.</p>\n<p>His HCM Tactical Growth Fund&nbsp;HCMGX,+0.35%beats its Russell 1000&nbsp;benchmark index and large-blend fund category by 8.5-10.4 percentage points annualized over the past five years, according to Morningstar. That is no small feat, and not only because it has to overcome a 2.22% fee. Beating the market is simply not easy. His HCM Dividend Sector PlusHCMQX,-0.05%) and HCM Income PlusHCMLX,+0.30%funds post similar outperformance.</p>\n<p>There are drawbacks, which I detail below. (Among them: Potentially long stretches of underperformance and regular tax bills.) But first, what can we learn from this winner?</p>\n<p>So-called quants never share all the details of their proprietary systems, but Howard shares a lot, as you’ll see. And this Texas rancher has a lot of good advice based on “horse sense” — not surprising, given his infectious passion for the markets, and his three decades of experience as a pro.</p>\n<p>Here are five lessons, 12 exchange traded funds (ETFs) and four stocks to consider, from a recent interview with him.</p>\n<p><b>Lesson #1: Don’t be emotional</b></p>\n<p>It’s no surprise so many people do poorly in the market. Evolution has programmed us to fail. For survival, we’ve learned to run from things that frightens us. And crave more of things that are pleasurable — like sweets or fats to store calories ahead of what might be a long stretch without food. But in the market, acting on the emotions of fear and greed invariably make us do the wrong thing at the wrong time. Sell at the bottom, buy at the top.</p>\n<p>Likewise, we’re programmed to believe being with the crowd brings safety. If you’re a zebra on the Savanna, you are more likely to get picked off by a predator if you go it alone. The problem here is being part of a crowd — and crowd psychology — dumb us down to a purely emotional level. This is why people in crowds do terrible things they would never do on their own. It doesn’t matter how smart you are. When you join a crowd, you lose a lot of IQ points. Base emotions take over.</p>\n<p>To do well in the market, you have to counteract these tendencies. “One of the biggest mistakes individual investors and money managers make is getting emotional,” says Howard. “Let your emotions go.”</p>\n<p><b>Lesson #2: Have a system and stick to it</b></p>\n<p>To exorcise emotion, have a system. “And don’t second guess it,” says Howard. “This keeps you from letting the pandemic or Afghanistan scare you out of the market.” He calls his system the HCM-BuyLine. It is basically a momentum and trend-following system — which often works well in the markets.</p>\n<p>The HCM-BuyLine basically works like this. First, rather than use the S&amp;P 500SPX,-0.03%or the Dow Jones Industrial AverageDJIA,-0.21%,Howard blends several stock indices to create his own index. Then he uses a moving average that tells him whether the market is in an uptrend or downtrend.</p>\n<p>When the moving average drops 3.5%, he sells 35%. If it drops 6.5%, he sells another 35%. He rarely goes to 100% cash.</p>\n<p>“If the BuyLine is positive, we will stay long no matter what,” he says. “We take all the emotion out of the equation by letting the math decide.”</p>\n<p>Right now, it’s bullish. (More on this below.)</p>\n<p>Your system also has to tell you when to get back in.</p>\n<p>“That’s where most people screw up,” he says. “They get out of the market, and they don’t know when to get back in.” The HCM-BuyLine gives a buy signal when his custom index trades above its moving average for six consecutive sessions, and then goes on to trade above the high hit during those six days.</p>\n<p>You don’t need a system that calls exact market tops or bottoms. Instead, the BuyLine keeps Howard out of down markets 85% of the time, and in for 85% of the good times.</p>\n<p>“If we can do that consistently, we have superior returns and a less stressful life,” he says. “Being all in during a bad tape is no fun.”</p>\n<p>His system is slow to get him out of the market, but quick to get him back in. Not even a 10% correction will necessarily move him out. He’s often buying those pullbacks. Getting back in fast makes sense, because recoveries off bottoms tend to happen fast.</p>\n<p>“The HCM-BuyLine takes all the emotion out of the process,” says Howard.</p>\n<p><b>Lesson #3: Don’t fight the tape</b></p>\n<p>This concept is one of the core pieces of wisdom from Marty Zweig’s classic book, “Winning on Wall Street.”</p>\n<p>“You have to stay on the right side of market,” agrees Howard. “If you try to trade long in a bad market, it is painful.”</p>\n<p>In other words, don’t try to be a hero.</p>\n<p>“Sometimes, not losing money is where you want to be,” he says.</p>\n<p>Likewise, don’t turn cautious just because the market hits new highs — like now. You should love new highs, because it is a sign of market strength that may likely endure.</p>\n<p><b>Lesson #4: Keep it simple</b></p>\n<p>As you’ll see below, Howard doesn’t use esoteric instruments such as derivatives, swaps or index options. He doesn’t even trade foreign stocks or currencies. This is refreshing for individual investors, because we have a harder time accessing those tools.</p>\n<p>“You don’t have to trade crazy stuff,” he says. “You can trade plain-vanilla ETFs and beat everybody out there.”</p>\n<p><b>Lesson #5: How to trade the current market</b></p>\n<p>First, be long.</p>\n<p>“The HCM-BuyLine is very positive. We are 100% in,” says Howard. “The market is broadening out. It is getting pretty exciting. We do not see it turn around any time soon. We are buying pullbacks.”</p>\n<p>One bullish signal is all the cash on the sidelines. “If there is any relief in Covid, we may see a big rally. We may end up with a great fall [season].”</p>\n<p>Howard uses momentum indicators to select stocks and ETFs, too. For sectors he favors the following.</p>\n<p>He likes health care, tradable through the iShares US HealthcareIYH,-0.04%and ProShares Ultra Health CareRXL,+0.12%ETFs. He’s turning more bullish on biotech, which he plays via the iShares Biotechnology ETFIBB,-0.11%.</p>\n<p>He likes consumer discretionary tradable through the iShares US Consumer ServicesIYC,-0.30%,and airlines via US Global JetsJETS,-1.17%.He also likes tech exposure via the Invesco QQQ TrustQQQ,+0.31%,iShares US TechnologyIYW,+0.50%and&nbsp;iShares SemiconductorSOXX,+0.75%.</p>\n<p>He likes small-caps via the Vanguard Small-Cap Growth Index FundVBK,+0.07%.And convertible bonds via SPDR Bloomberg Barclays Convertible SecuritiesCWB,+0.64%and iShares Convertible BondICVT,+0.37%.</p>\n<p>As for individual names, he singles out MicrosoftMSFT,-0.00%and AppleAAPL,+0.42%in tech, as well as Amazon.comAMZN,+0.43%and TeslaTSLA,+0.16%.</p>\n<p>Also consider Howard’s two ETFs: The HCM Defender 100 IndexQQH,+0.62%and HCM Defender 500 IndexLGH,+1.32%.</p>\n<p>He prefers to add to holdings on 1%-3% dips.</p>\n<p><b>A few drawbacks</b></p>\n<p>His HCM Tactical Growth fund has a history of posting two-year stretches of underperformance of 1.5% to 8.8%, since it was launched in 2015. The fund then came roaring back to net the very positive five-year outperformance cited above. Investing in his system can require patience.</p>\n<p>Every manager, including Warren Buffett, can have a stretch of underperformance, says Howard.</p>\n<p>“We are in the odds game,” he says. “Even in the odds game, you can have a bad hand or two thrown at you.”</p>\n<p>Another challenge is the high turnover, which is 140% a year for Tactical Growth. This means Uncle Sam takes a big cut in the good years. So if you buy Howard’s funds, you may want to do so in a tax-protected account.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beat the market with this quant system that’s very bullish on stocks at record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeat the market with this quant system that’s very bullish on stocks at record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-05 10:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/beat-the-market-with-this-quant-system-thats-very-bullish-on-stocks-at-record-highs-11630761531?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do so. So far his team of computer scientists’ strategy has paid off.\n\nImagine you had a money-making ...</p>\n\n<a href=\"https://www.marketwatch.com/story/beat-the-market-with-this-quant-system-thats-very-bullish-on-stocks-at-record-highs-11630761531?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/beat-the-market-with-this-quant-system-thats-very-bullish-on-stocks-at-record-highs-11630761531?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157895022","content_text":"Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do so. So far his team of computer scientists’ strategy has paid off.\n\nImagine you had a money-making machine to harvest gains in the stock market while you sat back to enjoy life.\nThat’s everyone’s dream, right? Investor Vance Howard thinks he’s found it.\nHoward and his small army of computer programmers atHoward Capital Managementin Roswell, Ga., have a quantitative system that posts great returns.\nHis HCM Tactical Growth Fund HCMGX,+0.35%beats its Russell 1000 benchmark index and large-blend fund category by 8.5-10.4 percentage points annualized over the past five years, according to Morningstar. That is no small feat, and not only because it has to overcome a 2.22% fee. Beating the market is simply not easy. His HCM Dividend Sector PlusHCMQX,-0.05%) and HCM Income PlusHCMLX,+0.30%funds post similar outperformance.\nThere are drawbacks, which I detail below. (Among them: Potentially long stretches of underperformance and regular tax bills.) But first, what can we learn from this winner?\nSo-called quants never share all the details of their proprietary systems, but Howard shares a lot, as you’ll see. And this Texas rancher has a lot of good advice based on “horse sense” — not surprising, given his infectious passion for the markets, and his three decades of experience as a pro.\nHere are five lessons, 12 exchange traded funds (ETFs) and four stocks to consider, from a recent interview with him.\nLesson #1: Don’t be emotional\nIt’s no surprise so many people do poorly in the market. Evolution has programmed us to fail. For survival, we’ve learned to run from things that frightens us. And crave more of things that are pleasurable — like sweets or fats to store calories ahead of what might be a long stretch without food. But in the market, acting on the emotions of fear and greed invariably make us do the wrong thing at the wrong time. Sell at the bottom, buy at the top.\nLikewise, we’re programmed to believe being with the crowd brings safety. If you’re a zebra on the Savanna, you are more likely to get picked off by a predator if you go it alone. The problem here is being part of a crowd — and crowd psychology — dumb us down to a purely emotional level. This is why people in crowds do terrible things they would never do on their own. It doesn’t matter how smart you are. When you join a crowd, you lose a lot of IQ points. Base emotions take over.\nTo do well in the market, you have to counteract these tendencies. “One of the biggest mistakes individual investors and money managers make is getting emotional,” says Howard. “Let your emotions go.”\nLesson #2: Have a system and stick to it\nTo exorcise emotion, have a system. “And don’t second guess it,” says Howard. “This keeps you from letting the pandemic or Afghanistan scare you out of the market.” He calls his system the HCM-BuyLine. It is basically a momentum and trend-following system — which often works well in the markets.\nThe HCM-BuyLine basically works like this. First, rather than use the S&P 500SPX,-0.03%or the Dow Jones Industrial AverageDJIA,-0.21%,Howard blends several stock indices to create his own index. Then he uses a moving average that tells him whether the market is in an uptrend or downtrend.\nWhen the moving average drops 3.5%, he sells 35%. If it drops 6.5%, he sells another 35%. He rarely goes to 100% cash.\n“If the BuyLine is positive, we will stay long no matter what,” he says. “We take all the emotion out of the equation by letting the math decide.”\nRight now, it’s bullish. (More on this below.)\nYour system also has to tell you when to get back in.\n“That’s where most people screw up,” he says. “They get out of the market, and they don’t know when to get back in.” The HCM-BuyLine gives a buy signal when his custom index trades above its moving average for six consecutive sessions, and then goes on to trade above the high hit during those six days.\nYou don’t need a system that calls exact market tops or bottoms. Instead, the BuyLine keeps Howard out of down markets 85% of the time, and in for 85% of the good times.\n“If we can do that consistently, we have superior returns and a less stressful life,” he says. “Being all in during a bad tape is no fun.”\nHis system is slow to get him out of the market, but quick to get him back in. Not even a 10% correction will necessarily move him out. He’s often buying those pullbacks. Getting back in fast makes sense, because recoveries off bottoms tend to happen fast.\n“The HCM-BuyLine takes all the emotion out of the process,” says Howard.\nLesson #3: Don’t fight the tape\nThis concept is one of the core pieces of wisdom from Marty Zweig’s classic book, “Winning on Wall Street.”\n“You have to stay on the right side of market,” agrees Howard. “If you try to trade long in a bad market, it is painful.”\nIn other words, don’t try to be a hero.\n“Sometimes, not losing money is where you want to be,” he says.\nLikewise, don’t turn cautious just because the market hits new highs — like now. You should love new highs, because it is a sign of market strength that may likely endure.\nLesson #4: Keep it simple\nAs you’ll see below, Howard doesn’t use esoteric instruments such as derivatives, swaps or index options. He doesn’t even trade foreign stocks or currencies. This is refreshing for individual investors, because we have a harder time accessing those tools.\n“You don’t have to trade crazy stuff,” he says. “You can trade plain-vanilla ETFs and beat everybody out there.”\nLesson #5: How to trade the current market\nFirst, be long.\n“The HCM-BuyLine is very positive. We are 100% in,” says Howard. “The market is broadening out. It is getting pretty exciting. We do not see it turn around any time soon. We are buying pullbacks.”\nOne bullish signal is all the cash on the sidelines. “If there is any relief in Covid, we may see a big rally. We may end up with a great fall [season].”\nHoward uses momentum indicators to select stocks and ETFs, too. For sectors he favors the following.\nHe likes health care, tradable through the iShares US HealthcareIYH,-0.04%and ProShares Ultra Health CareRXL,+0.12%ETFs. He’s turning more bullish on biotech, which he plays via the iShares Biotechnology ETFIBB,-0.11%.\nHe likes consumer discretionary tradable through the iShares US Consumer ServicesIYC,-0.30%,and airlines via US Global JetsJETS,-1.17%.He also likes tech exposure via the Invesco QQQ TrustQQQ,+0.31%,iShares US TechnologyIYW,+0.50%and iShares SemiconductorSOXX,+0.75%.\nHe likes small-caps via the Vanguard Small-Cap Growth Index FundVBK,+0.07%.And convertible bonds via SPDR Bloomberg Barclays Convertible SecuritiesCWB,+0.64%and iShares Convertible BondICVT,+0.37%.\nAs for individual names, he singles out MicrosoftMSFT,-0.00%and AppleAAPL,+0.42%in tech, as well as Amazon.comAMZN,+0.43%and TeslaTSLA,+0.16%.\nAlso consider Howard’s two ETFs: The HCM Defender 100 IndexQQH,+0.62%and HCM Defender 500 IndexLGH,+1.32%.\nHe prefers to add to holdings on 1%-3% dips.\nA few drawbacks\nHis HCM Tactical Growth fund has a history of posting two-year stretches of underperformance of 1.5% to 8.8%, since it was launched in 2015. The fund then came roaring back to net the very positive five-year outperformance cited above. Investing in his system can require patience.\nEvery manager, including Warren Buffett, can have a stretch of underperformance, says Howard.\n“We are in the odds game,” he says. “Even in the odds game, you can have a bad hand or two thrown at you.”\nAnother challenge is the high turnover, which is 140% a year for Tactical Growth. This means Uncle Sam takes a big cut in the good years. So if you buy Howard’s funds, you may want to do so in a tax-protected account.","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830718093,"gmtCreate":1629098391112,"gmtModify":1676529928975,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/830718093","repostId":"2159210604","repostType":2,"repost":{"id":"2159210604","pubTimestamp":1629097536,"share":"https://ttm.financial/m/news/2159210604?lang=&edition=fundamental","pubTime":"2021-08-16 15:05","market":"us","language":"en","title":"4 Pharma Stocks You Can Buy and Hold for 20 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2159210604","media":"Motley Fool","summary":"These drugmakers are built for the long run.","content":"<p><b>Key Points</b></p>\n<ul>\n <li>These two Motley Fool contributors picked two of the same big pharma stocks to buy and hold for 20 years: <a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> and <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a>.</li>\n <li>Bristol Myers Squibb and Pfizer also stand out as great pharma picks for the long term.</li>\n</ul>\n<p>A buy-and-hold strategy can work really well -- if you pick the right stocks.&nbsp;In this <i>Motley Fool Live</i> video <b>recorded on Aug. 4, 2021</b>, Motley Fool contributors Keith Speights and Brian Orelli discuss their top pharma stocks to buy and hold for 20 years.</p>\n<p><b>Keith Speights: </b>We had another question on Monday. I like this question. The person asked, \"Can you both rank your top three pharma/biotech holdings to hold for 10-20 years.\" Brian, I'll let you go first with your top three and then I'll chime in. Let's go with that longer time horizon of 20 years to hold.</p>\n<p><b>Brian Orelli:</b> Twenty years is an awful long time to hold. I think the obvious choice here is probably<b> <a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b>. Given the history and the diversity across the healthcare sector, I can almost guarantee it will be around in 20 years.</p>\n<p>I think it's probably also likely to beat the S&amp;P 500 over that time frame. The company does a really good job at growing earnings faster than revenue. That should drive the stock price. Even if the growth of the revenue is a little bit slower than the average S&amp;P 500 company.</p>\n<p>A few years ago, I probably would've gone with Celgene as my number two pick. But <b><a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb</a></b> obviously bought it out. A lot of that was due to the company's ability to do deals to in-license drugs and Bristol-Myers has a lot of those same qualities and where it looks to partner with companies and invest in them early and then develop those drugs. I'm going to pick up Bristol-Myers Squibb as my second pick, the ticker there's BMY.</p>\n<p>Then for my third pick, I'd go for <b><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></b>, taker there's VRTX. It's a bit more risky than the other two because we don't really know what Vertex's next growth franchise will be after it maximizes the opportunity in cystic fibrosis.</p>\n<p>But if you've been following the industry long enough and Vertex specifically long enough, you know, the Vertex was actually a hepatitis C drug developer pivoted to cystic fibrosis as its next move. That turned out to be a really good choice because <b>Gilead</b>&nbsp;came along with Sovaldi.</p>\n<p>Basically, that was so much of a better drug that doctors just stopped prescribing Vertex's Hepatitis C drug. But the company seemed to manage through that process fairly seamlessly. I think that they can manage through the next transition just as seamlessly, I hope.</p>\n<p><b>Speights:</b> Brian, I would definitely have to agree with you on Johnson &amp; Johnson, it's really diversified across healthcare. It's a leader in nearly every market, probably every market where it operates.</p>\n<p>The company is a cash cow. It has lots of money to invest and its own research and development plus make strategic acquisitions, and that's what it's done through the years. I think Johnson &amp; Johnson is an easy number <a href=\"https://laohu8.com/S/AONE.U\">one</a> pick to hold for 20 years. It's just so solid.</p>\n<p>I think I will go with Pfizer though maybe as my second pick. There's some uncertainty for the company with losing some exclusivity for drugs in the second half of this decade. But like Johnson and Johnson, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>&nbsp;has survived and thrived for a long time. It's adapted.</p>\n<p>The company has a huge pipeline. It's flushed with cash, especially with more money rolling in from its COVID-19 vaccine. I fully expect Pfizer to invest, if not in acquiring other companies and beefing up its pipeline through licensing deals.</p>\n<p>I think Pfizer is a pretty safe pick to hold for 20 years. Again, like Johnson and Johnson, it could beat the market. It might not give you these jaw-dropping returns, but I think it will be solid.</p>\n<p>My third pick, I hate to be a copycat, Brian, but I am going to go along with you on Vertex. I own the stock. I really like the stock. I think Vertex's monopoly in cystic fibrosis sets it up really nicely, at least into the next decade. There really aren't many competitors that are nipping at its heels at all. I think the most advanced CF drugs outside of Vertex's pipeline are in Phase II testing. Vertex just has a monopoly there.</p>\n<p>Also, look for the company to rack up some pipeline wins beyond CF. I'm not sure exactly where and I look for Vertex to make some acquisitions along the way too. It also has a really huge and growing cash stock policy. I like all those three.</p>\n<p>But you mentioned Bristol-Myers Squibb. I like it too. It's one of the stocks in my portfolio. I think investors couldn't go wrong with any of these stocks that we've mentioned.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Pharma Stocks You Can Buy and Hold for 20 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Pharma Stocks You Can Buy and Hold for 20 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-16 15:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/15/4-pharma-stocks-you-can-buy-and-hold-for-20-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nThese two Motley Fool contributors picked two of the same big pharma stocks to buy and hold for 20 years: Johnson & Johnson and Vertex Pharmaceuticals.\nBristol Myers Squibb and Pfizer also...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/15/4-pharma-stocks-you-can-buy-and-hold-for-20-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","VRTX":"福泰制药","PFE":"辉瑞","BMY":"施贵宝"},"source_url":"https://www.fool.com/investing/2021/08/15/4-pharma-stocks-you-can-buy-and-hold-for-20-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2159210604","content_text":"Key Points\n\nThese two Motley Fool contributors picked two of the same big pharma stocks to buy and hold for 20 years: Johnson & Johnson and Vertex Pharmaceuticals.\nBristol Myers Squibb and Pfizer also stand out as great pharma picks for the long term.\n\nA buy-and-hold strategy can work really well -- if you pick the right stocks. In this Motley Fool Live video recorded on Aug. 4, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss their top pharma stocks to buy and hold for 20 years.\nKeith Speights: We had another question on Monday. I like this question. The person asked, \"Can you both rank your top three pharma/biotech holdings to hold for 10-20 years.\" Brian, I'll let you go first with your top three and then I'll chime in. Let's go with that longer time horizon of 20 years to hold.\nBrian Orelli: Twenty years is an awful long time to hold. I think the obvious choice here is probably Johnson & Johnson. Given the history and the diversity across the healthcare sector, I can almost guarantee it will be around in 20 years.\nI think it's probably also likely to beat the S&P 500 over that time frame. The company does a really good job at growing earnings faster than revenue. That should drive the stock price. Even if the growth of the revenue is a little bit slower than the average S&P 500 company.\nA few years ago, I probably would've gone with Celgene as my number two pick. But Bristol-Myers Squibb obviously bought it out. A lot of that was due to the company's ability to do deals to in-license drugs and Bristol-Myers has a lot of those same qualities and where it looks to partner with companies and invest in them early and then develop those drugs. I'm going to pick up Bristol-Myers Squibb as my second pick, the ticker there's BMY.\nThen for my third pick, I'd go for Vertex Pharmaceuticals, taker there's VRTX. It's a bit more risky than the other two because we don't really know what Vertex's next growth franchise will be after it maximizes the opportunity in cystic fibrosis.\nBut if you've been following the industry long enough and Vertex specifically long enough, you know, the Vertex was actually a hepatitis C drug developer pivoted to cystic fibrosis as its next move. That turned out to be a really good choice because Gilead came along with Sovaldi.\nBasically, that was so much of a better drug that doctors just stopped prescribing Vertex's Hepatitis C drug. But the company seemed to manage through that process fairly seamlessly. I think that they can manage through the next transition just as seamlessly, I hope.\nSpeights: Brian, I would definitely have to agree with you on Johnson & Johnson, it's really diversified across healthcare. It's a leader in nearly every market, probably every market where it operates.\nThe company is a cash cow. It has lots of money to invest and its own research and development plus make strategic acquisitions, and that's what it's done through the years. I think Johnson & Johnson is an easy number one pick to hold for 20 years. It's just so solid.\nI think I will go with Pfizer though maybe as my second pick. There's some uncertainty for the company with losing some exclusivity for drugs in the second half of this decade. But like Johnson and Johnson, Pfizer has survived and thrived for a long time. It's adapted.\nThe company has a huge pipeline. It's flushed with cash, especially with more money rolling in from its COVID-19 vaccine. I fully expect Pfizer to invest, if not in acquiring other companies and beefing up its pipeline through licensing deals.\nI think Pfizer is a pretty safe pick to hold for 20 years. Again, like Johnson and Johnson, it could beat the market. It might not give you these jaw-dropping returns, but I think it will be solid.\nMy third pick, I hate to be a copycat, Brian, but I am going to go along with you on Vertex. I own the stock. I really like the stock. I think Vertex's monopoly in cystic fibrosis sets it up really nicely, at least into the next decade. There really aren't many competitors that are nipping at its heels at all. I think the most advanced CF drugs outside of Vertex's pipeline are in Phase II testing. Vertex just has a monopoly there.\nAlso, look for the company to rack up some pipeline wins beyond CF. I'm not sure exactly where and I look for Vertex to make some acquisitions along the way too. It also has a really huge and growing cash stock policy. I like all those three.\nBut you mentioned Bristol-Myers Squibb. I like it too. It's one of the stocks in my portfolio. I think investors couldn't go wrong with any of these stocks that we've mentioned.","news_type":1},"isVote":1,"tweetType":1,"viewCount":255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899234942,"gmtCreate":1628197535786,"gmtModify":1703502849384,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899234942","repostId":"1173170520","repostType":4,"isVote":1,"tweetType":1,"viewCount":84,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177851196,"gmtCreate":1627198834815,"gmtModify":1703485485946,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/177851196","repostId":"2153878189","repostType":2,"repost":{"id":"2153878189","pubTimestamp":1627179426,"share":"https://ttm.financial/m/news/2153878189?lang=&edition=fundamental","pubTime":"2021-07-25 10:17","market":"us","language":"en","title":"Amazon's stock looks tired. Consider buying shares of these five fast-growing e-commerce plays instead","url":"https://stock-news.laohu8.com/highlight/detail?id=2153878189","media":"MarketWatch","summary":"Amazon started the internet-retail revolution. Five other companies, including Sea and Coupang, are taking it further. Jeff Bezos has plenty of achievements under his belt, the most recent being his extraterrestrial excursion.But Amazon.com shareholders may not be so impressed. Bipartisan talk of antitrust actions against the e-commerce giant could mean that Amazon’s dominance could begin to face challenges from Washington. That comes as Bezos handed off the CEO role to Andy Jassy earlier this m","content":"<p>Amazon started the internet-retail revolution. Five other companies, including Sea and Coupang, are taking it further</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e897e40f58935774b2ab4c3f6bdce36a\" tg-width=\"700\" tg-height=\"392\" width=\"100%\" height=\"auto\"><span>Sea Ltd.'s Shopee e-commerce platform.</span></p>\n<p>Jeff Bezos has plenty of achievements under his belt, the most recent being his extraterrestrial excursion.</p>\n<p>But Amazon.com&nbsp;shareholders may not be so impressed. Bipartisan talk of&nbsp;antitrust actions&nbsp;against the e-commerce giant could mean that Amazon’s dominance could begin to face challenges from Washington. That comes as Bezos handed off the CEO role to Andy Jassy earlier this month.</p>\n<p>Shares of Amazon have underperformed the tech-heavy Nasdaq 100&nbsp;and the S&amp;P 500&nbsp;in 2021, even as the coronavirus pandemic forced Americans to rely on its service during the darkest days.</p>\n<p>Given all this, it is worth considering e-commerce alternatives if you’re worried that Amazon’s best days are behind it.</p>\n<p>Here are five smaller high-growth companies you may want to research:</p>\n<p><b>Sea</b></p>\n<p>Shares of&nbsp;Sea Ltd.&nbsp;are up about 45% in 2021, hitting new all-time highs as it continues its aggressive growth across Asia and Latin America.</p>\n<p>The Singapore-based company has a broad business model capitalizing on e-commerce and digital retail operations around the world. That includes its Garena digital entertainment platform that publishes video games and offers e-sports tie-ins, the Shopee e-commerce platform and SeaMoney digital financial services that include mobile payment services.</p>\n<p>Sea was a darling in 2020 as it rode the “stay at home trade” to great success. Revenue doubled year over year in 2020 to $4.4 billion, and the company’s momentum was the envy of Wall Street as Sea stock racked up roughly 640% gains on the calendar year.</p>\n<p>But the fundamentals shown by Sea in 2021 hint that the surge in share prices were justified. Consider that in its first-quarter report in May, revenue surged by about&nbsp;150%— while gross profit tripled year over year.</p>\n<p>With its next earnings report scheduled for mid-August, Sea stock could see another leg up as it continues to prove Amazon isn’t the only e-commerce name worth watching.</p>\n<p><b>Coupang</b></p>\n<p>While Sea has been a cult stock for a while in some circles, one Asian e-commerce stock that is still flying under the radar for many is Korea-based Coupang Inc..&nbsp;South Korea’s biggest e-commerce company began trading in March after an IPO that raised $4.6 billion, but since then shares have drifted lower — and other cult-like stocks have won all the attention.</p>\n<p>If you haven’t yet heard of Coupang, its model should be quite familiar. It sells various products including home goods, apparel, beauty products, sporting goods and electronics. It’s also looking beyond these tried-and-true categories to include a focus on fresh food and groceries, as well as services including travel and restaurant delivery.</p>\n<p>Though the fundamentals are light given its recent debut, the numbers we have do show this regional e-tailer is connecting in a big way in Korea. Namely, it saw net revenue growth of 74% in its first-quarter report in May, and gross profit up 70% year over year. Total customers grew 21%, and revenue per customer surged 44%.</p>\n<p>Admittedly, the total customer base in that quarter was just 16 million households — hardly Amazon-esque. And so far in 2021, share prices has slumped slightly, even though the S&amp;P 500 has powered higher. But remember, this is a company that just raised $4.6 billion — with a “B” — and is serious about growth. Considering the language and logistical barriers to competition in the markets it serves that clearly have long-term growth potential, investors may want to consider the lull in Coupang shares a buying opportunity.</p>\n<p><b>MercadoLibre</b></p>\n<p>Taking a page out of the playbook of Silicon Valley stocks that boast high share prices and a refusal to split, MercadoLibre Inc.&nbsp;is currently trading well above four figures — and based on recent history, seems as if it’s likely to stay there.</p>\n<p>MercadoLibre stock has cooled off in 2021 and is sitting on a slight loss year to date, compared with an uptrend broadly for U.S. stocks. However, that’s after this Latin American stock racked up 200% gains last year. Argentina-based MercadoLibre is hardly slowing down, however, as in the first quarter it reported&nbsp;70 million&nbsp;active users — an increase of 62% above the just over 43 million users in the prior year. Gross merchandise volume was up even more at a 77% year-over-year growth rate to just over $6 billion, compared with $3.4 billion in the first quarter of 2020.</p>\n<p>What’s really exciting for investors, however, is that the gains in core e-commerce transactions is supplemented by continued growth into financial services. MercadoLibre reported an impressive $2.9 billion in payment volume through its mobile wallet platform, and its Mercado Credito lending platform saw its portfolio grow to $576 million — more than doubling over the prior year.</p>\n<p>Amazon has taught e-commerce companies that dominating all aspects of the consumer experience is how to truly build a dominant operation. With MercadoLibre growing sales but also increasingly connecting on the financial side, it is setting up itself to be a force in Latin America — and a real competitor to even entrenched western e-commerce brands.</p>\n<p><b>Newegg</b></p>\n<p>Newegg Commerce Inc.&nbsp;is a consumer-electronics e-tailer that has a bit of a following in computer geek circles but largely has gone unnoticed by most consumers and investors. That is, until it spiked from $10 a share to a brief high above $60 a share in July.</p>\n<p>The inciting incident was news that Newegg would carry hard-to-get Nvidia&nbsp;graphics hardware, and theoretically see a big bump in revenue and profits as a result. However, Newegg may be proving that it is much more than just a tangential play piggybacking off Nvidia as it proves there is real value to specialty retailers that serve a specific audience — and can offer in-demand products instead of knock-offs propped up by fraudulent five-star reviews.</p>\n<p>Newegg went public via a SPAC, so it doesn’t have a lot of history to show investors just yet. But what little we know is proof that Newegg stock has potential. Consider it commands an impressive market share when it comes to core hardware items like PC processors, motherboards and the like. It also ranks as a top-five website worldwide when it comes to computer and electronics retailing sites, and is a go-to site for cryptocurrency miners as well as PC gamers.</p>\n<p>According to what we know about the financials, Newegg topped $2.1 billion in sales, thanks to its dominance in this profitable niche of computer components. And as evidenced by its recent Nvidia score, it has deep relationships with consumer electronics suppliers to ensure it is not just another Amazon clone selling cut-rate flat screens.</p>\n<p><b>Shopify</b></p>\n<p>If you’re interested in what life looks like for e-commerce beyond Amazon, look no further than Shopify Inc..This Canada-based tech company offers a platform for any company to build out web and mobile storefronts, integrate those operations into physical retail locations and then assist with the nitty gritty of inventory, shipping and payments.</p>\n<p>Shopify stock was one of those names that made a lot of headlines in 2020 as part of the pandemic-related surge in service providers made for social distancing. Shares surged from about $400 to $1,100 last year as a result of everyone looking to do business digitally. But in 2021, Shopify stock has tacked on almost 40% more, proving this is not just a COVID trade. After all, the e-commerce potential it helps merchants realize is real and lasting beyond the pandemic.</p>\n<p>Case in point:Fiscal first-quarter revenue growth&nbsp;reported at the end of April was a red hot 110%. But what long-term investors will like even more is that its subscription service metric MRR — that is, monthly recurring revenue — accelerated 62% year-over-year to prove that many of the initial spend on building out these platforms is sticking as clients maintain their Shopify presence.</p>\n<p>Shopify isn’t quite the scale of Amazon, but at $200 billion or so in market value right now with a comfortable operating profit to sustain it, investors who want to bet the field vs. Bezos &amp; Co. could do worse than plug into Shopify stock.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon's stock looks tired. Consider buying shares of these five fast-growing e-commerce plays instead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon's stock looks tired. Consider buying shares of these five fast-growing e-commerce plays instead\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-25 10:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/amazons-stock-looks-tired-consider-buying-shares-of-these-five-fast-growing-e-commerce-plays-instead-11627049582?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon started the internet-retail revolution. Five other companies, including Sea and Coupang, are taking it further\nSea Ltd.'s Shopee e-commerce platform.\nJeff Bezos has plenty of achievements under...</p>\n\n<a href=\"https://www.marketwatch.com/story/amazons-stock-looks-tired-consider-buying-shares-of-these-five-fast-growing-e-commerce-plays-instead-11627049582?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CPNG":"Coupang, Inc.","AMZN":"亚马逊","SE":"Sea Ltd","NEGG":"Newegg Comm Inc.","SHOP":"Shopify Inc","MELI":"MercadoLibre"},"source_url":"https://www.marketwatch.com/story/amazons-stock-looks-tired-consider-buying-shares-of-these-five-fast-growing-e-commerce-plays-instead-11627049582?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153878189","content_text":"Amazon started the internet-retail revolution. Five other companies, including Sea and Coupang, are taking it further\nSea Ltd.'s Shopee e-commerce platform.\nJeff Bezos has plenty of achievements under his belt, the most recent being his extraterrestrial excursion.\nBut Amazon.com shareholders may not be so impressed. Bipartisan talk of antitrust actions against the e-commerce giant could mean that Amazon’s dominance could begin to face challenges from Washington. That comes as Bezos handed off the CEO role to Andy Jassy earlier this month.\nShares of Amazon have underperformed the tech-heavy Nasdaq 100 and the S&P 500 in 2021, even as the coronavirus pandemic forced Americans to rely on its service during the darkest days.\nGiven all this, it is worth considering e-commerce alternatives if you’re worried that Amazon’s best days are behind it.\nHere are five smaller high-growth companies you may want to research:\nSea\nShares of Sea Ltd. are up about 45% in 2021, hitting new all-time highs as it continues its aggressive growth across Asia and Latin America.\nThe Singapore-based company has a broad business model capitalizing on e-commerce and digital retail operations around the world. That includes its Garena digital entertainment platform that publishes video games and offers e-sports tie-ins, the Shopee e-commerce platform and SeaMoney digital financial services that include mobile payment services.\nSea was a darling in 2020 as it rode the “stay at home trade” to great success. Revenue doubled year over year in 2020 to $4.4 billion, and the company’s momentum was the envy of Wall Street as Sea stock racked up roughly 640% gains on the calendar year.\nBut the fundamentals shown by Sea in 2021 hint that the surge in share prices were justified. Consider that in its first-quarter report in May, revenue surged by about 150%— while gross profit tripled year over year.\nWith its next earnings report scheduled for mid-August, Sea stock could see another leg up as it continues to prove Amazon isn’t the only e-commerce name worth watching.\nCoupang\nWhile Sea has been a cult stock for a while in some circles, one Asian e-commerce stock that is still flying under the radar for many is Korea-based Coupang Inc.. South Korea’s biggest e-commerce company began trading in March after an IPO that raised $4.6 billion, but since then shares have drifted lower — and other cult-like stocks have won all the attention.\nIf you haven’t yet heard of Coupang, its model should be quite familiar. It sells various products including home goods, apparel, beauty products, sporting goods and electronics. It’s also looking beyond these tried-and-true categories to include a focus on fresh food and groceries, as well as services including travel and restaurant delivery.\nThough the fundamentals are light given its recent debut, the numbers we have do show this regional e-tailer is connecting in a big way in Korea. Namely, it saw net revenue growth of 74% in its first-quarter report in May, and gross profit up 70% year over year. Total customers grew 21%, and revenue per customer surged 44%.\nAdmittedly, the total customer base in that quarter was just 16 million households — hardly Amazon-esque. And so far in 2021, share prices has slumped slightly, even though the S&P 500 has powered higher. But remember, this is a company that just raised $4.6 billion — with a “B” — and is serious about growth. Considering the language and logistical barriers to competition in the markets it serves that clearly have long-term growth potential, investors may want to consider the lull in Coupang shares a buying opportunity.\nMercadoLibre\nTaking a page out of the playbook of Silicon Valley stocks that boast high share prices and a refusal to split, MercadoLibre Inc. is currently trading well above four figures — and based on recent history, seems as if it’s likely to stay there.\nMercadoLibre stock has cooled off in 2021 and is sitting on a slight loss year to date, compared with an uptrend broadly for U.S. stocks. However, that’s after this Latin American stock racked up 200% gains last year. Argentina-based MercadoLibre is hardly slowing down, however, as in the first quarter it reported 70 million active users — an increase of 62% above the just over 43 million users in the prior year. Gross merchandise volume was up even more at a 77% year-over-year growth rate to just over $6 billion, compared with $3.4 billion in the first quarter of 2020.\nWhat’s really exciting for investors, however, is that the gains in core e-commerce transactions is supplemented by continued growth into financial services. MercadoLibre reported an impressive $2.9 billion in payment volume through its mobile wallet platform, and its Mercado Credito lending platform saw its portfolio grow to $576 million — more than doubling over the prior year.\nAmazon has taught e-commerce companies that dominating all aspects of the consumer experience is how to truly build a dominant operation. With MercadoLibre growing sales but also increasingly connecting on the financial side, it is setting up itself to be a force in Latin America — and a real competitor to even entrenched western e-commerce brands.\nNewegg\nNewegg Commerce Inc. is a consumer-electronics e-tailer that has a bit of a following in computer geek circles but largely has gone unnoticed by most consumers and investors. That is, until it spiked from $10 a share to a brief high above $60 a share in July.\nThe inciting incident was news that Newegg would carry hard-to-get Nvidia graphics hardware, and theoretically see a big bump in revenue and profits as a result. However, Newegg may be proving that it is much more than just a tangential play piggybacking off Nvidia as it proves there is real value to specialty retailers that serve a specific audience — and can offer in-demand products instead of knock-offs propped up by fraudulent five-star reviews.\nNewegg went public via a SPAC, so it doesn’t have a lot of history to show investors just yet. But what little we know is proof that Newegg stock has potential. Consider it commands an impressive market share when it comes to core hardware items like PC processors, motherboards and the like. It also ranks as a top-five website worldwide when it comes to computer and electronics retailing sites, and is a go-to site for cryptocurrency miners as well as PC gamers.\nAccording to what we know about the financials, Newegg topped $2.1 billion in sales, thanks to its dominance in this profitable niche of computer components. And as evidenced by its recent Nvidia score, it has deep relationships with consumer electronics suppliers to ensure it is not just another Amazon clone selling cut-rate flat screens.\nShopify\nIf you’re interested in what life looks like for e-commerce beyond Amazon, look no further than Shopify Inc..This Canada-based tech company offers a platform for any company to build out web and mobile storefronts, integrate those operations into physical retail locations and then assist with the nitty gritty of inventory, shipping and payments.\nShopify stock was one of those names that made a lot of headlines in 2020 as part of the pandemic-related surge in service providers made for social distancing. Shares surged from about $400 to $1,100 last year as a result of everyone looking to do business digitally. But in 2021, Shopify stock has tacked on almost 40% more, proving this is not just a COVID trade. After all, the e-commerce potential it helps merchants realize is real and lasting beyond the pandemic.\nCase in point:Fiscal first-quarter revenue growth reported at the end of April was a red hot 110%. But what long-term investors will like even more is that its subscription service metric MRR — that is, monthly recurring revenue — accelerated 62% year-over-year to prove that many of the initial spend on building out these platforms is sticking as clients maintain their Shopify presence.\nShopify isn’t quite the scale of Amazon, but at $200 billion or so in market value right now with a comfortable operating profit to sustain it, investors who want to bet the field vs. Bezos & Co. could do worse than plug into Shopify stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":9,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176050959,"gmtCreate":1626847929771,"gmtModify":1703479225203,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat huat","listText":"Huat huat","text":"Huat huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/176050959","repostId":"1109432059","repostType":4,"repost":{"id":"1109432059","pubTimestamp":1626847295,"share":"https://ttm.financial/m/news/1109432059?lang=&edition=fundamental","pubTime":"2021-07-21 14:01","market":"us","language":"en","title":"Jeff Bezos Reveals Blue Origin Has Sold $100M Worth Of Tickets, 'Demand Is Very, Very High'","url":"https://stock-news.laohu8.com/highlight/detail?id=1109432059","media":"Benzinga","summary":"Amazon.com, Inc Chair Jeff Bezos revealed Tuesday that his funded space tourism company Blue Origin ","content":"<p><b>Amazon.com, Inc</b>&nbsp;Chair&nbsp;<b>Jeff Bezos</b>&nbsp;revealed Tuesday&nbsp;that his funded space tourism company Blue Origin has sold $100 million worth of tickets for future flights.</p>\n<p><b>What Happened:</b>“The demand is very, very high,” Bezos&nbsp;said at the post-flight presentation of Blue Origin.</p>\n<p>On Tuesday, Bezos and three others including the world’s youngest and oldest humans to have reached space, successfully flewonboard the New Shepard rocket.</p>\n<p>No disclosures were made by Bezos on how much it would cost for a seat on New Shepard.</p>\n<p>Bezos revealed that Blue Origin is due to fly human missions two more times in 2021 but was “not sure yet” on the number of crewed flights in 2022, as per CNBC.</p>\n<p><b>Why It Matters:</b>Among the four passengers that flew to space on Tuesday with Blue Origin, only the 18-year-old&nbsp;<b>Oliver Daemen</b>&nbsp;was a paying one.</p>\n<p>An anonymous person who originally bid $28 billion to fly with Bezos did not do so due to “scheduling conflicts,” as per Blue Origin.</p>\n<p>Rival Sir Richard Branson-founded&nbsp;<b>Virgin Galactic Holdings</b>&nbsp;has600 reservationsfrom paying customers who are willing to shell out between $200,000 to $250,000 to go to space.</p>\n<p>Among the celebrities going to space with Virgin Galactic include&nbsp;<b>Justin Bieber</b>,<b>Leonardo DiCaprio,</b>and&nbsp;<b>Tesla Inc</b>TSLA 2.21%and SpaceX CEO&nbsp;<b>Elon Musk</b>.</p>\n<p><b>Wally Funk</b>, the co-passenger of Bezos, who at age 82&nbsp;became the oldest person to go to space, has alsoplaced a depositto fly with Virgin Galactic.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jeff Bezos Reveals Blue Origin Has Sold $100M Worth Of Tickets, 'Demand Is Very, Very High'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJeff Bezos Reveals Blue Origin Has Sold $100M Worth Of Tickets, 'Demand Is Very, Very High'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 14:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/07/22075328/jeff-bezos-reveals-blue-origin-has-sold-100m-worth-of-tickets-demand-is-very-very-high><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon.com, Inc Chair Jeff Bezos revealed Tuesday that his funded space tourism company Blue Origin has sold $100 million worth of tickets for future flights.\nWhat Happened:“The demand is very, very ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/07/22075328/jeff-bezos-reveals-blue-origin-has-sold-100m-worth-of-tickets-demand-is-very-very-high\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","SPCE":"维珍银河"},"source_url":"https://www.benzinga.com/news/21/07/22075328/jeff-bezos-reveals-blue-origin-has-sold-100m-worth-of-tickets-demand-is-very-very-high","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109432059","content_text":"Amazon.com, Inc Chair Jeff Bezos revealed Tuesday that his funded space tourism company Blue Origin has sold $100 million worth of tickets for future flights.\nWhat Happened:“The demand is very, very high,” Bezos said at the post-flight presentation of Blue Origin.\nOn Tuesday, Bezos and three others including the world’s youngest and oldest humans to have reached space, successfully flewonboard the New Shepard rocket.\nNo disclosures were made by Bezos on how much it would cost for a seat on New Shepard.\nBezos revealed that Blue Origin is due to fly human missions two more times in 2021 but was “not sure yet” on the number of crewed flights in 2022, as per CNBC.\nWhy It Matters:Among the four passengers that flew to space on Tuesday with Blue Origin, only the 18-year-old Oliver Daemen was a paying one.\nAn anonymous person who originally bid $28 billion to fly with Bezos did not do so due to “scheduling conflicts,” as per Blue Origin.\nRival Sir Richard Branson-founded Virgin Galactic Holdings has600 reservationsfrom paying customers who are willing to shell out between $200,000 to $250,000 to go to space.\nAmong the celebrities going to space with Virgin Galactic include Justin Bieber,Leonardo DiCaprio,and Tesla IncTSLA 2.21%and SpaceX CEO Elon Musk.\nWally Funk, the co-passenger of Bezos, who at age 82 became the oldest person to go to space, has alsoplaced a depositto fly with Virgin Galactic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173501697,"gmtCreate":1626666734619,"gmtModify":1703763005070,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat huat huat","listText":"Huat huat huat","text":"Huat huat huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/173501697","repostId":"1111084715","repostType":4,"repost":{"id":"1111084715","pubTimestamp":1626649255,"share":"https://ttm.financial/m/news/1111084715?lang=&edition=fundamental","pubTime":"2021-07-19 07:00","market":"us","language":"en","title":"Netflix, AT&T, Snap, Chipotle, Twitter, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1111084715","media":"Barrons","summary":"Second-quarter earnings season picks up this week, as 76 S&P 500 companies are scheduled to report. ","content":"<p>Second-quarter earnings season picks up this week, as 76 S&amp;P 500 companies are scheduled to report. <a href=\"https://laohu8.com/S/IBM\">IBM</a> and J.B. Hunt Transport Services will be Monday’s highlights, followed by Netflix, Chipotle Mexican Grill, Halliburton, Intuitive Surgical, and United Airlines Holdings on Tuesday.</p>\n<p>Wednesday will be busy, with SAP, Coca-Cola, Johnson &amp; Johnson, Texas Instruments, and Verizon Communications all releasing results. AT&amp;T, <a href=\"https://laohu8.com/S/TWTR\">Twitter</a>, Biogen, Snap, American Airlines Group, Intel, and Southwest Airlines go next on Thursday, before American <a href=\"https://laohu8.com/S/EXPR\">Express</a>, Honeywell International, and Schlumberger close the week on Friday.</p>\n<p>The economic calendar this week will bring plenty of data on the state of the U.S. housing market. On Monday, the National Association of Home Builders releases its NAHB/ Wells Fargo Housing Market Index for July, followed by the Census Bureau’s new residential construction data for June on Tuesday. Then, on Thursday, the National Association of Realtors reports existing-home sales for June. Economists on average expect a still robust housing market, but one that’s less explosively growing than earlier this year.</p>\n<p><img src=\"https://static.tigerbbs.com/7e83f1e4a91566400a5dd6174a1f8ecc\" tg-width=\"1564\" tg-height=\"662\" referrerpolicy=\"no-referrer\"></p>\n<p>Monday 7/19</p>\n<p>IBM, J.B. Hunt Transport Services, PPG Industries, Prologis, Tractor Supply, and Zions Bancorp report quarterly results.</p>\n<p>L Brands holds a conference call to discuss the spinoff of its Victoria’s Secret brand. The new company, to be called Victoria’s Secret, is expected to trade under the ticker VSCO on the New York Stock Exchange in early August. The remaining company will be renamed Bath &amp; Body Works, and also have a new stock symbol, BBWI.</p>\n<p>The National Association of Home Builders releases its NAHB/Wells Fargo Housing Market Index for July. Consensus estimate is for an 82 reading, slightly higher than the June data. Home builders remain quite bullish on the housing market, but the June figure was the lowest since August 2020, amid rising materials prices and supply-chain shortages.</p>\n<p>Tuesday 7/20</p>\n<p>Chipotle Mexican Grill, <a href=\"https://laohu8.com/S/CFG\">Citizens Financial Group</a>, Halliburton, HCA Healthcare, Intuitive Surgical, <a href=\"https://laohu8.com/S/KEY\">KeyCorp</a>, Netflix, Philip Morris International, <a href=\"https://laohu8.com/S/SYF\">Synchrony Financial</a>, Travelers, and United Airlines Holdings announce earnings.</p>\n<p>The Census Bureau reports new residential construction data for June. Economists forecast a seasonally adjusted annual rate of 1.6 million housing starts, slightly more than the June figure.</p>\n<p>Wednesday 7/21</p>\n<p>Anthem, ASML Holding, Baker Hughes, Coca-Cola, Crown Castle International, CSX, Johnson &amp; Johnson, Nasdaq, Northern Trust, Novartis, SAP, Seagate Technology Holdings, Texas Instruments, and Verizon Communications release quarterly results.</p>\n<p>Thursday 7/22</p>\n<p>The NAR reports existing-home sales for June. Economists forecast a seasonally adjusted annual rate of 5.8 million, matching the May figure. Existing-home sales have declined for four consecutive months.</p>\n<p>Abbott Laboratories, American Airlines Group, AT&amp;T, Biogen, Capital One Financial, D.R. Horton, Danaher, Intel, Marsh &amp; McLennan, Newmont, Nucor, Snap, Southwest Airlines, Twitter, and Union Pacific hold conference calls to discuss earnings.</p>\n<p>The Conference Board releases its Leading Economic Index for June. Consensus estimate is for a 1.1% month-over-month increase, after a 1.3% rise in May. The LEI has now surpassed its previous peak from January 2020.</p>\n<p>The European Central Bank announces its monetary-policy decision. The central bank is widely expected to keep its key short-term interest rate unchanged at negative 0.5%. The ECB recently changed its inflation goal to 2% over the medium term instead of targeting inflation of close to, but below, 2%.</p>\n<p>Friday 7/23</p>\n<p>American Express, Honeywell International, Kimberly-Clark, NextEra Energy, and Schlumberger report quarterly results.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix, AT&T, Snap, Chipotle, Twitter, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix, AT&T, Snap, Chipotle, Twitter, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-19 07:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/netflix-at-t-snap-chipotle-twitter-and-other-stocks-for-investors-to-watch-this-week-51626634814?mod=hp_LEAD_3><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Second-quarter earnings season picks up this week, as 76 S&P 500 companies are scheduled to report. IBM and J.B. Hunt Transport Services will be Monday’s highlights, followed by Netflix, Chipotle ...</p>\n\n<a href=\"https://www.barrons.com/articles/netflix-at-t-snap-chipotle-twitter-and-other-stocks-for-investors-to-watch-this-week-51626634814?mod=hp_LEAD_3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯","ISBC":"投资者银行"},"source_url":"https://www.barrons.com/articles/netflix-at-t-snap-chipotle-twitter-and-other-stocks-for-investors-to-watch-this-week-51626634814?mod=hp_LEAD_3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111084715","content_text":"Second-quarter earnings season picks up this week, as 76 S&P 500 companies are scheduled to report. IBM and J.B. Hunt Transport Services will be Monday’s highlights, followed by Netflix, Chipotle Mexican Grill, Halliburton, Intuitive Surgical, and United Airlines Holdings on Tuesday.\nWednesday will be busy, with SAP, Coca-Cola, Johnson & Johnson, Texas Instruments, and Verizon Communications all releasing results. AT&T, Twitter, Biogen, Snap, American Airlines Group, Intel, and Southwest Airlines go next on Thursday, before American Express, Honeywell International, and Schlumberger close the week on Friday.\nThe economic calendar this week will bring plenty of data on the state of the U.S. housing market. On Monday, the National Association of Home Builders releases its NAHB/ Wells Fargo Housing Market Index for July, followed by the Census Bureau’s new residential construction data for June on Tuesday. Then, on Thursday, the National Association of Realtors reports existing-home sales for June. Economists on average expect a still robust housing market, but one that’s less explosively growing than earlier this year.\n\nMonday 7/19\nIBM, J.B. Hunt Transport Services, PPG Industries, Prologis, Tractor Supply, and Zions Bancorp report quarterly results.\nL Brands holds a conference call to discuss the spinoff of its Victoria’s Secret brand. The new company, to be called Victoria’s Secret, is expected to trade under the ticker VSCO on the New York Stock Exchange in early August. The remaining company will be renamed Bath & Body Works, and also have a new stock symbol, BBWI.\nThe National Association of Home Builders releases its NAHB/Wells Fargo Housing Market Index for July. Consensus estimate is for an 82 reading, slightly higher than the June data. Home builders remain quite bullish on the housing market, but the June figure was the lowest since August 2020, amid rising materials prices and supply-chain shortages.\nTuesday 7/20\nChipotle Mexican Grill, Citizens Financial Group, Halliburton, HCA Healthcare, Intuitive Surgical, KeyCorp, Netflix, Philip Morris International, Synchrony Financial, Travelers, and United Airlines Holdings announce earnings.\nThe Census Bureau reports new residential construction data for June. Economists forecast a seasonally adjusted annual rate of 1.6 million housing starts, slightly more than the June figure.\nWednesday 7/21\nAnthem, ASML Holding, Baker Hughes, Coca-Cola, Crown Castle International, CSX, Johnson & Johnson, Nasdaq, Northern Trust, Novartis, SAP, Seagate Technology Holdings, Texas Instruments, and Verizon Communications release quarterly results.\nThursday 7/22\nThe NAR reports existing-home sales for June. Economists forecast a seasonally adjusted annual rate of 5.8 million, matching the May figure. Existing-home sales have declined for four consecutive months.\nAbbott Laboratories, American Airlines Group, AT&T, Biogen, Capital One Financial, D.R. Horton, Danaher, Intel, Marsh & McLennan, Newmont, Nucor, Snap, Southwest Airlines, Twitter, and Union Pacific hold conference calls to discuss earnings.\nThe Conference Board releases its Leading Economic Index for June. Consensus estimate is for a 1.1% month-over-month increase, after a 1.3% rise in May. The LEI has now surpassed its previous peak from January 2020.\nThe European Central Bank announces its monetary-policy decision. The central bank is widely expected to keep its key short-term interest rate unchanged at negative 0.5%. The ECB recently changed its inflation goal to 2% over the medium term instead of targeting inflation of close to, but below, 2%.\nFriday 7/23\nAmerican Express, Honeywell International, Kimberly-Clark, NextEra Energy, and Schlumberger report quarterly results.","news_type":1},"isVote":1,"tweetType":1,"viewCount":32,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860762857,"gmtCreate":1632215433279,"gmtModify":1676530726698,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860762857","repostId":"1169324317","repostType":4,"repost":{"id":"1169324317","pubTimestamp":1632214355,"share":"https://ttm.financial/m/news/1169324317?lang=&edition=fundamental","pubTime":"2021-09-21 16:52","market":"us","language":"en","title":"Why Apple, Facebook, Amazon, and Other Tech Stocks Dropped Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1169324317","media":"Motley Fool","summary":"Fear has returned to the global financial markets.\n\nWhat happened\nMounting concerns of a potential f","content":"<blockquote>\n <b>Fear has returned to the global financial markets.</b>\n</blockquote>\n<p><b>What happened</b></p>\n<p>Mounting concerns of a potential financial crisis in <a href=\"https://laohu8.com/S/CAAS\">China</a> drove investors to reduce risk on Monday.</p>\n<p>Here's how some of the largest and most popula&nbsp;rtech&nbsp;stocks fared Monday:</p>\n<ul>\n <li><b><a href=\"https://laohu8.com/S/AAPL\">Apple</a></b>, down 2.1%</li>\n <li><b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b>, down 2.5%</li>\n <li><b><a href=\"https://laohu8.com/S/AMZN\">Amazon.com</a></b>, down 3.1%</li>\n <li><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a></b>, down 3.5%</li>\n <li><b><a href=\"https://laohu8.com/S/NVDA\">NVIDIA Corp</a></b> , down 3.6%</li>\n</ul>\n<p><b>So what</b></p>\n<p>China Evergrande Group is struggling to pay its bills. The mammoth Chinese property developer has warned that it could default on its debt, which, in total, is believed to exceed a staggering $300 billion. <a href=\"https://laohu8.com/S/ISBC\">Investors</a>, in turn, are scared that Evergrande's seemingly imminent collapse could drive China's real estate and banking industries into a crisis -- and stall its massive economy.</p>\n<p>Should that worst-case scenario play out, U.S. companies like Apple and Nvidia that rely on China for a large portion of their raw materials and manufacturing capacity could experience supply chain disruptions. Additionally, e-commerce leaders like Amazon and Shopify, whose third-party merchants often source goods from China, could see their booming growth slow. Worse still, if China's economic slowdown and banking troubles spread to other global markets, advertisers might pull back on their marketing investments, thereby denting the profits of Facebook and other social media companies.</p>\n<p><b>Now what</b></p>\n<p>While certainly unsettling, Evergrande's troubles don't necessarily need to send the world's financial markets into a tailspin. The likelihood that a potential Evergrande collapse weakens the long-term prospects of these U.S.-based tech titans is faint, particularly if the Chinese government intervenes to reduce the chances of widespread carnage in its all-important real estate and banking industries. So, while we may see continued declines in the coming days as traders price in these risks, there's no reason for long-term investors to panic and sell their shares.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Apple, Facebook, Amazon, and Other Tech Stocks Dropped Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Apple, Facebook, Amazon, and Other Tech Stocks Dropped Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-21 16:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/20/why-apple-facebook-amazon-and-other-tech-stocks-dr/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fear has returned to the global financial markets.\n\nWhat happened\nMounting concerns of a potential financial crisis in China drove investors to reduce risk on Monday.\nHere's how some of the largest ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/20/why-apple-facebook-amazon-and-other-tech-stocks-dr/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","SHOP":"Shopify Inc","AAPL":"苹果","AMZN":"亚马逊"},"source_url":"https://www.fool.com/investing/2021/09/20/why-apple-facebook-amazon-and-other-tech-stocks-dr/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169324317","content_text":"Fear has returned to the global financial markets.\n\nWhat happened\nMounting concerns of a potential financial crisis in China drove investors to reduce risk on Monday.\nHere's how some of the largest and most popula rtech stocks fared Monday:\n\nApple, down 2.1%\nFacebook, down 2.5%\nAmazon.com, down 3.1%\nShopify, down 3.5%\nNVIDIA Corp , down 3.6%\n\nSo what\nChina Evergrande Group is struggling to pay its bills. The mammoth Chinese property developer has warned that it could default on its debt, which, in total, is believed to exceed a staggering $300 billion. Investors, in turn, are scared that Evergrande's seemingly imminent collapse could drive China's real estate and banking industries into a crisis -- and stall its massive economy.\nShould that worst-case scenario play out, U.S. companies like Apple and Nvidia that rely on China for a large portion of their raw materials and manufacturing capacity could experience supply chain disruptions. Additionally, e-commerce leaders like Amazon and Shopify, whose third-party merchants often source goods from China, could see their booming growth slow. Worse still, if China's economic slowdown and banking troubles spread to other global markets, advertisers might pull back on their marketing investments, thereby denting the profits of Facebook and other social media companies.\nNow what\nWhile certainly unsettling, Evergrande's troubles don't necessarily need to send the world's financial markets into a tailspin. The likelihood that a potential Evergrande collapse weakens the long-term prospects of these U.S.-based tech titans is faint, particularly if the Chinese government intervenes to reduce the chances of widespread carnage in its all-important real estate and banking industries. So, while we may see continued declines in the coming days as traders price in these risks, there's no reason for long-term investors to panic and sell their shares.","news_type":1},"isVote":1,"tweetType":1,"viewCount":410,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885466600,"gmtCreate":1631816594700,"gmtModify":1676530643827,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Genius","listText":"Genius","text":"Genius","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/885466600","repostId":"2167651799","repostType":4,"repost":{"id":"2167651799","pubTimestamp":1631806223,"share":"https://ttm.financial/m/news/2167651799?lang=&edition=fundamental","pubTime":"2021-09-16 23:30","market":"us","language":"en","title":"3 Ultra-Popular Stocks With 81% to 98% Downside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2167651799","media":"Motley Fool","summary":"Certain analysts and investment banks see these stocks losing a majority of their value.","content":"<p>A quick look at the long-term chart of the benchmark <b>S&amp;P 500</b> will demonstrate to any investor that optimism is rewarded over the long run. However, just because the broader market indexes head higher over time, it doesn't mean all stocks will be winners -- and Wall Street knows it.</p>\n<p>Although a vast majority of Wall Street ratings and price targets on publicly traded companies portend upside, some analysts see nothing short of calamity in the months and years that lie ahead for some of the most popular stocks. Based on the lowest Wall Street price target, the following three ultra-popular stocks could tumble between 81% and 98%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4445b731e2c9c6acb2e5395056b6719\" tg-width=\"700\" tg-height=\"524\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna: Implied downside of 81%</h2>\n<p>Biotech stock <b>Moderna</b> (NASDAQ:MRNA) has been <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the fastest-growing and most successful investments since the beginning of 2020. However, Leerink Partners analyst Mani Foroohar sees things differently. Foroohar and Leerink have stuck by their sell rating and $85 price target on the company as it's soared. If Moderna were to fall back to $85, it would shed 81% of its value.</p>\n<p>On one hand, Moderna has been practically unstoppable, thanks to the successful development of mRNA-1273, one of the coronavirus disease 2019 (COVID-19) vaccines to receive emergency-use authorization in the United States. In late-stage clinical studies released last November, Moderna's two-dose regimen of mRNA-1273 led to a vaccine efficacy (VE) of 94.1%. Even though recent studies have shown that VE wanes over time, the initial VE offered by mRNA-1273 has made it one of the two most-popular inoculation options in developed markets.</p>\n<p>Also working in Moderna's favor is the possibility that COVID-19 vaccines could become a recurring/seasonal thing. Mutations and variations of COVID-19 make it increasingly likely that it'll become an endemic disease. Without the ability to rid COVID-19 from the U.S. and other countries, booster shots may be necessary to combat it. In other words, Moderna's one-hit wonder could become a regular revenue stream.</p>\n<p>On the other hand, mRNA-1273 is Moderna's only revenue-producing asset, and competition in the vaccine space is only destined to become more crowded. Even if Moderna's vaccine remains toward the top end in terms of efficacy, the sheer volume of doses that need to be administered globally will open the door to other successful drugmakers.</p>\n<p>While Leerink's price target is potentially too aggressive to the downside, Moderna does have a lot to prove with a $181 billion market cap and only one marketed drug.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642857%2Flordstown-endurance-steve-burns-ceo.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Now-former CEO Steve Burns standing next to a prototype of the Endurance all-electric. pickup. Image source: Lordstown Motors.</span></p>\n<h2>Lordstown Motors: Implied downside of 84%</h2>\n<p>Over the next decade, electric vehicles (EVs) could be one of the fastest-growing industries in North America. But Wall Street isn't too keen on one EV manufacturer, in particular: <b>Lordstown Motors</b> (NASDAQ:RIDE).</p>\n<p>According to analyst Joseph Spak at RBC Capital, Lordstown is worthy of an underperform rating and a $1 price target. If this price target becomes a reality, Lordstown's shares will have fallen 84%.</p>\n<p>Whereas there was both a clear bull and bear argument to share about Moderna above, the same can't be said of Lordstown Motors. It's been nothing short of a disaster.</p>\n<p>In March, a number of allegations were levied against the company by short-side firm Hindenburg Research. Although a number of these allegations proved to be without merit, a committee formed by Lordstown's independent directors found that the company had exaggerated the number of pre-orders of its Endurance EV pickup. Both Lordstown's CEO Steve Burns and CFO Julio Rodriguez resigned in the wake of these findings.</p>\n<p>To make matters worse, Lordstown Motors may not have enough capital to survive the next year. It costs a pretty penny to build a new automaker from the ground up. Even though the company ended June with $366 million in cash, it reported a second-quarter loss of $108 million.</p>\n<p>The real issue, as my auto-focused colleague John Rosevear notes, is that the company's Endurance pickup isn't anywhere close to being on schedule. Lordstown will probably see Endurance deliveries to customers commence in the second quarter of 2022, which doesn't exactly align with the idea put forward by the company that production would begin in September.</p>\n<p>With few avenues to raise cash and lukewarm demand for Endurance, a $1 price target may even prove too generous.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/15eab863c856018bec9ca4a17856fe6d\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment: Implied downside of 98%</h2>\n<p>And then there was meme stock kingpin <b>AMC Entertainment</b> (NYSE:AMC). AMC shouldn't be a surprise on this list, as the most bullish investment bank on Wall Street sees the company losing nearly 70% of its value, as of this past weekend. On the other end of the spectrum, Alan Gould at Loop Capital foresees AMC eventually heading back to $1 a share. That would be a decline of 98%, for those of you keeping score at home.</p>\n<p>The reason AMC has shot out of a cannon and pushed well beyond Wall Street's collective price targets is the unwavering support of retail investors who believe it'll undergo another short squeeze. This is a very short-term event whereby pessimists who are betting against a stock (i.e., short-sellers) run for the exit at the same time. Since short-sellers have to buy shares to cover their short positions, it can cause a rising stock price to briefly go parabolic.</p>\n<p>But as Gould and other analysts have noted with AMC, the numbers don't add up. While it's impossible to pinpoint when emotion will stop being the driving force behind AMC, the operating performance of a company and its balance sheet always dictate the long-term price performance of a company's stock. In this respect, the movie-theater industry has been in a nearly two-decade decline, with streaming services siphoning off moviegoers and AMC building up share in an industry where the proverbial pie is getting smaller.</p>\n<p>The far greater concern for AMC is the amount of leverage it took on to survive the pandemic. Although the company ended June with $2.023 billion in liquidity ($1.81 billion of which is cash), it's also sitting on nearly $5.5 billion in corporate debt, $420 million in deferred rent, and close to $4.9 billion in lease liabilities.</p>\n<p>By the end of 2023, the company expects to lay out $2.51 billion, at minimum, for lease liabilities and will likely have to repay its $420 million in back rent. That's $2.9 billion in upcoming payments over a 30-month period for a company that's still burning cash and has only $2 billion in liquidity.</p>\n<p>To boot, AMC's retail investors won't approve any additional share offerings, leaving the company with no avenues to further raise capital. As with Lordstown, even a $1 price target might be generous when given enough time.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With 81% to 98% Downside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With 81% to 98% Downside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-16 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/16/3-ultra-popular-stocks-with-81-to-98-downside/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A quick look at the long-term chart of the benchmark S&P 500 will demonstrate to any investor that optimism is rewarded over the long run. However, just because the broader market indexes head higher ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/16/3-ultra-popular-stocks-with-81-to-98-downside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/16/3-ultra-popular-stocks-with-81-to-98-downside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167651799","content_text":"A quick look at the long-term chart of the benchmark S&P 500 will demonstrate to any investor that optimism is rewarded over the long run. However, just because the broader market indexes head higher over time, it doesn't mean all stocks will be winners -- and Wall Street knows it.\nAlthough a vast majority of Wall Street ratings and price targets on publicly traded companies portend upside, some analysts see nothing short of calamity in the months and years that lie ahead for some of the most popular stocks. Based on the lowest Wall Street price target, the following three ultra-popular stocks could tumble between 81% and 98%.\nImage source: Getty Images.\nModerna: Implied downside of 81%\nBiotech stock Moderna (NASDAQ:MRNA) has been one of the fastest-growing and most successful investments since the beginning of 2020. However, Leerink Partners analyst Mani Foroohar sees things differently. Foroohar and Leerink have stuck by their sell rating and $85 price target on the company as it's soared. If Moderna were to fall back to $85, it would shed 81% of its value.\nOn one hand, Moderna has been practically unstoppable, thanks to the successful development of mRNA-1273, one of the coronavirus disease 2019 (COVID-19) vaccines to receive emergency-use authorization in the United States. In late-stage clinical studies released last November, Moderna's two-dose regimen of mRNA-1273 led to a vaccine efficacy (VE) of 94.1%. Even though recent studies have shown that VE wanes over time, the initial VE offered by mRNA-1273 has made it one of the two most-popular inoculation options in developed markets.\nAlso working in Moderna's favor is the possibility that COVID-19 vaccines could become a recurring/seasonal thing. Mutations and variations of COVID-19 make it increasingly likely that it'll become an endemic disease. Without the ability to rid COVID-19 from the U.S. and other countries, booster shots may be necessary to combat it. In other words, Moderna's one-hit wonder could become a regular revenue stream.\nOn the other hand, mRNA-1273 is Moderna's only revenue-producing asset, and competition in the vaccine space is only destined to become more crowded. Even if Moderna's vaccine remains toward the top end in terms of efficacy, the sheer volume of doses that need to be administered globally will open the door to other successful drugmakers.\nWhile Leerink's price target is potentially too aggressive to the downside, Moderna does have a lot to prove with a $181 billion market cap and only one marketed drug.\nNow-former CEO Steve Burns standing next to a prototype of the Endurance all-electric. pickup. Image source: Lordstown Motors.\nLordstown Motors: Implied downside of 84%\nOver the next decade, electric vehicles (EVs) could be one of the fastest-growing industries in North America. But Wall Street isn't too keen on one EV manufacturer, in particular: Lordstown Motors (NASDAQ:RIDE).\nAccording to analyst Joseph Spak at RBC Capital, Lordstown is worthy of an underperform rating and a $1 price target. If this price target becomes a reality, Lordstown's shares will have fallen 84%.\nWhereas there was both a clear bull and bear argument to share about Moderna above, the same can't be said of Lordstown Motors. It's been nothing short of a disaster.\nIn March, a number of allegations were levied against the company by short-side firm Hindenburg Research. Although a number of these allegations proved to be without merit, a committee formed by Lordstown's independent directors found that the company had exaggerated the number of pre-orders of its Endurance EV pickup. Both Lordstown's CEO Steve Burns and CFO Julio Rodriguez resigned in the wake of these findings.\nTo make matters worse, Lordstown Motors may not have enough capital to survive the next year. It costs a pretty penny to build a new automaker from the ground up. Even though the company ended June with $366 million in cash, it reported a second-quarter loss of $108 million.\nThe real issue, as my auto-focused colleague John Rosevear notes, is that the company's Endurance pickup isn't anywhere close to being on schedule. Lordstown will probably see Endurance deliveries to customers commence in the second quarter of 2022, which doesn't exactly align with the idea put forward by the company that production would begin in September.\nWith few avenues to raise cash and lukewarm demand for Endurance, a $1 price target may even prove too generous.\nImage source: Getty Images.\nAMC Entertainment: Implied downside of 98%\nAnd then there was meme stock kingpin AMC Entertainment (NYSE:AMC). AMC shouldn't be a surprise on this list, as the most bullish investment bank on Wall Street sees the company losing nearly 70% of its value, as of this past weekend. On the other end of the spectrum, Alan Gould at Loop Capital foresees AMC eventually heading back to $1 a share. That would be a decline of 98%, for those of you keeping score at home.\nThe reason AMC has shot out of a cannon and pushed well beyond Wall Street's collective price targets is the unwavering support of retail investors who believe it'll undergo another short squeeze. This is a very short-term event whereby pessimists who are betting against a stock (i.e., short-sellers) run for the exit at the same time. Since short-sellers have to buy shares to cover their short positions, it can cause a rising stock price to briefly go parabolic.\nBut as Gould and other analysts have noted with AMC, the numbers don't add up. While it's impossible to pinpoint when emotion will stop being the driving force behind AMC, the operating performance of a company and its balance sheet always dictate the long-term price performance of a company's stock. In this respect, the movie-theater industry has been in a nearly two-decade decline, with streaming services siphoning off moviegoers and AMC building up share in an industry where the proverbial pie is getting smaller.\nThe far greater concern for AMC is the amount of leverage it took on to survive the pandemic. Although the company ended June with $2.023 billion in liquidity ($1.81 billion of which is cash), it's also sitting on nearly $5.5 billion in corporate debt, $420 million in deferred rent, and close to $4.9 billion in lease liabilities.\nBy the end of 2023, the company expects to lay out $2.51 billion, at minimum, for lease liabilities and will likely have to repay its $420 million in back rent. That's $2.9 billion in upcoming payments over a 30-month period for a company that's still burning cash and has only $2 billion in liquidity.\nTo boot, AMC's retail investors won't approve any additional share offerings, leaving the company with no avenues to further raise capital. As with Lordstown, even a $1 price target might be generous when given enough time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":667,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836342371,"gmtCreate":1629459916593,"gmtModify":1676530047873,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836342371","repostId":"2160166577","repostType":4,"repost":{"id":"2160166577","pubTimestamp":1629459420,"share":"https://ttm.financial/m/news/2160166577?lang=&edition=fundamental","pubTime":"2021-08-20 19:37","market":"us","language":"en","title":"3 Reasons BioNTech Isn't Nearly as Big as Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2160166577","media":"Motley Fool","summary":"Bigger isn't always better.","content":"<p><b>Moderna </b>(NASDAQ:MRNA) has delivered impressive stock gains so far in 2021. However,&nbsp;<b>BioNTech</b> (NASDAQ:BNTX) is by far the bigger winner year to date, with its stock skyrocketing more than 330%.</p>\n<p>Despite its stronger stock performance this year, BioNTech's market cap is only a little over half the size of Moderna's. Here are three reasons BioNTech isn't nearly as big as Moderna right now.</p>\n<p><img src=\"https://static.tigerbbs.com/39e79871581641e56cbbd05d9f8a3450\" tg-width=\"700\" tg-height=\"525\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Lower expected sales</h3>\n<p>It makes sense that a company with significantly lower revenue and earnings would have a lower market cap than a rival with stronger financial results. But BioNTech actually outperformed Moderna on both fronts in the companies' latest quarterly updates.</p>\n<p>In the second quarter, BioNTech reported revenue of 5.3 billion euros (around $6.2 billion). The German biotech posted earnings of nearly 2.8 billion euros (close to $3.3 billion). By comparison, Moderna's Q2 revenue totaled $4.4 billion, and it generated earnings of $2.8 billion.</p>\n<p>So why does BioNTech have a lower valuation than Moderna? One main reason is that the company projects lower sales for full-year 2021. BioNTech expects full-year sales of 15.9 billion euros (roughly $18.6 billion). Moderna looks for full-year revenue of $20 billion. BioNTech and <b>Pfizer</b>&nbsp;split the profits on the sales of their COVID-19 vaccine. Moderna, however, pockets all of the revenue from its vaccine.</p>\n<p>Neither BioNTech nor Moderna has provided guidance for 2022 yet. However, Moderna revealed that it has already secured advanced purchase agreements totaling around $12 billion for next year with options worth another $8 billion.</p>\n<h3>2. Less advanced pipeline</h3>\n<p>The differences between BioNTech's and Moderna's financial results don't fully explain the discrepancy in the valuations of the two vaccine stocks. There's another factor likely at play, though.</p>\n<p>Investors are always looking to the future. For biotechs like BioNTech and Moderna, that means their pipelines are important to their valuations. And investors probably are more excited about Moderna's pipeline.</p>\n<p>BioNTech doesn't currently have any late-stage candidate other than its COVID-19 vaccine. Moderna plans to advance its mRNA-1647 cytomegalovirus (CMV) vaccine into late-stage testing this year. The company thinks the CMV vaccine could generate sales of between $2 billion and $5 billion if it goes on to win regulatory approvals.</p>\n<p>Moderna also has a much larger cash stockpile to use in bolstering its pipeline than BioNTech does. As of June 30, 2021, Moderna's cash, cash equivalents, and investments totaled $12.2 billion. BioNTech's cash position stood at 914.1 million euros (nearly $1.1 billion) at the end of the second quarter.</p>\n<h3>3. Lower profile</h3>\n<p>There's another reason why BioNTech is so much smaller than Moderna that could be more important than you might think. BioNTech has a much lower public profile than Moderna does.</p>\n<p>Part of the challenge for BioNTech on this front is that it's overshadowed (especially in the U.S.) by its big partner, Pfizer. Many people refer only to the Pfizer and Moderna vaccines, leaving BioNTech out altogether.</p>\n<p>I wouldn't go as far as to call BioNTech the Rodney Dangerfield of biotech stocks. Unlike the late comedian, BioNTech does get respect from investors. Its sizzling stock performance this year proves the point. However, BioNTech hasn't received nearly as much hype as Moderna has.</p>\n<h3>Bigger isn't always better</h3>\n<p>For right or wrong, these three reasons go a long way toward explaining why BioNTech isn't nearly as big as Moderna. But bigger isn't always better.</p>\n<p>There are major questions about how sustainable Moderna's sky-high market cap actually is. One prominent analyst predicts that the stock will plunge close to 70% because its present valuation isn't warranted.</p>\n<p>Granted, quite a few Wall Street analysts think that BioNTech is overpriced at current levels, as well. However, there's an old saying: \"The bigger they are, the harder they fall.\" BioNTech's smaller size in comparison to Moderna just might be an advantage in the not-too-distant future.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Reasons BioNTech Isn't Nearly as Big as Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Reasons BioNTech Isn't Nearly as Big as Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 19:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/20/3-reasons-biontech-isnt-nearly-as-big-as-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna (NASDAQ:MRNA) has delivered impressive stock gains so far in 2021. However, BioNTech (NASDAQ:BNTX) is by far the bigger winner year to date, with its stock skyrocketing more than 330%.\nDespite...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/20/3-reasons-biontech-isnt-nearly-as-big-as-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/20/3-reasons-biontech-isnt-nearly-as-big-as-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160166577","content_text":"Moderna (NASDAQ:MRNA) has delivered impressive stock gains so far in 2021. However, BioNTech (NASDAQ:BNTX) is by far the bigger winner year to date, with its stock skyrocketing more than 330%.\nDespite its stronger stock performance this year, BioNTech's market cap is only a little over half the size of Moderna's. Here are three reasons BioNTech isn't nearly as big as Moderna right now.\n\nImage source: Getty Images.\n1. Lower expected sales\nIt makes sense that a company with significantly lower revenue and earnings would have a lower market cap than a rival with stronger financial results. But BioNTech actually outperformed Moderna on both fronts in the companies' latest quarterly updates.\nIn the second quarter, BioNTech reported revenue of 5.3 billion euros (around $6.2 billion). The German biotech posted earnings of nearly 2.8 billion euros (close to $3.3 billion). By comparison, Moderna's Q2 revenue totaled $4.4 billion, and it generated earnings of $2.8 billion.\nSo why does BioNTech have a lower valuation than Moderna? One main reason is that the company projects lower sales for full-year 2021. BioNTech expects full-year sales of 15.9 billion euros (roughly $18.6 billion). Moderna looks for full-year revenue of $20 billion. BioNTech and Pfizer split the profits on the sales of their COVID-19 vaccine. Moderna, however, pockets all of the revenue from its vaccine.\nNeither BioNTech nor Moderna has provided guidance for 2022 yet. However, Moderna revealed that it has already secured advanced purchase agreements totaling around $12 billion for next year with options worth another $8 billion.\n2. Less advanced pipeline\nThe differences between BioNTech's and Moderna's financial results don't fully explain the discrepancy in the valuations of the two vaccine stocks. There's another factor likely at play, though.\nInvestors are always looking to the future. For biotechs like BioNTech and Moderna, that means their pipelines are important to their valuations. And investors probably are more excited about Moderna's pipeline.\nBioNTech doesn't currently have any late-stage candidate other than its COVID-19 vaccine. Moderna plans to advance its mRNA-1647 cytomegalovirus (CMV) vaccine into late-stage testing this year. The company thinks the CMV vaccine could generate sales of between $2 billion and $5 billion if it goes on to win regulatory approvals.\nModerna also has a much larger cash stockpile to use in bolstering its pipeline than BioNTech does. As of June 30, 2021, Moderna's cash, cash equivalents, and investments totaled $12.2 billion. BioNTech's cash position stood at 914.1 million euros (nearly $1.1 billion) at the end of the second quarter.\n3. Lower profile\nThere's another reason why BioNTech is so much smaller than Moderna that could be more important than you might think. BioNTech has a much lower public profile than Moderna does.\nPart of the challenge for BioNTech on this front is that it's overshadowed (especially in the U.S.) by its big partner, Pfizer. Many people refer only to the Pfizer and Moderna vaccines, leaving BioNTech out altogether.\nI wouldn't go as far as to call BioNTech the Rodney Dangerfield of biotech stocks. Unlike the late comedian, BioNTech does get respect from investors. Its sizzling stock performance this year proves the point. However, BioNTech hasn't received nearly as much hype as Moderna has.\nBigger isn't always better\nFor right or wrong, these three reasons go a long way toward explaining why BioNTech isn't nearly as big as Moderna. But bigger isn't always better.\nThere are major questions about how sustainable Moderna's sky-high market cap actually is. One prominent analyst predicts that the stock will plunge close to 70% because its present valuation isn't warranted.\nGranted, quite a few Wall Street analysts think that BioNTech is overpriced at current levels, as well. However, there's an old saying: \"The bigger they are, the harder they fall.\" BioNTech's smaller size in comparison to Moderna just might be an advantage in the not-too-distant future.","news_type":1},"isVote":1,"tweetType":1,"viewCount":180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123253765,"gmtCreate":1624426215657,"gmtModify":1703836329371,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/123253765","repostId":"2145067304","repostType":4,"repost":{"id":"2145067304","pubTimestamp":1624420440,"share":"https://ttm.financial/m/news/2145067304?lang=&edition=fundamental","pubTime":"2021-06-23 11:54","market":"us","language":"en","title":"Sprinklr Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2145067304","media":"PR Newswire","summary":"NEW YORK, June 22, 2021 /PRNewswire/ -- Sprinklr, the unified customer experience management (Unifie","content":"<div>\n<p>NEW YORK, June 22, 2021 /PRNewswire/ -- Sprinklr, the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced the pricing of its initial public offering ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sprinklr-announces-pricing-initial-public-032900718.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sprinklr Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSprinklr Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 11:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/sprinklr-announces-pricing-initial-public-032900718.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, June 22, 2021 /PRNewswire/ -- Sprinklr, the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced the pricing of its initial public offering ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sprinklr-announces-pricing-initial-public-032900718.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00626":"大众金融控股","CXM":"Sprinklr, Inc."},"source_url":"https://finance.yahoo.com/news/sprinklr-announces-pricing-initial-public-032900718.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2145067304","content_text":"NEW YORK, June 22, 2021 /PRNewswire/ -- Sprinklr, the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced the pricing of its initial public offering of its Class A common stock at a price of $16.00 per share. Sprinklr is offering 16,625,000 shares of its Class A common stock.\nIn addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,662,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the New York Stock Exchange on June 23, 2021 under the symbol \"CXM,\" and the offering is expected to close on June 25, 2021, subject to customary closing conditions.\nIn connection with and subject to completion of this offering, certain existing stockholders, including our Founder, Chairman and Chief Executive Officer and entities affiliated with Hellman & Friedman LLC, Battery Ventures and ICONIQ Strategic Partners, have agreed to purchase 3,125,000 out of the 16,625,000 shares of the Class A common stock offered by Sprinklr.\nMorgan Stanley, J.P. Morgan, Citigroup, Barclays, and Wells Fargo Securities are acting as lead book-running managers for the proposed offering, and JMP Securities, KeyBanc Capital Markets, Oppenheimer & Co., Stifel, William Blair, Blaylock Van, LLC, C.L. King & Associates, Ramirez & Co., Inc and Roberts & Ryan are acting as co-managers for the offering.\nA registration statement relating to this offering was declared effective by the Securities and Exchange Commission on June 22, 2021. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from:: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146, or by email at prospectus@citi.com.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Sprinklr\nSprinklr is the unified platform for all customer-facing functions. We call it unified customer experience management (Unified-CXM). We help companies deliver human experiences to every customer, every time, across any modern channel, at a once impossible scale. Headquartered in New York City with over 2,400 employees globally, Sprinklr works with more than 1,000 of the world's most valuable enterprises — global brands like Microsoft, P&G, Samsung and more than 50% of the Fortune 100.","news_type":1},"isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":191224023,"gmtCreate":1620882571162,"gmtModify":1704349861070,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/191224023","repostId":"2135364193","repostType":4,"repost":{"id":"2135364193","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1620882211,"share":"https://ttm.financial/m/news/2135364193?lang=&edition=fundamental","pubTime":"2021-05-13 13:03","market":"fut","language":"en","title":"Oil pulls back from 8-week high as coronavirus cases surge in India","url":"https://stock-news.laohu8.com/highlight/detail?id=2135364193","media":"Reuters","summary":"TOKYO, May 13 (Reuters) - Oil prices fell on Thursday, pulling back from an eight-week high as conce","content":"<p>TOKYO, May 13 (Reuters) - Oil prices fell on Thursday, pulling back from an eight-week high as concerns about the coronavirus crisis in India, the world's third-biggest importer of crude, tempered a rally driven by IEA and OPEC predictions that demand is coming back strongly.</p>\n<p>Brent crude was down 66 cents, or 1%, at $68.66 a barrel by 0444 GMT, after gaining 1% on Wednesday. West Texas Intermediate <a href=\"https://laohu8.com/S/WTI\">$(WTI)$</a> was down 67 cents, or 1%, to $65.41 a barrel, having risen 1.2% in the previous session.</p>\n<p>\"The path for crude prices appears to be higher but until the situation improves in India, WTI will probably struggle to break above the early March high,\" Edward Moya, senior market analyst at OANDA, said in a note.</p>\n<p>Oil demand is already outstripping supply and the shortfall is expected to grow further even if Iran boosts exports, the International Energy Agency <a href=\"https://laohu8.com/S/IEA\">$(IEA)$</a> said in its monthly report on Wednesday.</p>\n<p>A day earlier, the Organization of the Petroleum Exporting Countries (OPEC) stuck to its forecast for a strong return of world oil demand in 2021, with growth in China and the United States cancelling out the impact of the coronavirus crisis in India.</p>\n<p>But global concern is rising over the situation in India, the world's second-most populous country, where a variant of the coronavirus is rampaging through the countryside in the deadliest 24 hours since the pandemic began.</p>\n<p>Medical professionals are still unable to say for sure when new infections will plateau and other countries are alarmed over the transmissibility of the variant that is now spreading worldwide.</p>\n<p>Meanwhile, fuel shortages are getting worse in the southeastern United States six days since the shutdown of the Colonial Pipeline, the largest fuel pipeline network in the world's biggest oil consumer.</p>\n<p>Colonial, which pipes more than 2.5 million barrels per day, said it is hoping to get a large portion of the network operating by the end of the week.</p>\n<p>\"While the disruption is meaningful for local retail markets, its impact is still likely to be transient as there is no physical damage to the pipeline,\" Goldman Sachs analysts wrote in a new report.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil pulls back from 8-week high as coronavirus cases surge in India</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil pulls back from 8-week high as coronavirus cases surge in India\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-13 13:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, May 13 (Reuters) - Oil prices fell on Thursday, pulling back from an eight-week high as concerns about the coronavirus crisis in India, the world's third-biggest importer of crude, tempered a rally driven by IEA and OPEC predictions that demand is coming back strongly.</p>\n<p>Brent crude was down 66 cents, or 1%, at $68.66 a barrel by 0444 GMT, after gaining 1% on Wednesday. West Texas Intermediate <a href=\"https://laohu8.com/S/WTI\">$(WTI)$</a> was down 67 cents, or 1%, to $65.41 a barrel, having risen 1.2% in the previous session.</p>\n<p>\"The path for crude prices appears to be higher but until the situation improves in India, WTI will probably struggle to break above the early March high,\" Edward Moya, senior market analyst at OANDA, said in a note.</p>\n<p>Oil demand is already outstripping supply and the shortfall is expected to grow further even if Iran boosts exports, the International Energy Agency <a href=\"https://laohu8.com/S/IEA\">$(IEA)$</a> said in its monthly report on Wednesday.</p>\n<p>A day earlier, the Organization of the Petroleum Exporting Countries (OPEC) stuck to its forecast for a strong return of world oil demand in 2021, with growth in China and the United States cancelling out the impact of the coronavirus crisis in India.</p>\n<p>But global concern is rising over the situation in India, the world's second-most populous country, where a variant of the coronavirus is rampaging through the countryside in the deadliest 24 hours since the pandemic began.</p>\n<p>Medical professionals are still unable to say for sure when new infections will plateau and other countries are alarmed over the transmissibility of the variant that is now spreading worldwide.</p>\n<p>Meanwhile, fuel shortages are getting worse in the southeastern United States six days since the shutdown of the Colonial Pipeline, the largest fuel pipeline network in the world's biggest oil consumer.</p>\n<p>Colonial, which pipes more than 2.5 million barrels per day, said it is hoping to get a large portion of the network operating by the end of the week.</p>\n<p>\"While the disruption is meaningful for local retail markets, its impact is still likely to be transient as there is no physical damage to the pipeline,\" Goldman Sachs analysts wrote in a new report.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DWT":"三倍做空原油ETN","UCO":"二倍做多彭博原油ETF","DDG":"ProShares做空石油与天然气ETF","SCO":"二倍做空彭博原油指数ETF","USO":"美国原油ETF","DUG":"二倍做空石油与天然气ETF(ProShares)"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2135364193","content_text":"TOKYO, May 13 (Reuters) - Oil prices fell on Thursday, pulling back from an eight-week high as concerns about the coronavirus crisis in India, the world's third-biggest importer of crude, tempered a rally driven by IEA and OPEC predictions that demand is coming back strongly.\nBrent crude was down 66 cents, or 1%, at $68.66 a barrel by 0444 GMT, after gaining 1% on Wednesday. West Texas Intermediate $(WTI)$ was down 67 cents, or 1%, to $65.41 a barrel, having risen 1.2% in the previous session.\n\"The path for crude prices appears to be higher but until the situation improves in India, WTI will probably struggle to break above the early March high,\" Edward Moya, senior market analyst at OANDA, said in a note.\nOil demand is already outstripping supply and the shortfall is expected to grow further even if Iran boosts exports, the International Energy Agency $(IEA)$ said in its monthly report on Wednesday.\nA day earlier, the Organization of the Petroleum Exporting Countries (OPEC) stuck to its forecast for a strong return of world oil demand in 2021, with growth in China and the United States cancelling out the impact of the coronavirus crisis in India.\nBut global concern is rising over the situation in India, the world's second-most populous country, where a variant of the coronavirus is rampaging through the countryside in the deadliest 24 hours since the pandemic began.\nMedical professionals are still unable to say for sure when new infections will plateau and other countries are alarmed over the transmissibility of the variant that is now spreading worldwide.\nMeanwhile, fuel shortages are getting worse in the southeastern United States six days since the shutdown of the Colonial Pipeline, the largest fuel pipeline network in the world's biggest oil consumer.\nColonial, which pipes more than 2.5 million barrels per day, said it is hoping to get a large portion of the network operating by the end of the week.\n\"While the disruption is meaningful for local retail markets, its impact is still likely to be transient as there is no physical damage to the pipeline,\" Goldman Sachs analysts wrote in a new report.","news_type":1},"isVote":1,"tweetType":1,"viewCount":86,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819581245,"gmtCreate":1630077296487,"gmtModify":1676530219561,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819581245","repostId":"1113000704","repostType":4,"repost":{"id":"1113000704","pubTimestamp":1630076703,"share":"https://ttm.financial/m/news/1113000704?lang=&edition=fundamental","pubTime":"2021-08-27 23:05","market":"us","language":"en","title":"Palantir Stock Will Stay Strong Until the Markets Get Volatile","url":"https://stock-news.laohu8.com/highlight/detail?id=1113000704","media":"InvestorPlace","summary":"PLTR stock may be vulnerable to a market correction caused by the Fed's tightening\nIs going long Pal","content":"<p>PLTR stock may be vulnerable to a market correction caused by the Fed's tightening</p>\n<p>Is going long&nbsp;<b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) stock a bet on the big data dynamo continuing to knock things out of the park? Or is it a bet that the “growth at any price” environment that the market continues to be in will stay intact? The answer is a little bit of Column A, but mostly Column B.</p>\n<p>As shown by its latest earnings report, the company is still knocking the ball out of the park. It beat analysts’ average&nbsp; revenue estimates for the second quarter. And that growth was driven not by its government business, but by its commercial segment. That may signal that the company has more than deep ties with the U.S. federal government on its side.</p>\n<p>Even so, a lot of the stock’s continued strength is derived from the fact that it benefits the most from the U.S. Federal Reserve’s aggressive monetary policy. As a result, its shares will likely remain strong until that policy changes.</p>\n<p>Of course,&nbsp; the Fed’s easy money policies may soon be over, creating a problem for PLTR stock. If the market enters a correction following tightening moves by the central bank, stocks like Palantir could suffer outsized declines.</p>\n<p>But that doesn’t exactly make the shares a sell. Those who believe that the market will experience a soft rather than a hard landing following the Fed’s tightening may think that the long-term potential of Palantir’s&nbsp;“wonderful business”&nbsp; outweighs any possible temporary declines.</p>\n<p><b>Palantir’s Earnings and Why You Shouldn’t Bet Against It</b></p>\n<p>After growing its sales 49% year-over-year&nbsp;in Q2, Palantir remains firmly on the growth train. Not only that, but its success last quarter came from an area that used to be one of its weaknesses. Specifically, its sales to the private sector jumped a stunning 90% year-over-year.</p>\n<p>That stat may put to bed one of the key arguments that bears have made about PLTR stock: their belief that its struggles winning over commercial clients will shorten its growth runway. If the company’s commercial growth continues at similar rates in the upcoming quarters, it could meet or beat its goal of achieving long-term annual revenue growth above 30%.</p>\n<p>One factor that could keep it in high growth mode is its&nbsp;unique strategy of locking in&nbsp; customers over the long-term. That strategy is its PIPE (private investment in public equity) investments in scores of SPACs (special purpose acquisition companies). The SPACs in which it’s invested $310 million purchased just $3 million of its services last quarter. But the company believes that over the long-term, the potential value of the contracts from these clients could be as much as $428 million.</p>\n<p>Palantir’s blowout quarter shows that, despite the hype surrounding the company, no one should bet against. But the stock isn’t&nbsp; bulletproof.</p>\n<p>Again, much of the strong&nbsp; performance of PLTR stock since its debut last fall has been driven by the market’s continued love for high-flying growth names like Palantir. That may be set to change, depending on how the market reacts to the Federal Reserve’s policy changes in the months ahead.</p>\n<p><b>A Correction Could Punish Palantir Stock</b></p>\n<p>Following Palantir’s Q2 earnings, PLTR stock has started to bounce back. In recent weeks, the shares have climbed back from roughly $22 to around $24.87 per share as of yesterday’s market close.</p>\n<p>With&nbsp; the stock’s rich valuation, it may be tough for the shares to make another leap higher. At today’s prices, the stock trades at a forward price-earnings, or P/E, ratio of 153 times. Its forward price-sales ratio&nbsp; of 32 times is sky-high as well.</p>\n<p>Given this factor, the shares may continue to hold steady near their current prices. But while it may be tough for Palantir to add to its gains, a negative catalyst could send it much lower.</p>\n<p>That is the Fed’s likely policy changes, which could soon kick off. As “bond king” Jeffrey Gundlach recently stated in an interview, the start of the Fed’s bond tapering program could&nbsp;put pressure on the stock market. Growth stocks like Palantir would be the most affected by such a development.</p>\n<p>Tightening by the Fed may not push PLTR stock back down to its single-digit lows. Yet even after a 50% drop, its P/E ratio would still be 76.4 times. So it’s best not to shrug off the potential downside risk of PLTR stock.</p>\n<p><b>Despite Its Risks, You May Still Find Palantir Appealing</b></p>\n<p>Not everyone is as bearish as Gundlach on the likely Fed tapering.Depending on the speed of the tapering and when it begins, it may not have that much of an impact on stock prices. So richly priced growth stocks like Palantir may not be at risk of substantial declines.</p>\n<p>If you believe that, at worst, the markets will experience a soft landing once the runaway bull market gives way to a bear market,&nbsp; the long-term potential of PLTR stock may outweigh any upcoming volatility.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir Stock Will Stay Strong Until the Markets Get Volatile</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir Stock Will Stay Strong Until the Markets Get Volatile\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/pltr-stock-stay-strong-until-markets-get-volatile/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PLTR stock may be vulnerable to a market correction caused by the Fed's tightening\nIs going long Palantir(NYSE:PLTR) stock a bet on the big data dynamo continuing to knock things out of the park? Or ...</p>\n\n<a href=\"https://investorplace.com/2021/08/pltr-stock-stay-strong-until-markets-get-volatile/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/08/pltr-stock-stay-strong-until-markets-get-volatile/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113000704","content_text":"PLTR stock may be vulnerable to a market correction caused by the Fed's tightening\nIs going long Palantir(NYSE:PLTR) stock a bet on the big data dynamo continuing to knock things out of the park? Or is it a bet that the “growth at any price” environment that the market continues to be in will stay intact? The answer is a little bit of Column A, but mostly Column B.\nAs shown by its latest earnings report, the company is still knocking the ball out of the park. It beat analysts’ average  revenue estimates for the second quarter. And that growth was driven not by its government business, but by its commercial segment. That may signal that the company has more than deep ties with the U.S. federal government on its side.\nEven so, a lot of the stock’s continued strength is derived from the fact that it benefits the most from the U.S. Federal Reserve’s aggressive monetary policy. As a result, its shares will likely remain strong until that policy changes.\nOf course,  the Fed’s easy money policies may soon be over, creating a problem for PLTR stock. If the market enters a correction following tightening moves by the central bank, stocks like Palantir could suffer outsized declines.\nBut that doesn’t exactly make the shares a sell. Those who believe that the market will experience a soft rather than a hard landing following the Fed’s tightening may think that the long-term potential of Palantir’s “wonderful business”  outweighs any possible temporary declines.\nPalantir’s Earnings and Why You Shouldn’t Bet Against It\nAfter growing its sales 49% year-over-year in Q2, Palantir remains firmly on the growth train. Not only that, but its success last quarter came from an area that used to be one of its weaknesses. Specifically, its sales to the private sector jumped a stunning 90% year-over-year.\nThat stat may put to bed one of the key arguments that bears have made about PLTR stock: their belief that its struggles winning over commercial clients will shorten its growth runway. If the company’s commercial growth continues at similar rates in the upcoming quarters, it could meet or beat its goal of achieving long-term annual revenue growth above 30%.\nOne factor that could keep it in high growth mode is its unique strategy of locking in  customers over the long-term. That strategy is its PIPE (private investment in public equity) investments in scores of SPACs (special purpose acquisition companies). The SPACs in which it’s invested $310 million purchased just $3 million of its services last quarter. But the company believes that over the long-term, the potential value of the contracts from these clients could be as much as $428 million.\nPalantir’s blowout quarter shows that, despite the hype surrounding the company, no one should bet against. But the stock isn’t  bulletproof.\nAgain, much of the strong  performance of PLTR stock since its debut last fall has been driven by the market’s continued love for high-flying growth names like Palantir. That may be set to change, depending on how the market reacts to the Federal Reserve’s policy changes in the months ahead.\nA Correction Could Punish Palantir Stock\nFollowing Palantir’s Q2 earnings, PLTR stock has started to bounce back. In recent weeks, the shares have climbed back from roughly $22 to around $24.87 per share as of yesterday’s market close.\nWith  the stock’s rich valuation, it may be tough for the shares to make another leap higher. At today’s prices, the stock trades at a forward price-earnings, or P/E, ratio of 153 times. Its forward price-sales ratio  of 32 times is sky-high as well.\nGiven this factor, the shares may continue to hold steady near their current prices. But while it may be tough for Palantir to add to its gains, a negative catalyst could send it much lower.\nThat is the Fed’s likely policy changes, which could soon kick off. As “bond king” Jeffrey Gundlach recently stated in an interview, the start of the Fed’s bond tapering program could put pressure on the stock market. Growth stocks like Palantir would be the most affected by such a development.\nTightening by the Fed may not push PLTR stock back down to its single-digit lows. Yet even after a 50% drop, its P/E ratio would still be 76.4 times. So it’s best not to shrug off the potential downside risk of PLTR stock.\nDespite Its Risks, You May Still Find Palantir Appealing\nNot everyone is as bearish as Gundlach on the likely Fed tapering.Depending on the speed of the tapering and when it begins, it may not have that much of an impact on stock prices. So richly priced growth stocks like Palantir may not be at risk of substantial declines.\nIf you believe that, at worst, the markets will experience a soft landing once the runaway bull market gives way to a bear market,  the long-term potential of PLTR stock may outweigh any upcoming volatility.","news_type":1},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832631073,"gmtCreate":1629616839292,"gmtModify":1676530080641,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/832631073","repostId":"2161743804","repostType":4,"repost":{"id":"2161743804","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629604860,"share":"https://ttm.financial/m/news/2161743804?lang=&edition=fundamental","pubTime":"2021-08-22 12:01","market":"hk","language":"en","title":"Expect Fed tapering to start in November and look like this, says BofA Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2161743804","media":"Dow Jones","summary":"BofA: Timing of Fed tapering will be a key, but so will the pace and composition of cutbacks.\n\nBack-","content":"<blockquote>\n BofA: Timing of Fed tapering will be a key, but so will the pace and composition of cutbacks.\n</blockquote>\n<p>Back-to-school isn't the only item on the agenda this fall that could have a big economic impact.</p>\n<p>BofA Global analysts also have penciled in November as the likely start date for the Federal Reserve to make cutbacks to its large-scale asset purchases, up from an earlier forecast for a January kickoff.</p>\n<p>The stepped up timeline comes days after the Federal Reserve's July Federal Open Markets Committee (FOMC) meeting minutes showed most of the 19 top central bank officials felt it appropriate to start reducing the pace of its $120 billion per month bond purchases this year.</p>\n<p>The Fed's program of buying Treasurys and mortgage-backed securities <a href=\"https://laohu8.com/S/MBB\">$(MBB)$</a> each month has been credited with helping to stave off a broader financial crisis during the pandemic, mostly by keeping markets liquid and credit conditions loose, while fueling the economic recovery.</p>\n<p>With children across the nation expected to return to classrooms this fall, hopefully freeing up more parents to return to the workforce, the Fed also looks increasingly poised to begin the process of getting markets back to functioning on their own.</p>\n<p>\"The July FOMC minutes altered our base case for taper, pulling the timeline forward by about two months from January to November, though affirmed our expectation for the Fed to move more slowly and be data-dependent,\" Meghan Swiber's team at BofA Research wrote in a note Friday.</p>\n<p>While the timing of tapering will be a key, so will the pace and composition of cutbacks, the team said.</p>\n<p>To that end, BofA Global put forth this new forecast of what the pullback could look like. Their base-case shows purchases ending around next September.</p>\n<p>Swiber's team argued that the U.S. economic recovery keeps heading toward the Fed's goal of \"substantial further progress\" from the worst shocks of the pandemic last year, but also that any decisions by the central bank on pulling back its extreme monetary support will remain \"data dependent.\"</p>\n<p>Dallas Fed President Rob Kaplan on Friday told Fox Business Network that he may rethink his call for the Fed to quickly start to taper its monthly purchases if it looks like the spread of the coronavirus delta variant is slowing economic growth.</p>\n<p>While a lifeline for markets, the Fed program also has drawn criticism. Some experts fear the central bank's Goliath footprint has eroded risk-based pricing in markets, which can help keep bubbles in check, and fueled an uneven \"K-shaped\" recovery, where most wealth accumulated has been by the rich, not the poor, as stocks, financial assets and home prices have set record highs during the pandemic.</p>\n<p>Read: Home prices could cool when the Fed tapers its bond-buying program. But a crisis? Unlikely .</p>\n<p>The major U.S. stock benchmarks were trading higher Friday, but with the Dow Jones Industrial Average headed for a 1% weekly loss and the S&amp;P 500 index about 0.6% lower on the week, according to FactSet data.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Expect Fed tapering to start in November and look like this, says BofA Global</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExpect Fed tapering to start in November and look like this, says BofA Global\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-22 12:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n BofA: Timing of Fed tapering will be a key, but so will the pace and composition of cutbacks.\n</blockquote>\n<p>Back-to-school isn't the only item on the agenda this fall that could have a big economic impact.</p>\n<p>BofA Global analysts also have penciled in November as the likely start date for the Federal Reserve to make cutbacks to its large-scale asset purchases, up from an earlier forecast for a January kickoff.</p>\n<p>The stepped up timeline comes days after the Federal Reserve's July Federal Open Markets Committee (FOMC) meeting minutes showed most of the 19 top central bank officials felt it appropriate to start reducing the pace of its $120 billion per month bond purchases this year.</p>\n<p>The Fed's program of buying Treasurys and mortgage-backed securities <a href=\"https://laohu8.com/S/MBB\">$(MBB)$</a> each month has been credited with helping to stave off a broader financial crisis during the pandemic, mostly by keeping markets liquid and credit conditions loose, while fueling the economic recovery.</p>\n<p>With children across the nation expected to return to classrooms this fall, hopefully freeing up more parents to return to the workforce, the Fed also looks increasingly poised to begin the process of getting markets back to functioning on their own.</p>\n<p>\"The July FOMC minutes altered our base case for taper, pulling the timeline forward by about two months from January to November, though affirmed our expectation for the Fed to move more slowly and be data-dependent,\" Meghan Swiber's team at BofA Research wrote in a note Friday.</p>\n<p>While the timing of tapering will be a key, so will the pace and composition of cutbacks, the team said.</p>\n<p>To that end, BofA Global put forth this new forecast of what the pullback could look like. Their base-case shows purchases ending around next September.</p>\n<p>Swiber's team argued that the U.S. economic recovery keeps heading toward the Fed's goal of \"substantial further progress\" from the worst shocks of the pandemic last year, but also that any decisions by the central bank on pulling back its extreme monetary support will remain \"data dependent.\"</p>\n<p>Dallas Fed President Rob Kaplan on Friday told Fox Business Network that he may rethink his call for the Fed to quickly start to taper its monthly purchases if it looks like the spread of the coronavirus delta variant is slowing economic growth.</p>\n<p>While a lifeline for markets, the Fed program also has drawn criticism. Some experts fear the central bank's Goliath footprint has eroded risk-based pricing in markets, which can help keep bubbles in check, and fueled an uneven \"K-shaped\" recovery, where most wealth accumulated has been by the rich, not the poor, as stocks, financial assets and home prices have set record highs during the pandemic.</p>\n<p>Read: Home prices could cool when the Fed tapers its bond-buying program. But a crisis? Unlikely .</p>\n<p>The major U.S. stock benchmarks were trading higher Friday, but with the Dow Jones Industrial Average headed for a 1% weekly loss and the S&amp;P 500 index about 0.6% lower on the week, according to FactSet data.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MBB":"美国按揭抵押债券ETF-iShares"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161743804","content_text":"BofA: Timing of Fed tapering will be a key, but so will the pace and composition of cutbacks.\n\nBack-to-school isn't the only item on the agenda this fall that could have a big economic impact.\nBofA Global analysts also have penciled in November as the likely start date for the Federal Reserve to make cutbacks to its large-scale asset purchases, up from an earlier forecast for a January kickoff.\nThe stepped up timeline comes days after the Federal Reserve's July Federal Open Markets Committee (FOMC) meeting minutes showed most of the 19 top central bank officials felt it appropriate to start reducing the pace of its $120 billion per month bond purchases this year.\nThe Fed's program of buying Treasurys and mortgage-backed securities $(MBB)$ each month has been credited with helping to stave off a broader financial crisis during the pandemic, mostly by keeping markets liquid and credit conditions loose, while fueling the economic recovery.\nWith children across the nation expected to return to classrooms this fall, hopefully freeing up more parents to return to the workforce, the Fed also looks increasingly poised to begin the process of getting markets back to functioning on their own.\n\"The July FOMC minutes altered our base case for taper, pulling the timeline forward by about two months from January to November, though affirmed our expectation for the Fed to move more slowly and be data-dependent,\" Meghan Swiber's team at BofA Research wrote in a note Friday.\nWhile the timing of tapering will be a key, so will the pace and composition of cutbacks, the team said.\nTo that end, BofA Global put forth this new forecast of what the pullback could look like. Their base-case shows purchases ending around next September.\nSwiber's team argued that the U.S. economic recovery keeps heading toward the Fed's goal of \"substantial further progress\" from the worst shocks of the pandemic last year, but also that any decisions by the central bank on pulling back its extreme monetary support will remain \"data dependent.\"\nDallas Fed President Rob Kaplan on Friday told Fox Business Network that he may rethink his call for the Fed to quickly start to taper its monthly purchases if it looks like the spread of the coronavirus delta variant is slowing economic growth.\nWhile a lifeline for markets, the Fed program also has drawn criticism. Some experts fear the central bank's Goliath footprint has eroded risk-based pricing in markets, which can help keep bubbles in check, and fueled an uneven \"K-shaped\" recovery, where most wealth accumulated has been by the rich, not the poor, as stocks, financial assets and home prices have set record highs during the pandemic.\nRead: Home prices could cool when the Fed tapers its bond-buying program. But a crisis? Unlikely .\nThe major U.S. stock benchmarks were trading higher Friday, but with the Dow Jones Industrial Average headed for a 1% weekly loss and the S&P 500 index about 0.6% lower on the week, according to FactSet data.","news_type":1},"isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896421758,"gmtCreate":1628602439074,"gmtModify":1676529793251,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/896421758","repostId":"2158475046","repostType":4,"repost":{"id":"2158475046","pubTimestamp":1628600400,"share":"https://ttm.financial/m/news/2158475046?lang=&edition=fundamental","pubTime":"2021-08-10 21:00","market":"us","language":"en","title":"5 Growth Stocks With 110% to 393% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2158475046","media":"Motley Fool","summary":"Analysts are calling for significant gains in these fast-paced stocks.","content":"<p>For the past nine months, the stock market has been practically unstoppable. The benchmark <b>S&amp;P 500</b> hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March 23, 2020.</p>\n<p>But despite this record-breaking rally, Wall Street still sees value in a number of high-growth stocks. Based on the highest price target issued by a Wall Street investment bank or analyst, the following five growth stocks are expected to return 110% to as much as 393% to shareholders.</p>\n<h2>Coinbase Global: Implied upside of 152%</h2>\n<p>The first rapidly growing stock with abundant upside, at least according to investment firm D.A. Davidson, is cryptocurrency brokerage and ecosystem <b>Coinbase Global</b> (NASDAQ:COIN). If the lofty $650 price target set by D.A. Davidson comes to fruition, Coinbase would deliver gains of 152% to its shareholders, relative to where it closed this past weekend.</p>\n<p>On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, revenue and profits have soared for Coinbase. Net revenue in the first quarter catapulted to $1.6 billion from $179 million in the year-ago period, with net income of $771 million, up from $32 million.&nbsp; Growing institutional interest in digital currencies like <b>Bitcoin</b>&nbsp;and <b>Ethereum</b>, along with rapidly rising prices for the Big <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> in crypto, drove investors to the platform.</p>\n<p>On the other hand, the Coinbase operating model has virtually no barriers to entry, and its trading fees are at risk of constantly being undercut by other cryptocurrency exchanges. Additionally, instead of thriving off of innovation, Coinbase is effectively held hostage by external interest in Bitcoin and Ethereum and the price performance of the Big <a href=\"https://laohu8.com/S/TWOA\">Two</a> digital currencies. When Bitcoin declined by 80% following its late 2017 peak, Coinbase's revenue was nearly halved.</p>\n<p>Long story short, while sales growth has been impressive, Coinbase isn't charting its own path to success. Its reliance on external factors makes $650 a target that's unlikely to be reached.</p>\n<h2>Cresco Labs: Implied upside of 160%</h2>\n<p>One industry where you'll find no shortage of aggressive price targets is cannabis -- specifically the U.S. pot industry. If the highest price target assigned by Wall Street of nearly $29 for <b>Cresco Labs</b> (OTC:CRLBF) proves accurate, investors in this marijuana stock could enjoy upside of 160%. And unlike Coinbase, this is a price target that I believe can eventually be achieved.</p>\n<p>Like other multistate operators, Cresco is expanding its retail operations organically and via acquisition. In June, it opened its 33rd dispensary nationally, and it holds enough retail licenses in its back pocket to eventually have closer to four dozen operating dispensaries.</p>\n<p>From a retail perspective, Cresco appears to be focusing its efforts on high-dollar states, as well as those that issue licenses on a limited basis (e.g., Illinois, Ohio, and Pennsylvania). The advantage of limited-license states is they're purposefully reining in competition. That means Cresco will have a genuine opportunity to build up its brands in key markets without the fear of being overrun by a multistate operator with deeper pockets.</p>\n<p>Cresco is also the cannabis industry's leading wholesaler of weed. Even though wholesale cannabis produces weaker margins than retail, Cresco Labs has more than enough volume to make up for it. That's because it holds one of only a handful of cannabis distribution licenses in California. This license gives the company access to more than 575 dispensaries throughout the Golden State.</p>\n<h2>Baidu: Implied upside of 141%</h2>\n<p>In spite of a recent crackdown by the Chinese government on a host of tech stocks, Wall Street remains largely undeterred that China-based internet search giant <b>Baidu</b> (NASDAQ:BIDU) will head higher. In fact, based on the high-water analyst price target of nearly $395, Baidu could offer gains of as much as 141%.</p>\n<p>The most obvious catalyst for Baidu is its domestically dominant internet search engine. According to GlobalStats, Baidu has controlled between 66.9% and 79.9% of all internet search share in China over the trailing 12 months.&nbsp; Just as advertisers line up for placement on <b>Alphabet</b>'s leading internet search engine Google, they're willing to pay big bucks to reach internet users in China.</p>\n<p>Beyond the sustainable double-digit sales growth potential of internet search, Baidu is seeing exceptional early returns from its investment in cloud services and artificial intelligence (AI). Though these ancillary operations only accounted for 21% of first-quarter sales, revenue jumped by 70%.&nbsp; What's more, cloud services and AI offer higher margins, relative to marketing revenue. Over time, we should see these ancillary segments really boost Baidu's cash flow generation.</p>\n<p>While I wouldn't count on $395 anytime soon, I do believe $395 is a reasonable future price target for the fast-growing Baidu.</p>\n<h2><a href=\"https://laohu8.com/S/ICPT\">Intercept Pharmaceuticals</a>: Implied upside of 393%</h2>\n<p>If you're looking for a company with make-or-break opportunity, biotech stock <b>Intercept Pharmaceuticals</b> (NASDAQ:ICPT) might be for you. This polarizing small-cap drug developer with a focus on therapies to treat liver diseases has price targets from Wall Street ranging from as low as $16 to as high as $82. If this upper target comes to fruition, shareholders would nearly quintuple their money.</p>\n<p>The promise and peril for Intercept lies with obeticholic acid (OCA), an experimental treatment for nonalcoholic steatohepatitis (NASH), which affects between 2% and 5% of adults in this country and has no cure. In one respect, OCA met one of its two co-primary endpoints in the phase 3 Regenerate study -- a statistically significant improvement in fibrosis without a worsening of NASH. However, the highest and most-effective dose also led to a large number of cases of pruritus (itching) in trial participants.</p>\n<p>Ultimately, Intercept's top drug candidate received a Complete Response Letter from the Food and Drug Administration. The plan for Intercept is to provide additional safety and trial data, with the goal of resubmitting the application. Even if OCA is approved and targeted at a small subset of the sickest patients, it could offer blockbuster sales potential in this untapped indication.</p>\n<p>The other consideration here is Ocaliva (the brand-name version of OCA) is already approved to treat primary biliary cholangitis and is on track to bring in $325 million to $340 million in sales this year.&nbsp; With an existing safety profile and a modestly growing sales floor, Intercept's risk/reward ratio looks favorable.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h2>Nio: Implied upside of 110%</h2>\n<p>A fifth and final growth stock with serious upside, according to Wall Street, is China-based electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO). If the loftiest price target of more than $92 were to come true, investors would see their shares more than double in value.</p>\n<p>The excitement surrounding Nio has to do with the impending electrification of China's automobiles. The Society of Automotive Engineers of China predicted back in 2018 that half of all vehicles sold in the world's largest auto market would run on alternative energy by 2035. With the EV industry predominantly nascent in China, the door is wide open for multiple companies to gobble up significant share.</p>\n<p>Having resolved any funding concerns with capital raises, the focus now is on Nio's production expansion. Even facing industrywide chip shortages, Nio still managed to deliver almost 21,900 EVs during the second quarter, which was more than double what it delivered in the year-ago period.&nbsp; Assuming chip supply issues can be resolved somewhat soon, Nio's annual EV run-rate output should climb toward 150,000.</p>\n<p>Additionally, Nio is enticing new buyers with its battery-as-a-service program. Enrolling in this monthly fee-based program can lop thousands of dollars off the initial purchase price of a vehicle, all while improving buyer loyalty for Nio.</p>\n<p>A $92 price target might be a bit much for a company that's produced fewer than 118,000 EVs inception. Nevertheless, its execution of late is commendable.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Growth Stocks With 110% to 393% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Growth Stocks With 110% to 393% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past nine months, the stock market has been practically unstoppable. The benchmark S&P 500 hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRLBF":"Cresco Labs Inc.","COIN":"Coinbase Global, Inc.","BIDU":"百度","ICPT":"Intercept Pharmaceuticals","NIO":"蔚来"},"source_url":"https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158475046","content_text":"For the past nine months, the stock market has been practically unstoppable. The benchmark S&P 500 hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March 23, 2020.\nBut despite this record-breaking rally, Wall Street still sees value in a number of high-growth stocks. Based on the highest price target issued by a Wall Street investment bank or analyst, the following five growth stocks are expected to return 110% to as much as 393% to shareholders.\nCoinbase Global: Implied upside of 152%\nThe first rapidly growing stock with abundant upside, at least according to investment firm D.A. Davidson, is cryptocurrency brokerage and ecosystem Coinbase Global (NASDAQ:COIN). If the lofty $650 price target set by D.A. Davidson comes to fruition, Coinbase would deliver gains of 152% to its shareholders, relative to where it closed this past weekend.\nOn one hand, revenue and profits have soared for Coinbase. Net revenue in the first quarter catapulted to $1.6 billion from $179 million in the year-ago period, with net income of $771 million, up from $32 million.  Growing institutional interest in digital currencies like Bitcoin and Ethereum, along with rapidly rising prices for the Big Two in crypto, drove investors to the platform.\nOn the other hand, the Coinbase operating model has virtually no barriers to entry, and its trading fees are at risk of constantly being undercut by other cryptocurrency exchanges. Additionally, instead of thriving off of innovation, Coinbase is effectively held hostage by external interest in Bitcoin and Ethereum and the price performance of the Big Two digital currencies. When Bitcoin declined by 80% following its late 2017 peak, Coinbase's revenue was nearly halved.\nLong story short, while sales growth has been impressive, Coinbase isn't charting its own path to success. Its reliance on external factors makes $650 a target that's unlikely to be reached.\nCresco Labs: Implied upside of 160%\nOne industry where you'll find no shortage of aggressive price targets is cannabis -- specifically the U.S. pot industry. If the highest price target assigned by Wall Street of nearly $29 for Cresco Labs (OTC:CRLBF) proves accurate, investors in this marijuana stock could enjoy upside of 160%. And unlike Coinbase, this is a price target that I believe can eventually be achieved.\nLike other multistate operators, Cresco is expanding its retail operations organically and via acquisition. In June, it opened its 33rd dispensary nationally, and it holds enough retail licenses in its back pocket to eventually have closer to four dozen operating dispensaries.\nFrom a retail perspective, Cresco appears to be focusing its efforts on high-dollar states, as well as those that issue licenses on a limited basis (e.g., Illinois, Ohio, and Pennsylvania). The advantage of limited-license states is they're purposefully reining in competition. That means Cresco will have a genuine opportunity to build up its brands in key markets without the fear of being overrun by a multistate operator with deeper pockets.\nCresco is also the cannabis industry's leading wholesaler of weed. Even though wholesale cannabis produces weaker margins than retail, Cresco Labs has more than enough volume to make up for it. That's because it holds one of only a handful of cannabis distribution licenses in California. This license gives the company access to more than 575 dispensaries throughout the Golden State.\nBaidu: Implied upside of 141%\nIn spite of a recent crackdown by the Chinese government on a host of tech stocks, Wall Street remains largely undeterred that China-based internet search giant Baidu (NASDAQ:BIDU) will head higher. In fact, based on the high-water analyst price target of nearly $395, Baidu could offer gains of as much as 141%.\nThe most obvious catalyst for Baidu is its domestically dominant internet search engine. According to GlobalStats, Baidu has controlled between 66.9% and 79.9% of all internet search share in China over the trailing 12 months.  Just as advertisers line up for placement on Alphabet's leading internet search engine Google, they're willing to pay big bucks to reach internet users in China.\nBeyond the sustainable double-digit sales growth potential of internet search, Baidu is seeing exceptional early returns from its investment in cloud services and artificial intelligence (AI). Though these ancillary operations only accounted for 21% of first-quarter sales, revenue jumped by 70%.  What's more, cloud services and AI offer higher margins, relative to marketing revenue. Over time, we should see these ancillary segments really boost Baidu's cash flow generation.\nWhile I wouldn't count on $395 anytime soon, I do believe $395 is a reasonable future price target for the fast-growing Baidu.\nIntercept Pharmaceuticals: Implied upside of 393%\nIf you're looking for a company with make-or-break opportunity, biotech stock Intercept Pharmaceuticals (NASDAQ:ICPT) might be for you. This polarizing small-cap drug developer with a focus on therapies to treat liver diseases has price targets from Wall Street ranging from as low as $16 to as high as $82. If this upper target comes to fruition, shareholders would nearly quintuple their money.\nThe promise and peril for Intercept lies with obeticholic acid (OCA), an experimental treatment for nonalcoholic steatohepatitis (NASH), which affects between 2% and 5% of adults in this country and has no cure. In one respect, OCA met one of its two co-primary endpoints in the phase 3 Regenerate study -- a statistically significant improvement in fibrosis without a worsening of NASH. However, the highest and most-effective dose also led to a large number of cases of pruritus (itching) in trial participants.\nUltimately, Intercept's top drug candidate received a Complete Response Letter from the Food and Drug Administration. The plan for Intercept is to provide additional safety and trial data, with the goal of resubmitting the application. Even if OCA is approved and targeted at a small subset of the sickest patients, it could offer blockbuster sales potential in this untapped indication.\nThe other consideration here is Ocaliva (the brand-name version of OCA) is already approved to treat primary biliary cholangitis and is on track to bring in $325 million to $340 million in sales this year.  With an existing safety profile and a modestly growing sales floor, Intercept's risk/reward ratio looks favorable.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: Implied upside of 110%\nA fifth and final growth stock with serious upside, according to Wall Street, is China-based electric vehicle (EV) manufacturer Nio (NYSE:NIO). If the loftiest price target of more than $92 were to come true, investors would see their shares more than double in value.\nThe excitement surrounding Nio has to do with the impending electrification of China's automobiles. The Society of Automotive Engineers of China predicted back in 2018 that half of all vehicles sold in the world's largest auto market would run on alternative energy by 2035. With the EV industry predominantly nascent in China, the door is wide open for multiple companies to gobble up significant share.\nHaving resolved any funding concerns with capital raises, the focus now is on Nio's production expansion. Even facing industrywide chip shortages, Nio still managed to deliver almost 21,900 EVs during the second quarter, which was more than double what it delivered in the year-ago period.  Assuming chip supply issues can be resolved somewhat soon, Nio's annual EV run-rate output should climb toward 150,000.\nAdditionally, Nio is enticing new buyers with its battery-as-a-service program. Enrolling in this monthly fee-based program can lop thousands of dollars off the initial purchase price of a vehicle, all while improving buyer loyalty for Nio.\nA $92 price target might be a bit much for a company that's produced fewer than 118,000 EVs inception. Nevertheless, its execution of late is commendable.","news_type":1},"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896429923,"gmtCreate":1628602346362,"gmtModify":1676529793100,"author":{"id":"3582928782122574","authorId":"3582928782122574","authorIdStr":"3582928782122574","name":"Hoba","avatar":"https://static.tigerbbs.com/59c2266c2e959396b467872738c290cc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582928782122574"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896429923","repostId":"2158047569","repostType":4,"repost":{"id":"2158047569","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628600820,"share":"https://ttm.financial/m/news/2158047569?lang=&edition=fundamental","pubTime":"2021-08-10 21:07","market":"us","language":"en","title":"U.S. Senate poised to pass $1 trillion infrastructure bill, debate $3.5 trillion budget plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2158047569","media":"Reuters","summary":"WASHINGTON, Aug 10 (Reuters) - The U.S. Senate on Tuesday is set to hand President Joe Biden a $1 tr","content":"<p>WASHINGTON, Aug 10 (Reuters) - The U.S. Senate on Tuesday is set to hand President Joe Biden a $1 trillion victory when it votes to pass <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the largest infrastructure investment bills in decades and then launches debate on a budget framework aimed at setting the stage for $3.5 trillion in additional investments.</p>\n<p>Taken together, the measures, if eventually enacted into law, would jump-start road and bridge-building projects across the United States over the next five years and new social programs over the next decade.</p>\n<p>Democratic Senate Majority Leader Chuck Schumer late on Monday set the vote on the bipartisan infrastructure bill for 11 a.m. (1500 GMT) on Tuesday.</p>\n<p>If the Senate, as expected, passes the bill, many rural communities would be in line to get broadband internet service, potentially boosting their economies.</p>\n<p>Once passed, the legislation would go to the Democratic-controlled House of Representatives for consideration sometime this fall.</p>\n<p>An around-the-clock session could then be in store for the Senate as it aims to debate and pass the larger, $3.5 trillion budget plan.</p>\n<p>In order to move through the evenly divided Senate without Republican support, Democrats aim to employ a \"reconciliation\" procedure that would allow them to advance the budget plan this week and implementing legislation later this year on simple majority votes.</p>\n<p>The budget plan would provide various Senate committees with top-line spending levels for a wide range of federal initiatives, including helping the elderly get home healthcare and more families afford early childhood education.</p>\n<p>It also would provide tuition-free community college and foster major investments in programs to significantly reduce carbon emissions blamed for climate change.</p>\n<p>Later, Senate committees would have to fill in the details for scores of federal programs.</p>\n<p>The budget blueprint was formally unveiled on Monday, the same day a U.N. climate panel warned that global warming was reaching emergency levels, or what United Nations Secretary-General Antonio Guterres described as a \"code red for humanity.\"</p>\n<p>Referring to the budget initiative, Democratic Senator Gary Peters, who represents the auto-manufacturing state of Michigan, said during debate on Monday: \"Not only will this set us on a path to a more sustainable future, it helps grow America's domestic manufacturing sector.\"</p>\n<p>Republicans, however, have dismissed the Democrats' budget plan as a \"socialist\" waste of money. They vow to oppose it.</p>\n<p>House Speaker Nancy Pelosi, the top Democrat in Congress, has warned that the Senate must pass both the $1 trillion infrastructure bill and the $3.5 trillion measures before it will act.</p>\n<p>Senate passage of the infrastructure bill and the budget plan would clear the way for it to begin a month-long summer break.</p>\n<p>When Congress returns in September, it will not only debate the large investment measures but have to fund government activities for the fiscal year beginning on Oct. 1, increase Washington's borrowing authority and possibly try to pass a voting reform bill.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Senate poised to pass $1 trillion infrastructure bill, debate $3.5 trillion budget plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Senate poised to pass $1 trillion infrastructure bill, debate $3.5 trillion budget plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-10 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WASHINGTON, Aug 10 (Reuters) - The U.S. Senate on Tuesday is set to hand President Joe Biden a $1 trillion victory when it votes to pass <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the largest infrastructure investment bills in decades and then launches debate on a budget framework aimed at setting the stage for $3.5 trillion in additional investments.</p>\n<p>Taken together, the measures, if eventually enacted into law, would jump-start road and bridge-building projects across the United States over the next five years and new social programs over the next decade.</p>\n<p>Democratic Senate Majority Leader Chuck Schumer late on Monday set the vote on the bipartisan infrastructure bill for 11 a.m. (1500 GMT) on Tuesday.</p>\n<p>If the Senate, as expected, passes the bill, many rural communities would be in line to get broadband internet service, potentially boosting their economies.</p>\n<p>Once passed, the legislation would go to the Democratic-controlled House of Representatives for consideration sometime this fall.</p>\n<p>An around-the-clock session could then be in store for the Senate as it aims to debate and pass the larger, $3.5 trillion budget plan.</p>\n<p>In order to move through the evenly divided Senate without Republican support, Democrats aim to employ a \"reconciliation\" procedure that would allow them to advance the budget plan this week and implementing legislation later this year on simple majority votes.</p>\n<p>The budget plan would provide various Senate committees with top-line spending levels for a wide range of federal initiatives, including helping the elderly get home healthcare and more families afford early childhood education.</p>\n<p>It also would provide tuition-free community college and foster major investments in programs to significantly reduce carbon emissions blamed for climate change.</p>\n<p>Later, Senate committees would have to fill in the details for scores of federal programs.</p>\n<p>The budget blueprint was formally unveiled on Monday, the same day a U.N. climate panel warned that global warming was reaching emergency levels, or what United Nations Secretary-General Antonio Guterres described as a \"code red for humanity.\"</p>\n<p>Referring to the budget initiative, Democratic Senator Gary Peters, who represents the auto-manufacturing state of Michigan, said during debate on Monday: \"Not only will this set us on a path to a more sustainable future, it helps grow America's domestic manufacturing sector.\"</p>\n<p>Republicans, however, have dismissed the Democrats' budget plan as a \"socialist\" waste of money. They vow to oppose it.</p>\n<p>House Speaker Nancy Pelosi, the top Democrat in Congress, has warned that the Senate must pass both the $1 trillion infrastructure bill and the $3.5 trillion measures before it will act.</p>\n<p>Senate passage of the infrastructure bill and the budget plan would clear the way for it to begin a month-long summer break.</p>\n<p>When Congress returns in September, it will not only debate the large investment measures but have to fund government activities for the fiscal year beginning on Oct. 1, increase Washington's borrowing authority and possibly try to pass a voting reform bill.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158047569","content_text":"WASHINGTON, Aug 10 (Reuters) - The U.S. Senate on Tuesday is set to hand President Joe Biden a $1 trillion victory when it votes to pass one of the largest infrastructure investment bills in decades and then launches debate on a budget framework aimed at setting the stage for $3.5 trillion in additional investments.\nTaken together, the measures, if eventually enacted into law, would jump-start road and bridge-building projects across the United States over the next five years and new social programs over the next decade.\nDemocratic Senate Majority Leader Chuck Schumer late on Monday set the vote on the bipartisan infrastructure bill for 11 a.m. (1500 GMT) on Tuesday.\nIf the Senate, as expected, passes the bill, many rural communities would be in line to get broadband internet service, potentially boosting their economies.\nOnce passed, the legislation would go to the Democratic-controlled House of Representatives for consideration sometime this fall.\nAn around-the-clock session could then be in store for the Senate as it aims to debate and pass the larger, $3.5 trillion budget plan.\nIn order to move through the evenly divided Senate without Republican support, Democrats aim to employ a \"reconciliation\" procedure that would allow them to advance the budget plan this week and implementing legislation later this year on simple majority votes.\nThe budget plan would provide various Senate committees with top-line spending levels for a wide range of federal initiatives, including helping the elderly get home healthcare and more families afford early childhood education.\nIt also would provide tuition-free community college and foster major investments in programs to significantly reduce carbon emissions blamed for climate change.\nLater, Senate committees would have to fill in the details for scores of federal programs.\nThe budget blueprint was formally unveiled on Monday, the same day a U.N. climate panel warned that global warming was reaching emergency levels, or what United Nations Secretary-General Antonio Guterres described as a \"code red for humanity.\"\nReferring to the budget initiative, Democratic Senator Gary Peters, who represents the auto-manufacturing state of Michigan, said during debate on Monday: \"Not only will this set us on a path to a more sustainable future, it helps grow America's domestic manufacturing sector.\"\nRepublicans, however, have dismissed the Democrats' budget plan as a \"socialist\" waste of money. They vow to oppose it.\nHouse Speaker Nancy Pelosi, the top Democrat in Congress, has warned that the Senate must pass both the $1 trillion infrastructure bill and the $3.5 trillion measures before it will act.\nSenate passage of the infrastructure bill and the budget plan would clear the way for it to begin a month-long summer break.\nWhen Congress returns in September, it will not only debate the large investment measures but have to fund government activities for the fiscal year beginning on Oct. 1, increase Washington's borrowing authority and possibly try to pass a voting reform bill.","news_type":1},"isVote":1,"tweetType":1,"viewCount":136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}